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Cognitive impairments are a core feature of schizophrenia and the best predictor of 
functional outcome, though current pharmacotherapies offer only limited cognitive 
improvement. Cognitive deficits span multiple domains and thus may reflect an 
overarching alteration in cognitive control, the ability to adjust thoughts or behaviors to 
achieve goals. Cognitive control depends on the dorsolateral prefrontal cortex (DLPFC), 
which exhibits altered activity in schizophrenia. DLPFC dysfunction is thought to be due, 
at least partially, to alterations in interneurons, which are regulated by levels of the 
GABA synthesizing enzyme glutamic acid decarboxylase (GAD). A deficit in the 67 kDa 
isoform (GAD67), responsible for the majority of cortical GABA synthesis, has been 
widely replicated in the DLPFC of subjects with schizophrenia and is particularly 
prominent in the parvalbumin (PV)-containing subclass of interneurons. However, little 
is known about the relationship of DLPFC GAD67 mRNA levels and medication use, 
substance abuse, and illness severity and chronicity; translation of the transcript into 
protein; or protein levels in axon terminals, a key site of GABA production and function. 
Additionally, alterations in other GABA neurotransmission markers, including lower PV 
and GABA membrane transporter 1 (GAT1), are also present, and thought to result from 
lower GAD67 in PV neurons, though this hypothesis has not been directly tested. 
Accordingly, here we measured GAD67 mRNA, tissue-level protein, and axon terminal 
protein in PV cells, and examined whether lower PV and GAT1 mRNA are 
consequences of lower GAD67 protein in PV neurons. GAD67 mRNA levels were 
significantly 15% lower in schizophrenia subjects, but transcript levels were not 
associated with medication use, substance abuse, predictors or measures of disease 
severity, or illness chronicity. GAD67 protein levels were significantly 10% lower in total 
gray matter and 49% lower in PV axon terminals. These data provide an extensive 
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characterization of the GAD67 deficit in schizophrenia, and provide novel evidence of a 
functional impairment in PV neurons that may underlie cognitive deficits. Additionally, 
PV and GAT1 mRNAs were not altered in two mouse models with lower GAD67 
expression, suggesting that lower GAD67 is unlikely to be the cause of reduced PV and 
GAT1 mRNA in schizophrenia. 
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1.0  GENERAL INTRODUCTION 
1.1 OVERVIEW OF SCHIZOPHRENIA 
1.1.1 Burden of schizophrenia 
Schizophrenia is a devastating neuropsychiatric illness that affects approximately 0.5-
1% of the population worldwide (Lewis and Lieberman, 2000). Symptoms generally 
appear in late adolescence or early adulthood, and most affected individuals experience 
a life-long course of illness characterized by difficulties with employment, personal 
relationships, and self-care. Schizophrenia is the 14th leading cause of disability 
worldwide and accounts for 3% of the total of years of healthy life lost due to disability 
(Global Burden of Disease: 2004 Update, 2008). In fact, approximately 30% of 
schizophrenia patients have attempted suicide (Radomsky et al., 1999), and around 5% 
will eventually die from it (Hor and Taylor, 2010; Palmer et al., 2005).  
In addition to the personal suffering experienced by patients themselves, 
schizophrenia also places a substantial burden on caregivers as well as society. Family 
members are often the primary caretakers, and as such experience a significant 
emotional as well as financial load (Gibbons et al., 1984). Schizophrenia is also very 
costly to society as a whole. In 2002, schizophrenia cost the U.S. an estimated $62.7 
billion dollars (Wu et al., 2005). This figure includes $22.7 billion in direct health care 
costs as a result of pharmacological treatment and inpatient hospitalizations, as well as 
$32.4 billion in indirect costs of loss of productivity due to unemployment and premature 
mortality. In fact, reports from the U.S. and European countries estimate that the cost of 
schizophrenia is 1-3% of the total national healthcare expenditure (Knapp et al., 2004). 
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1.1.2 Clinical features of schizophrenia 
Symptoms of schizophrenia fall principally into 3 categories: positive, negative, and 
cognitive. Positive symptoms, present in addition to or as a distortion of normal 
behavior, are broadly characterized by an altered perception of reality, and are 
generally the features of schizophrenia that first bring an individual to clinical attention. 
Positive symptoms include delusions, hallucinations, disorganized thought and 
behavior, and catatonia. Delusions, false beliefs that persist in the face of contrary 
evidence, typically include one or more themes (e.g. persecution, reference, religion, or 
grandeur). The most common forms are delusions of persecution, where the patient 
believes he or she is being harassed or tormented, and delusions of reference, in which 
the patient believes certain environmental cues, such as newspaper headlines, are 
being purposely directed at him or her. Hallucinations, sensory perceptions in the 
absence of external stimuli, can occur in any sensory modality, but most often are 
auditory, with the patient hearing voices (often two or more in conversation with each 
other) that are distinct from their own thoughts. Disorganized thought describes 
language deficits that are assumed to result from impairments in thought, and focuses 
on speech problems (disorganized speech) that can be easily assessed in a clinical 
setting. Disorganized speech can manifest in a variety of ways, such as difficulty 
maintaining a single topic, providing unrelated answers in response to a question, and 
even total incoherence known as “word salad.” Disorganized behavior is also similarly 
heterogeneous, and may include disheveled appearance, inappropriate sexual 
behavior, or unpredictable agitation or silliness. Finally, catatonia, a decreased or totally 
absent response to the surrounding environment, can range from rigid posturing, to 
resistance to movement, to total unawareness [Diagnostic and Statistical Manual for 
Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR), 2000]. 
Conversely, negative symptoms represent a loss of behavior generally present in 
normal individuals, and result in impaired emotional expression and social functioning. 
The three main negative symptoms are flattened affect, alogia, and avolition, though 
others such as anhedonia may also be present. Flattened affect is the most common, 
and results in the patient exhibiting a reduced range of emotional expressions, as well 
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as diminished eye contact and body language. Alogia, or poverty of speech, is 
characterized by laconic and empty verbal responses. Avolition, or lack of motivation, 
results in difficulty initiating and pursuing actions and consequently little or no 
engagement in work or social activity. Anhedonia is an inability to take pleasure from 
activities that used to be enjoyable (DSM-IV-TR, 2000).  
Currently, the DSM-IV-TR  (2000) diagnostic criteria of schizophrenia are based 
solely on clinical symptoms and a diagnosis is made following a behavioral disturbance 
lasting at least 6 months. During this time, the patient must exhibit impaired social 
and/or occupational functioning (such as work, interpersonal relationships, or self-care) 
for a majority of the time, as well as the presence of two or more of the following acute 
symptom classes during the majority of a 1-month period: delusions, hallucinations, 
disorganized speech, disorganized or catatonic behavior, and negative symptoms. 
Finally, cognitive impairments, not presently included in the diagnostic criteria, 
but featured prominently in the DSM-IV-TR (2000) description of the illness, are thought 
to represent a core feature of schizophrenia (Elvevag and Goldberg, 2000), which will 
be explored in more detail below. The National Institute of Mental Health has 
recognized the need for better treatment of cognitive symptoms in schizophrenia, and, 
to that end, has formed several initiatives including Cognitive Neuroscience Treatment 
to Improve Cognition in Schizophrenia (CNTRICS) (Carter and Barch, 2007). CNTRICS 
has identified six cognitive domains that are altered in schizophrenia: working memory, 
executive function, episodic memory, attention, perception, and social/emotional 
processing (Carter et al., 2008). 
1.1.3 Etiology of schizophrenia 
Substantial evidence suggests that genetics play a strong role in schizophrenia, with 
current heritability estimates around 80% (reviewed in Cardno and Gottesman, 2000). In 
contrast to the 1% risk of developing schizophrenia in the general population, relatives 
of schizophrenia patients have an increased risk of developing the disorder, and this 
risk is directly proportional to genetic relatedness to the affected individual (Gottesman, 
1991). Data pooled from 40 studies of twin pairs conducted between 1920 and 1987 in 
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western Europe demonstrate that the lifetime risk of developing schizophrenia is 17% 
for the unaffected twin of a dizygotic pair, but 48% for the unaffected twin of a 
monozygotic pair (Gottesman, 1991), who share 50% and 100% of their DNA with the 
affected twin, respectively. Additionally, an elevated risk of developing schizophrenia is 
present in both the adopted-away biological offspring of schizophrenia patients 
(Rosenthal et al., 1971), as well as offspring of monozygotic twins discordant for 
schizophrenia, regardless of whether the parent was the affected or unaffected twin 
(Gottesman and Bertelsen, 1989). In fact, numerous studies have demonstrated that 
many regions of the genome, as well as a plethora of individual genes, are associated 
with schizophrenia, (reviewed in Owen et al., 2004; Gejman et al., 2010). To date, 
however, the effects of the identified variants have been disappointingly small, and 
unable to account for such high heritability of the illness (Insel, 2010).  
In addition to highlighting the role of genetics in schizophrenia, twin studies also 
point to a substantial role for the environment in the etiology of schizophrenia. If genetic 
liability was the sole pathogenic feature of schizophrenia, then monozygotic twin pairs 
would be 100% concordant for the presence or absence of the illness, which, as 
reviewed above, is not the case. Additionally, some 60% of individuals with 
schizophrenia do not have a first or second degree relative with the illness (Gottesman, 
1991). This suggests that environmental factors must also play a role. In fact, several 
environmental risk factors, ranging throughout development, have been identified. Early 
developmental risk factors include advanced paternal age (Sipos et al., 2004), winter or 
spring birth season (Torrey et al., 1997; Davies et al., 2003), abnormal fetal growth and 
development, complications of pregnancy, and complications of delivery (Cannon et al., 
2002a). Risk factors later in development include an urban upbringing versus a rural 
one (McGrath et al., 2004; March et al., 2008), migrant as opposed to native-born 
individuals (Bourque et al., 2011; McGrath et al., 2004; Cantor-Graae and Selten, 
2005), childhood trauma (Read et al., 2005; Schreier et al., 2009), and cannabis use 
during adolescence (Zammit et al., 2002; Minozzi et al., 2010). 
Since neither genes nor environment can explain schizophrenia alone, current 
etiological models of schizophrenia posit the combined role of multiple genetic and 
environmental “hits” (Bayer et al., 1999; Maynard et al., 2001). Based on the idea that 
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many risk factors occur during early development, long before symptom onset, this 
neurodevelopmental hypothesis of schizophrenia suggests that combined genetic and 
environmental risk factors affect normal developmental processes to produce disease 
onset much later during the protracted maturation that occurs during adolescence and 
early adulthood (Weinberger, 1987; Insel, 2010). 
1.1.4 Cognitive symptoms are a central feature of schizophrenia 
In 1887, Dr. Emile Kraeplin first described a group of symptoms he called “dementia 
praecox” (Kraepelin, 1919), which was later termed “schizophrenia” by Eugene Bleuler 
in 1911 (Bleuler, 1950). Although cognitive impairments were prominently featured in 
Kraeplin’s description of the illness, modern diagnostic criteria do not include cognitive 
symptoms (DSM-IV-TR, 2000). Recently, however, the cognitive aspects of 
schizophrenia have received increased attention, and are now thought to represent a 
core feature of schizophrenia for a number of reasons (reviewed in Elvevag and 
Goldberg, 2000; Gold, 2004). First, a large body of literature has replicated broad and 
severe cognitive deficits in schizophrenia, with nearly all cognitive domains affected to 
some degree by the illness (Heinrichs and Zakzanis, 1998; Nuechterlein et al., 2004) 
and patients performing, on average, 1-2 standard deviations below the mean of 
comparison subjects (Heaton et al., 2001; Wilk et al., 2004). Second, cognitive 
impairment in schizophrenia is widespread, and the majority (70-80%) of patients 
perform worse than the average of comparison subjects on neuropsychological tests 
(Palmer et al., 1997; Wilk et al., 2004). In fact, cognitive impairments may actually be 
even more prevalent than these data suggest, since even patients who score within the 
normal range of these tests do exhibit some form of cognitive dysfunction (Allen et al., 
2003; Kremen et al., 2000). Additionally, when cognitive dysfunction is defined as falling 
below predicted levels (based on premorbid intellectual functioning and parental 
education), 98% of schizophrenia patients are impaired (Keefe et al., 2005). Moreover, 
in studies of monozygotic twins discordant for schizophrenia, the ill twin performed 
worse than the healthy twin in nearly all cases (Goldberg et al., 1990; Goldberg et al., 
1995). 
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Cognitive deficits appear to be a primary factor of the illness. Treatment with 
antipsychotics provides little to no relief from cognitive symptoms (Goldberg et al., 1993; 
Gold, 2004; Meltzer and McGurk, 1999; Harvey and Keefe, 2001) and the severity of 
positive symptoms is not related to the severity of cognitive impairment (Heydebrand et 
al., 2004), suggesting that cognitive impairments are not secondary to the psychotic 
symptoms. In fact, cognitive impairments are present long before illness onset in 
children (Reichenberg et al., 2010; Niendam et al., 2003) and adolescents (Davidson et 
al., 1999; Cornblatt et al., 1999) who later go on to develop schizophrenia, and therefore 
may represent a risk factor for later developing schizophrenia. Unaffected relatives of 
patients exhibit similar, though milder, cognitive impairments (Sitskoorn et al., 2004; 
Egan et al., 2001), which suggests a genetic component to these symptoms. 
Additionally, the severity and pattern of cognitive deficits is stable across the course of 
the illness (Aleman et al., 1999; Censits et al., 1997) and deficits are present in 
medication-naïve, first-episode patients (Mohamed et al., 1999; Saykin et al., 1994), 
suggesting that cognitive impairment is not a consequence of treatment, length of 
illness, or hospitalization.  
Finally, cognitive impairments are the best predictor of long-term functional 
outcome (reviewed in Green et al., 2000), better than both positive and negative 
symptoms. Studies that utilize composite measures of cognition (Velligan et al., 1997; 
Harvey et al., 1998; Bartels et al., 1997), as well as those that have examined specific 
cognitive domains (Addington and Addington, 1999; Lysaker et al., 1995), have 
demonstrated that cognitive ability predicts social and occupational functioning, self-
care, and quality of life. For example, a recent meta-analysis that examined 62 studies 
published since 1998 found that cognitive functioning, but not severity of positive 
symptoms, was a significant predictor of employment outcome (Tsang et al., 2010). 
1.1.5 Treatment and outcome in schizophrenia 
Since their introduction in the 1950s, antipsychotic drugs have been the mainstay of 
pharmacological treatment for schizophrenia. Early drugs, such as chlorpromazine, 
belong to the class of “typical” antipsychotics, and act through a blockade of dopamine 
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D2 receptors. The more recently developed “atypical” antipsychotics, such as clozapine 
and olanzapine, are associated with fewer side effects and block serotonin as well as 
dopamine receptors. In general, both generations of antipsychotics reduce the positive 
symptoms of the illness, but have consistently been shown to have little to no effect on 
the negative (Buchanan et al., 1998) and cognitive symptoms of schizophrenia 
(Goldberg et al., 1993; Harvey and Keefe, 2001). Despite the widespread use of 
antipsychotics today, outcome in schizophrenia is still bleak (Insel, 2010). Five years 
after a first psychotic episode, only 14% of patients have experienced a prolonged 
recovery period (Robinson et al., 2004), and only an additional 16% are in recovery 15 
years later (Harrison et al., 2001).  
A number of epidemiological factors predict the severity of schizophrenia 
symptoms. For example, there is a dramatic sex effect in the illness. Relative to 
females, males have a higher incidence of schizophrenia (McGrath et al., 2004; Aleman 
et al., 2003), an earlier onset of symptoms (Shimizu et al., 1988; Castle et al., 1998), 
and a more severe illness course (Goldstein, 1988; Grossman et al., 2008). Additionally, 
a diagnosis of “pure” schizophrenia, as opposed to schizoaffective disorder, which is 
defined by the addition of significant mood symptoms, is also associated with greater 
positive, negative, and cognitive symptom severity (Cheniaux et al., 2008). A positive 
family history of schizophrenia is a third predictive factor of both more severe negative 
symptoms (Malaspina et al., 2000) and cognitive dysfunction (Tabarés-Seisdedos et al., 
2003). Finally, a lower age of onset (< 18 years) is also associated with a more severe 
illness course (Werry et al., 1994; Hollis, 2000). 
In addition to factors that predict more severe schizophrenia symptomatology, a 
number of general life benchmarks, including history of marriage, employment, 
educational achievement, and independent living, can be used as indices of functional 
outcome (Figueira and Brissos, 2011; Jönsson and Jonsson, 1992; Thara and 
Srinivasan, 1997). In fact, it is somewhat obvious that patients who are able to fulfill 
societal roles of spouse, employee, student, and friend are less functionally impaired. 
Since antipsychotics have little to no effect on cognitive symptoms (Goldberg et al., 
1993), the best predictor of functional outcome (Green et al., 2000), it is not surprising 
that antipsychotic treatment has not significantly improved functional outcome in the 
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illness (Insel, 2010). For example, recent employment rates among European 
schizophrenia subjects are below 20% (Marwaha et al., 2007), and nearly 20% of U.S. 
patients are homeless (Folsom et al., 2005). Thus, treatments to ameliorate cognitive 
deficits and consequently improve functional outcome in schizophrenia are of 
paramount importance. 
1.2 IMPAIRMENTS IN COGNTIVE CONTROL: ROLE OF DORSOLATERAL 
PREFRONTAL CORTICAL GABA NEURONS 
Cognitive impairments in schizophrenia are a core feature of the illness (Elvevag and 
Goldberg, 2000), have the most severe impact on patient quality of life (Hyman and 
Fenton, 2003), and are the best predictor of functional outcome (Green et al., 2000). 
Unfortunately, current treatments for schizophrenia have little effect on cognitive 
symptoms (Gold, 2004). Central to the development of new treatment targets for 
cognitive deficits is an understanding of the underlying abnormalities in the brain 
regions, circuits, and cells that are affected in the illness. 
1.2.1 Cognitive impairments in schizophrenia may reflect an overarching deficit 
in cognitive control 
As reviewed above, schizophrenia is characterized by a broad pattern of cognitive 
deficits across a variety of domains. One hypothesis is that these deficits reflect distinct 
alterations in multiple cognitive systems; however, since a single neuropsychological 
test typically activates multiple cognitive processes, it is difficult to determine the 
affected domains (Dickinson and Gold, 2008). Alternatively, a more recent and 
parsimonious idea suggests that impaired cognition in schizophrenia may reflect an 
overarching dysfunction in cognitive control, the ability to adjust thoughts or behaviors in 
order to achieve goals, which manifests as deficits in multiple cognitive domains 
(reviewed in Lesh et al., 2011). In fact, this view was shared by Kraeplin, who, in his 
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original account of the illness, described the schizophrenia brain quite elegantly as an 
“orchestra without a conductor” (Kraepelin, 1919).  
 A simple illustration of cognitive control is observed in the classic measure of 
directed attention, the Stroop task (Stroop, 1935), in which the subject is presented with 
various color words (red, blue, green, etc.) written in an ink color that is either congruent 
or incongruent with the word (e.g. the word “blue” written in blue ink, and the word “blue” 
written in red ink, respectively). In the low cognitive control condition, the subject must 
read the word, ignoring the ink color. In the more difficult, higher cognitive control 
condition, the patient must ignore the prepotent word-reading response and instead 
name the ink color (Figure 1). When presented with conflicting behavioral choices, this 
flexible adaptation that allows for the appropriate response selection is the essence of 
cognitive control (Lesh et al., 2011). Schizophrenia subjects consistently perform worse 
than healthy comparison subjects on the Stroop task, exhibiting longer reaction times 
and an increased number of errors (Breton et al., 2011; Cohen et al., 1999). 
 
 
 
Figure 1. Cognitive control illustrated using the Stroop task. Subjects must either 
read the word or name the color of ink the word is printed in. The correct responses for 
each condition are outlined in green. In the low cognitive control condition, the subject is 
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easily able to give the predominant response and read the word, correctly answering 
“blue”. In the more difficult, high cognitive control condition, the subject must ignore the 
prepotent word-reading tendency, and instead name the word color, “red”. Adapted by 
permission from Macmillan Publishers Ltd: Neuropsychopharmacology (Lesh et al., 
36:316-18), copyright 2011. 
 
 
 
 
In fact, cognitive control involves multiple cognitive processes besides attention, 
including the well-studied domain of working memory (Lesh et al., 2011). Schizophrenia 
subjects exhibit deficits on a variety of tasks that engage cognitive control, including 
those that involve working memory (Fleming et al., 1995; Gold et al., 1997; Goldberg et 
al., 1998; Perlstein et al., 2001). Working memory, the active maintenance of a small 
amount of information for a short period of time in order to influence future thought or 
behavior, is thought to be composed of four components: 1) an articulatory loop that 
maintains and rehearses verbal information, 2) a visuospatial scratchpad that maintains 
visual information, 3) an episodic buffer that stores information integrated from multiple 
modalities and 4) a central executive system that manipulates and controls information 
within the first three storage buffers (Baddeley, 1992; Baddeley, 2000). Consistent with 
an overarching deficit in cognitive control, subjects with schizophrenia are consistently 
impaired on measures of the central executive component (reviewed in Barch, 2006; 
Kim et al., 2004). 
1.2.2 Role of the DLPFC in cognitive control deficits in schizophrenia 
Cognitive control depends on a number of brain regions, including dorsolateral 
prefrontal cortex (DLPFC), anterior cingulate cortex, and parietal cortex (Braver et al., 
1997; Cohen et al., 1997; Pardo et al., 1990; Paus et al., 1993; Bench et al., 1993; 
Braver et al., 2003). Based on its widespread anatomical connections with a variety of 
other brain regions, including sensory, motor, and intrinsic connections to other 
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prefrontal cortex (PFC) regions, the PFC is thought to play an especially central role in 
cognitive control (reviewed in Miller and Cohen, 2001). The PFC is critical for top-down 
control of behavior, and through the integration of extrinsic and intrinsic information from 
other brain areas, its neural activity represents the rules required to perform a given 
task (Asaad et al., 1998; White and Wise, 1999; Petrides, 1990). Specifically, the 
DLPFC is thought to be critically involved in maintenance of rules and selection of the 
appropriate response (Asaad et al., 2000; Watanabe, 1990; Watanabe, 1992).    
 Impairments in DLPFC functioning in schizophrenia are well-established 
(reviewed in Weinberger, 2001). The first evidence came from a regional cerebral blood 
flow (rCBF) study, reflective of neuronal activity, demonstrating hypofrontality in 
schizophrenia (Ingvar and Franzén, 1974). About a decade later, a series of seminal 
rCBF studies found reduced DLPFC activation at rest and during a cognitive control 
task, the Wisconsin Card Sort, in both medication-free (Weinberger et al., 1986; 
Weinberger et al., 1988) and antipsychotic-treated (Berman et al., 1986) schizophrenia 
subjects. Additionally, DLPFC rCBF was significantly correlated with performance on 
the Wisconsin Card Sort (Weinberger et al., 1986). An abundance of functional 
magnetic resonance imaging (fMRI) studies have since examined DLPFC function 
during cognitive control tasks. Consistent with the rCBF data, the majority of studies 
have reported DLPFC hypoactivity (Minzenberg et al., 2009; Glahn et al., 2005; Taylor, 
1996; Andreasen et al., 1992; Perlstein et al., 2001), though others have demonstrated 
hyperactivity (Callicott et al., 2000; Manoach et al., 2000; Manoach et al., 1999). It 
seems that subjects with schizophrenia exhibit a relationship between working memory 
load, behavioral performance, and DLPFC activation that is more complex than a simple 
decrease or increase in function. It has been demonstrated that healthy subjects exhibit 
an “inverted U”-shaped relationship between DLPFC activation and working memory 
load, exhibiting lower activation levels at both low loads and high loads, and higher 
activation at intermediate loads (Callicott et al., 1999). In schizophrenia subjects, this 
inverted U is thought to be shifted to the left, so that schizophrenia subjects exhibit 
greater DLPFC activation and have relatively normal performance at low working 
memory loads, but reach the peak of the inverted U sooner, resulting in reduced 
activation and impaired performance at higher loads (Callicott et al., 2003; Van 
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Snellenberg et al., 2006; Potkin et al., 2009; Manoach, 2003). Additionally, affected 
monozygotic twins exhibit reduced gray matter volume in the DLPFC compared to their 
unaffected twin, and these reductions correlate with the degree of cognitive impairment 
(Cannon et al., 2002b). 
1.2.3 DLPFC γ oscillations underlie cognitive control and are impaired in 
schizophrenia 
Oscillations in the γ band, the synchronized activity of networks of pyramidal neurons at 
30-80 Hz, are thought to underlie higher order cognitive processes (Fries, 2009). 
Studies in humans have shown that γ band activity is induced during the delay period of 
working memory tasks (Tallon-Baudry et al., 1998), and that the power, or amplitude, of 
γ synchrony increases in proportion to working memory load (Howard et al., 2003). 
However, this increase in γ band power is absent in subjects with schizophrenia (Cho et 
al., 2006; Haenschel et al., 2009; Minzenberg et al., 2010). Additionally, the phase-
locking of γ oscillations at the onset of a stimulus during a working memory task is 
impaired in schizophrenia patients (Spencer et al., 2003). Importantly, first-episode, 
medication-naïve patients exhibit γ oscillation impairments (Minzenberg et al., 2010), 
indicating that they are not likely a consequence of illness chronicity or medication use.  
Therefore, the impairments in cognitive control that are observed in schizophrenia may 
be due to impaired γ oscillations in the DLPFC. 
1.2.4 Role of DLPFC interneurons in γ oscillations and cognitive control 
Oscillations are dependent on signaling through interneurons that signal via the 
inhibitory neurotransmitter γ-aminobutyric acid (GABA) (Bartos et al., 2007; Whittington 
et al., 1995). A single interneuron not only makes multiple contacts onto a pyramidal 
cell, but also contacts several different pyramidal cells (Gonzalez-Burgos and Lewis, 
2008). This places interneurons in a position to exert strong inhibitory control over large 
numbers of pyramidal cells, so that firing of an interneuron transiently silences many 
pyramidal cells. When the pyramidal cells are then released from inhibition, they fire in 
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concert (Gonzalez-Burgos and Lewis, 2008). Thus, inhibitory postsynaptic potentials 
(IPSPs) arising from a single GABA neuron are thought to be capable of synchronizing 
its postsynaptic target cells (Cobb et al., 1995). Furthermore, interneurons are 
connected to other interneurons by both chemical and electrical synapses (gap 
junctions) (Mann and Paulsen, 2007), and modeling studies have demonstrated that 
connected interneurons are a mechanism of synchrony (Van Vreeswijk et al., 1994). 
Different subtypes of GABA interneurons appear to play distinct roles in the generation 
of oscillations of different frequencies (reviewed in Klausberger and Somogyi, 2008), 
and the parvalbumin (PV)-expressing subclass of interneurons are especially crucial in 
γ oscillations (reviewed in Gonzalez-Burgos, 2010). 
1.3 IMPAIRMENTS IN DLPFC INTERNEURONS IN SCHIZOPHRENIA 
Cognitive control and normal γ oscillatory activity relies on the proper functioning of 
DLPFC GABA neurons. Disturbances in GABA neurotransmission, then, are a plausible 
mechanism underlying cognitive control and γ oscillatory deficits in schizophrenia. 
Given the divergent roles of interneuron subtypes in DLPFC function, knowledge of the 
affected cells and molecules involved in schizophrenia will inform future treatment 
targets. 
1.3.1 GABA synthesis is consistently impaired in schizophrenia 
Early findings of decreased activity (Bird et al., 1979; Sherman et al., 1991) of glutamic 
acid decarboxylase (GAD), the enzyme that produces GABA, and reduced GABA 
release (Sherman et al., 1991) and uptake (Simpson et al., 1989) suggested that 
cortical GABA signaling is lower in schizophrenia. The most consistent evidence in favor 
of this hypothesis are reports of a deficit in the mRNA encoding the 67 kilodalton (kDa) 
isoform of GAD (GAD67), the isoform responsible for the majority of GABA synthesis in 
the cortex, in the DLPFC of subjects with schizophrenia (reviewed in Gonzalez-Burgos, 
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2010). First demonstrated by Akbarian and colleagues using in situ hybridization (ISH) 
(1995b), lower GAD67 mRNA in the DLPFC has since been widely replicated using 
DNA microarray, quantitative PCR (qPCR), and ISH (Volk et al., 2000; Guidotti et al., 
2000; Mirnics et al., 2000; Vawter et al., 2002; Hashimoto et al., 2005; Straub et al., 
2007; Huang et al., 2007; Huang and Akbarian, 2007; Hashimoto et al., 2008b; 
Hashimoto et al., 2008a; Woo et al., 2008; Duncan et al., 2010).  
On a cellular level, the density of GAD67 mRNA+ neurons is reduced by 25-35% 
across DLPFC layers I-V of subjects with schizophrenia (Akbarian et al., 1995b; Volk et 
al., 2000; Woo et al., 2008). However, in the remaining GAD67+ neurons, the 
expression level per neuron is not different from that of comparison subjects (Volk et al., 
2000). One interpretation of these data is that a portion of GAD67 mRNA+ neurons are 
lost in schizophrenia. However, in light of several studies demonstrating no changes in 
total neuron number in the PFC in schizophrenia (Akbarian et al., 1995b; Thune et al., 
2001), a more plausible hypothesis is that most GABA neurons in schizophrenia 
express normal levels of GAD67 mRNA, and a subset express the transcript at levels 
below detectability.  
Although the decrement in GAD67 mRNA is one of the best-replicated findings in 
postmortem schizophrenia research, small sample sizes and often overlapping subject 
cohorts (in which different studies utilize a portion of the same subjects) point to the 
need for a large-scale study. Additionally, across the literature, substantial 
heterogeneity in levels of GAD67 are present within a cohort: most subjects with 
schizophrenia have lower GAD67 mRNA levels, but some subjects exhibit normal or 
even increased levels (Volk et al., 2000; Hashimoto et al., 2005; Hashimoto et al., 
2008b). Just how common the GAD67 mRNA deficit is, as well as the factors that may 
be associated with the heterogeneity, is unknown. For example, although lower GAD67 
is thought to underlie the cognitive deficits of the illness (Lewis et al., 2005), which are 
known to be the best predictors of functional outcome (Green et al., 2000; see 1.1.4), 
the relationship between GAD67 mRNA levels and indices of functional outcome has 
not yet been examined. Furthermore, since GAD67 expression is activity-dependent 
(Benson et al., 1994), lower expression might just index the less stimulating social, 
occupational and intellectual environment associated with illness chronicity. Therefore, 
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further research is needed to address the heterogeneity of the deficit and examine the 
relationship between GAD67 mRNA, functional outcome, and length of illness.  
Furthermore, despite the widely-replicated mRNA finding, GAD67 protein levels 
in the DLPFC have only been measured in a few studies, with both decreased (Guidotti 
et al., 2000) and unchanged (Dracheva et al., 2004; Straub et al., 2007) levels reported. 
Knowledge of protein levels is of particular importance given that mRNA and protein 
levels are not necessarily correlated, since a number of factors regulate transcription 
and translation (Nelson and Keller, 2007). For example, pharmacological manipulation 
of GABA levels is associated with changes in GAD67 protein but not mRNA (Rimvall et 
al., 1993). Additionally, GAD67 protein levels at the axon terminal, the principal site of 
GABA production and function, are unknown. Thus, studies are needed to establish 
GAD67 protein levels in schizophrenia.  
In contrast to the reductions in GAD67, the mRNA and protein levels of the 65 
kDa isoform of GAD (GAD65), the other enzyme responsible for GABA synthesis, are 
reportedly unaltered (Guidotti et al., 2000; Hashimoto et al., 2008a) or only slightly 
reduced (Hashimoto et al., 2008b) in the DLPFC in schizophrenia. The density of 
GAD65-immunoreactive (-IR) terminals is also unchanged (Benes et al., 2000). Thus, 
schizophrenia is characterized by a selective deficit in GAD67, but not GAD65, in the 
DLPFC.  
The two GAD enzymes decarboxylate glutamate to form GABA and, together, 
GAD65 and GAD67 account for virtually all GABA synthesis in the cortex, although they 
each appear to have distinct roles. They are encoded by separate genes on different 
chromosomes (Erlander et al., 1991), subject to different post-translational modifications 
(Christgau et al., 1992), and have distinct intracellular distributions, although most 
GABA neurons appear to contain both isoforms (Hendrickson et al., 1994; Esclapez et 
al., 1994). GAD65 is primarily located at axon terminals, while GAD67 appears to be 
distributed throughout the neuron (Kaufman et al., 1991; Esclapez et al., 1994). Both 
GAD65 and GAD67 are subject to regulation by the cofactor pyridoxal 5’-phosphate, 
which activates and inactivates the enzyme when it is bound and released, respectively. 
GAD65 exists largely in the inactive form, with low levels of cofactor binding, and is 
highly regulated, while most GAD67 is saturated with cofactor and therefore in the 
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active form (Kaufman et al., 1991). Unlike GAD65, GAD67 is thought to be responsible 
for the majority of GABA synthesis in the cortex (Battaglioli et al., 2003; Mason et al., 
2001). Elimination of the GAD65 gene in mice does not change levels of GABA in the 
cortex (Asada et al., 1996), while reducing GAD67 results in reduced GAD activity and 
GABA content (Asada et al., 1997). GAD65, on the other hand, seems to be mainly 
active during conditions of high synaptic demand (Battaglioli et al., 2003; Patel et al., 
2006). Finally, GAD67 seems to be more sensitive to perturbation of the GABA system 
than GAD65 (Soghomonian and Martin, 1998), which is consistent with the selective 
reduction of GAD67 but not GAD65 in schizophrenia. Therefore, the reductions in 
GAD67 that are observed in the DLPFC of subjects with schizophrenia are thought to 
result in a reduction of cortical GABA levels that significantly impairs synaptic 
transmission and inhibition of their postsynaptic targets. 
1.3.2 Deficits in other aspects of GABA neurotransmission are also present in 
schizophrenia 
Findings suggest that deficits in GABA reuptake are also present in the DLPFC of 
subjects with schizophrenia. Expression of the mRNA for the GABA membrane 
transporter 1 (GAT1), which removes GABA that has been released into the synapse, is 
decreased in the DLPFC of schizophrenia subjects (Ohnuma et al., 1999; Hashimoto et 
al., 2008a; Hashimoto et al., 2008b). There is also a lower density of GAT1 mRNA+ 
neurons (Volk et al., 2001). The deficits in GAD67 and GAT1 may be occurring in the 
same cells, since, in the same cohort of subjects, the pairwise differences in GAD67 
and GAT1 mRNA+ neuron density were similar in laminar pattern and significantly 
correlated (Volk et al., 2001). Lower density of GAT1-IR structures (Woo et al., 1998; 
Pierri et al., 1999) and reduced GAT1 binding (Schleimer et al., 2004) has also been 
reported. These findings suggest that, in schizophrenia, there is a reduction in both the 
synthesis and reuptake of cortical GABA in a subpopulation of interneurons.  
Alterations in postsynaptic ionotropic GABAA receptors are also present in 
schizophrenia. The GABAA receptor is composed of 5 subunits that form a central ion 
pore, with the most common composition being two α, two β, and one γ subunit (Tretter 
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et al., 1997). Activation of these receptors results in an increased chloride conductance, 
inward chloride ion flow, and hyperpolarizing IPSPs. Lower mRNA levels of α1 
(Akbarian et al., 1995a; Hashimoto et al., 2008b; Hashimoto et al., 2008a; Beneyto and 
Lewis, 2010; but see Duncan et al., 2010), β2 (Beneyto et al., 2011), and γ2 (Akbarian 
et al., 1995a; Hashimoto et al., 2008a) subunits, which coassemble together in more 
than 60% of GABAA receptors in the cortex (Möhler, 2006), have been reported in the 
DLPFC. The lower α1 mRNA levels are present on pyramidal neurons but not 
interneurons (Glausier and Lewis, 2011). Other GABAA receptor subunits are also 
altered in schizophrenia; α2 mRNA levels are higher (Beneyto et al., 2011), while mRNA 
levels of α5 (Duncan et al., 2010; Beneyto et al., 2011) and δ (Hashimoto et al., 2008b; 
Maldonado-Avilés et al., 2009) are lower. 
Thus, schizophrenia is thought to be characterized by alterations in both pre- and 
postsynaptic functioning of GABA neurons in the DLPFC. Markers of GABA synthesis 
and reuptake are lower, while levels of different GABAA receptor subunits are either 
increased or decreased. Taken together, these data point to altered GABA 
neurotransmission and subsequent impaired inhibition of postsynaptic pyramidal 
neurons. 
1.3.3 Parvalbumin neurons are particularly affected in schizophrenia 
GABA neurons in the primate DLPFC can be divided into distinct subclasses based on 
their electrophysiological, molecular, and anatomical properties (reviewed in Gonzalez-
Burgos and Lewis, 2008; Conde et al., 1994; Gabbott and Bacon, 1996; DeFelipe, 
1997; Kawaguchi and Kubota, 1993; Krimer et al., 2005; Zaitsev et al., 2005). 
Electrophysiologically, interneurons can be divided into fast-spiking (FS) and non-fast 
spiking (non-FS) categories, based on membrane potential changes in response to 
current injection. FS cells contain the Ca2+ binding protein PV, do not contain any 
neuropeptides, and target the soma, proximal dendrites, and axon initial segment of 
pyramidal cells (hereafter referred to as PV cells). Non-FS cells are more 
heterogeneous and are made up of several different subpopulations. One subpopulation 
expresses the Ca2+ binding protein calbindin and the neuropeptide somatostatin (SST), 
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and targets the distal dendrites of pyramidal cells. Another subtype contains the Ca2+ 
binding protein calretinin (CR) and the neuropeptide vasoactive intestinal peptide (VIP), 
and mainly targets other interneurons. A third group does not express any Ca2+ binding 
proteins, contains the neuropeptide cholecystokinin (CCK) and the cannabinoid 1 
receptor (CB1), and synapses onto the perisomatic region of pyramidal cells. Given the 
different electrical, molecular, and anatomical properties of the different subtypes of 
interneurons, the functional outcome of impaired GABA neurotransmission in 
schizophrenia depends on the subpopulation(s) of neurons affected. 
PV neurons comprise ~25% of primate DLPFC GABA neurons (Conde et al., 
1994) and can be divided into two main classes: 1) basket cells (PVb) that target the 
soma and proximal dendrites of pyramidal cells and 2) chandelier cells (PVch) that target 
axon initial segments (AIS), forming distinct vertical arrays termed cartridges (Lewis and 
Lund, 1990). Axons of PVb neurons have a much larger spread than those of PVch cells, 
and are much more numerous (Zaitsev et al., 2005). These two classes of PV cells also 
differ in the postsynaptic GABAA receptor subunits that predominate at their synapses: 
PVch synapses preferentially express α2-containing GABAA receptors, while PVb 
synapses predominately contain α1 receptors (Nusser et al., 1996).  
 PV cells are one subtype of GABA interneuron that contain lower GAD67 mRNA 
in schizophrenia. In the DLPFC of subjects with schizophrenia, dual label ISH has 
shown that approximately 50% of PV mRNA+ neurons lack detectable levels of GAD67 
(Hashimoto et al., 2003). The expression of PV mRNA is significantly decreased 
(Hashimoto et al., 2003; Hashimoto et al., 2008b; Mellios et al., 2009), and laminar 
analyses have revealed that this reduction occurs in layers 3 and 4 (Hashimoto et al., 
2003; Hashimoto et al., 2008b), layers in which GAD67 mRNA is also lower in 
schizophrenia. However, in contrast to GAD67 mRNA, although the expression of PV 
mRNA per neuron is decreased, neither the density of neurons with detectable PV 
mRNA levels (Hashimoto et al., 2003), nor the density of PV-IR neurons (Woo et al., 
1997; Beasley et al., 2002) is changed. Furthermore, the within-pair PV mRNA 
expression per neuron is significantly correlated with change in density of GAD67 
mRNA+ neurons (Hashimoto et al., 2003). These data suggest that PV neurons are not 
lost, but that GAD67 mRNA expression is reduced in PV-expressing neurons with lower, 
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although still detectable, levels of PV mRNA. Evidence suggests that both PVch and PVb 
cells may contain less GAD67 mRNA. The density of PVch cartridges that are 
immunoreactive for GAT1 is 40% lower in schizophrenia, although the density of other 
GAT1-IR structures is unaltered (Woo et al., 1998). Given that the changes in GAD67 
and GAT1 seem to be present in the same neurons (Volk et al., 2001), this suggests 
that PVch cells exhibit lower GAD67. Moreover, the number of GABAA α2-containing AIS 
is increased in the DLPFC, which has been interpreted as a compensatory response to 
lower GABA signaling in PVch cells (Volk et al., 2002). Additionally, the density of PV-IR 
puncta, possibly the axon terminals of PVb cells, is 24% lower in the middle layers of the 
cortex (Lewis et al., 2001), suggesting that PVb cells may also exhibit a GAD67 deficit. 
Thus, alterations in a variety of markers of GABA neurotransmission are present in 
DLPFC of subjects with schizophrenia (Figure 2). 
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Figure 2. Schematic of alterations in GABA neurotransmission markers in the 
DLPFC of subjects with schizophrenia. Basket cells (PVb) contact the soma and 
proximal dendrites of pyramidal cells (P), which contain lower levels of GABAA α1 
mRNA. Chandelier cells (PVch) synapse exclusively onto the pyramidal cell AIS, which 
contains increased GABAA α2 and decreased GAT1 immunoreactivity. Both types of PV 
cells are thought to contain less GAD67 and PV. 
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Abnormalities in PV neurons alone may not account for the reductions in GAD67 
mRNA. In addition to the observed reductions in layers 3-4 in the DLPFC, lower levels 
of GAD67 mRNA have also been observed in layers 1, 2, and 5, where relatively few 
PV-expressing GABA neurons are located and where PV mRNA expression is 
unaltered (Hashimoto et al., 2003). This suggests that other subsets of interneurons 
residing outside layers 3 and 4 may also exhibit reductions in GAD67. One candidate 
population is those neurons expressing CCK and CB1. Lower levels of CCK mRNA 
(Hashimoto et al., 2008a) and CB1 mRNA and protein (Eggan et al., 2008; Hashimoto 
et al., 2008a) have been found in the DLPFC of subjects with schizophrenia, and 
changes in GAD67, CCK, and CB1 mRNA are significantly correlated in the same 
subject pairs (Eggan et al., 2008). A third population of interneurons thought to be 
affected in the illness is those expressing SST. SST mRNA is reduced in the DLPFC of 
subjects with schizophrenia (Hashimoto et al., 2008a; Morris et al., 2008; Hashimoto et 
al., 2008b), and the reductions are significantly correlated with the deficit observed in 
GAD67 mRNA in the same subject cohort. In contrast, the 50% of cortical interneurons 
that express CR (Conde et al., 1994) do not seem to be affected in schizophrenia, as 
there are no changes in CR mRNA, -IR neurons, or –IR axon terminals in schizophrenia 
subjects relative to comparison subjects (Hashimoto et al., 2003; Hashimoto et al., 
2008b; Woo et al., 1997; Cotter et al., 2002). 
1.3.4 Lower PV and GAT1 in schizophrenia: compensation for lower GAD67 in 
PV interneurons? 
Reductions in PV in the DLPFC of subjects with schizophrenia may represent a 
compensatory response to a deficit in GAD67 (Lewis et al., 2005). Neurotransmitter is 
released from vesicles at chemical synapses following an influx of Ca2+ ions into the 
nerve terminal through voltage-gated Ca2+ channels. PV, a member of the E-F hand 
family of Ca2+ binding proteins, is a slow Ca2+ buffer that increases the rate at which 
residual Ca2+ transients are decayed in GABA nerve terminals after neurotransmitter 
release (Collin et al., 2005; Muller et al., 2007). Therefore, during repetitive firing, 
reduced PV levels should result in increased GABA release (Figure 3), and, in fact, PV-
  22 
deficient mice do exhibit enhanced facilitation of GABA release and increased IPSP 
amplitude from fast-spiking neurons (Collin et al., 2005; Vreugdenhil et al., 2003). 
 
 
 
Figure 3. Effect of lower PV on GABA release and postsynaptic functioning. In the 
presence of normal PV levels (left), Ca2+ released following repetitive firing is 
sequestered, leading to lower levels available to stimulate GABA release, and 
producing a normal inhibitory postsynaptic current (IPSC) amplitude. In the presence of 
reduced PV levels (right), more Ca2+ is available to promote GABA release, resulting in 
increased GABA release and a larger IPSC amplitude. 
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Reductions in GAT1 in the DLPFC of subjects with schizophrenia are also 
thought to be a compensation for reduced GAD67 (Lewis et al., 2005). GAT1 is one of 
four high-affinity Na+/Cl- transporters that take up extracellular GABA, and is the most 
abundant GABA transporter in the cortex. It is expressed on the plasma membranes of 
primarily neurons but also some astrocytes (Conti et al., 1998; Minelli et al., 1995). The 
majority of GAT1 protein is localized to interneuron axon terminals that contact 
pyramidal cells, though it is also observed in terminals that contact other interneurons 
(Minelli et al., 1995; Conti et al., 1998). Consistent with a role for GAT1 in removing 
GABA from synapses, 3[GABA] uptake is virtually absent in the hippocampus of GAT1 
knockout (KO) mice (Jensen et al., 2003). Additionally, tonic GABAA receptor-mediated 
current is increased substantially in the hippocampus after treatment with a GAT1 
inhibitor (Nusser and Mody, 2002), and in GAT1 KO mice (Jensen et al., 2003). When 
nearby synapses are activated synchronously, blockade of GAT1 results in longer 
evoked IPSCs (Overstreet and Westbrook, 2003) (Figure 4), which suggests that a 
reduction in GAT1 in schizophrenia would maximize the effect of the existing, 
presumably lower, GABA levels. 
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Figure 4. Effect of lower GAT1 on GABA release and postsynaptic functioning. In 
the presence of normal GAT1 levels (left), some of the GABA released into the synaptic 
cleft is removed via GAT1, producing a normal IPSC duration. In the presence of 
reduced GAT1 levels (right), GABA remains in the synaptic cleft for longer, prolonging 
the postsynaptic IPSC. 
 
 
 
Importantly, given that schizophrenia is characterized by deficits in DLPFC 
function and cognitive control, the hypothesized compensations of PV and GAT1 are 
presumably insufficient to completely counteract lower GAD67 and restore GABA 
signaling to normal levels. Thus, GABA levels are still lower than in healthy individuals, 
and functional impairments remain. 
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1.3.5 Alterations in GABA neurons are specific to the disease process of 
schizophrenia 
An important consideration is whether the alterations in markers of GABA 
neurotransmission described above are specific to the disease process of 
schizophrenia, or may be a consequence of having, or being treated for, the illness 
(Lewis et al., 2005). First, due to the large proportion of patients receiving 
antipsychotics, as well as antidepressants, benzodiazepines, and valproic acid due to 
the presence of comorbid depression and anxiety (reviewed in Green et al., 2003), the 
effects of these medications on markers of GABA neurotransmission need to be 
evaluated. Indeed, studies have demonstrated that monkeys treated with clinically-
relevant doses of antipsychotic medications do not have lower levels of GAD67 (Volk et 
al., 2000), PV (Hashimoto et al., 2003), and GAT1 (Volk et al., 2001) mRNAs. In 
addition, no effect of benzodiazepines or valproic acid was observed in any of these 
transcripts (Hashimoto et al., 2008b). Second, although schizophrenia patients 
experience prevalent comorbid substance abuse (Green et al., 2003), alcohol use does 
not seem to affect GAD67, PV, and GAT1 mRNA levels (Volk et al., 2000; Volk et al., 
2001; Hashimoto et al., 2003; Hashimoto et al., 2008b), although the effect of nicotine 
and cannabis use have not yet been examined. However, one limitation of the analyses 
that have been performed to date is that small sample sizes that have resulted from 
parsing the cohorts into smaller groups to examine these potentially confounding 
variables. Thus, a large study is needed to confirm these findings.  
1.4 GOALS AND RELEVANCE OF THIS DISSERTATION 
Although many studies have replicated lower mean GAD67 mRNA in the DLPFC of 
subjects with schizophrenia, several aspects of this deficit are currently unknown, and a 
number of important questions remain unanswered. First, given the substantial 
heterogeneity in GAD67 mRNA levels across subjects with schizophrenia, just how 
common is a GAD67 mRNA deficit?  Second, what sources may contribute to the 
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heterogeneity in GAD67 mRNA levels? For example, such variability may result from 
potential confounds such as medication use, substance abuse, or illness chronicity. 
Alternatively, since lower GAD67 is thought to underlie the cognitive deficits of the 
illness (Lewis et al., 2005), which are known to be the best predictors of functional 
outcome (Green et al., 2000), there may be a relationship between GAD67 mRNA 
levels and indices of illness severity and functional outcome. Third, since mRNA levels 
are not necessarily predictive protein levels, does the mRNA deficit extend to the 
protein level? Fourth, if there is a protein deficit, does it occur specifically in PV neurons 
like the mRNA deficit? Fifth, what are the levels of GAD67 protein at the principal site of 
GABA production and function, the axon terminal? Finally, what are the consequences 
of a reduction of GAD67 in PV cells? Accordingly, this dissertation measured GAD67 
mRNA, tissue-level protein, and axon terminal protein in PV cells, and examined the 
consequences of lower GAD67 protein in PV neurons. These data provide an extensive 
characterization of the GAD67 deficit in the DLPFC of subjects with schizophrenia, and 
provide novel evidence of a functional impairment in PV neurons that is thought to 
underlie cognitive impairments. 
Since the measurement of protein levels in schizophrenia was associated with 
significant challenges, Chapter 2 describes these difficulties and the strategies used to 
overcome them. The following two experimental sections (Chapters 3 and 4) address 
the questions raised above. Chapter 5 concludes with a discussion and interpretation of 
the data. 
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2.0  STRATEGIES TO OVERCOME THE METHODOLOGICAL CHALLENGES OF 
ASSESSING PROTEIN LEVELS IN POSTMORTEM HUMAN TISSUE 
2.1 ABSTRACT 
In this dissertation, using gray matter from dorsolateral prefrontal cortex (DLPFC) area 9 
in schizophrenia subjects, we measured 1) total GAD67 protein using Western blotting 
and 2) GAD67 protein levels in PV axon terminals using immunofluorescence. However, 
the assessment of protein levels in postmortem human tissue is challenging for a 
number of reasons. This chapter outlines these challenges and discusses the strategies 
used to overcome them. Since protein measures are confounded by postmortem 
interval (PMI), prior to assessing total GAD67 protein levels in schizophrenia we 
measured the effect of PMI on GAD67 protein in order to select a cohort of subjects with 
minimal GAD67 degradation. Additionally, due to substantial Western blotting variability, 
we utilized a study design that minimized and controlled for such variability, selected a 
stable normalizer, and determined an appropriate protein load that would ensure 
accurate quantification. In order to accurately assess the low GAD67 axon terminal 
protein levels predicted in schizophrenia, we characterized the sensitivity of our 
confocal system, developed an approach to apply stereology, and adapted a recently-
developed threshold/morphological segmentation and data analysis approach to 
postmortem human tissue. Additionally, we developed a novel approach to eliminate the 
autofluorescence of lipofuscin, an intracellular protein that confounds fluorescent 
intensity measures. The data resulting from these approaches are presented in Chapter 
3. 
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2.2 INTRODUCTION 
Expression of mRNA is not necessarily predictive of protein levels (Tian et al., 2004), 
and it is the protein product of a gene that ultimately carries out its function. Thus, the 
examination of protein levels in schizophrenia provides an important complement to 
mRNA studies. In this dissertation two measures of GAD67 protein in DLPFC area 9 
gray matter in postmortem human tissue were made: 1) total protein by Western blot 
and 2) axon terminal protein within PV neurons by immunfluorescence. Prior to these 
assessments, several methodological hurdles first needed to be overcome. Here, these 
challenges are outlined and the strategies we utilized to surmount them are presented. 
The development and implication of these strategies formed a significant portion of this 
dissertation, and thus they are highlighted here. The resulting data produced using 
these methodologies are presented in Chapter 3. 
2.3 ASSESSMENT OF TOTAL GAD67 PROTEIN LEVELS USING WESTERN 
BLOTTING 
2.3.1 Challenges 
Measurement of total protein levels in postmortem human tissue using Western blotting 
is associated with two major challenges. First, protein measures are subject to several 
confounds. Most problematic is postmortem interval (PMI; 2.3.2), the time between 
death and processing of the tissue, which can have variable effects on different proteins 
(reviewed in Lewis, 2002). For example, PMI effects can differ substantially between 
members of the same family of proteins (Hayes et al., 1991), and between brain regions 
(Irving et al., 1997). Therefore, we first assessed the effect of PMI on GAD67 protein in 
DLPFC tissue prior to examining GAD67 protein in schizophrenia, in order to select a 
cohort of subjects with PMIs associated with minimal GAD67 degradation. A second 
major challenge we faced, to our surprise, was that Western blotting of postmortem 
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human tissue was associated with substantial variability, particularly across gels. 
Reliable quantification of human postmortem Western blotting data requires a strategy 
to minimize the effects of this variation. Accordingly, we employed a study design that 
was able to restrict, and control for, such variation (2.3.3). Third, the use of a normalizer 
protein in Western blotting is important to control for differences in the amount of protein 
loaded between wells; however, this normalizer must not only be stable across multiple 
experiments and subjects, but also unaltered in schizophrenia. Therefore, we performed 
a comparison of two commonly used normalizers (2.3.4). Fourth, the amount of protein 
loaded per well needs to be within the range of linearity and proportionality of the 
antibodies utilized in order to ensure accurate quantification. Accordingly, we 
characterized both antibodies utilized in order to determine an appropriate protein load 
(2.3.5). 
2.3.2 Effect of postmortem interval on GAD67 protein levels 
To assess the effects of PMI on GAD67 protein levels, we used tissue samples from 6 
male, white healthy subjects, aged 53-55 years. Subjects were divided into 2 triads, 
each containing a subject with a short, medium, and long PMI (Triad 1 PMIs: 8.0, 15.5, 
and 23.2 hrs; Triad 2 PMIs: 6.4, 15.4, and 28.0 hrs). Members of a triad were processed 
together throughout all steps. Tissue collection, tissue preparation, and Western blotting 
was performed as described in Appendix A. Mean (standard deviation; SD) tubulin-
corrected (see 2.3.4 for selection of normalizer) GAD67 optical densities (ODs) for the 
short, medium, and long PMIs were 0.49 (0.12), 0.43 (0.10), and 0.40 (0.10), 
respectively. GAD67 protein levels were reasonably well-preserved across PMI, with 88 
and 82% of the level present in the short PMI group (7.2 hrs) still present at 16 and 26 
hrs, respectively. 
 In order to verify and extend the human findings, we performed a similar 
analysis in DLPFC tissue from an adult male macaque monkey in which in vivo levels 
(i.e., PMI of 0 hr) could be obtained. Monkey DLPFC tissue was collected as described 
previously (Hayes et al., 1991). Briefly, the animal was sedated with ketamine 
hydrochloride, intubated, anesthetized with 1% halothane in 28% oxygen, and placed in 
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a stereotaxic apparatus. The skull was opened and biopsy blocks were removed from 
the PFC. A single block containing the DLPFC was frozen immediately in isopentane (0 
hr PMI), and 3 others were stored in room temperature artificial cerebrospinal fluid for 6, 
12, or 24 hrs and then frozen (6, 12, and 24 hr PMI). Tissue sections were collected 
from the blocks on a cryostat, protein was extracted, and samples prepared for Western 
blotting as described in Appendix A. 
Mean (SD) tubulin-corrected GAD67 ODs for the 0, 6, 12, and 24 hr PMIs were 
0.39 (0.05), 0.30 (0.04), 0.27 (0.04), and 0.30 (0.05), respectively. GAD67 protein levels 
in monkey DLPFC were relatively well-preserved across all PMIs with 78, 69, and 76% 
of the baseline GAD67 level retained at the 6, 12, and 24 hr time points, respectively. 
However, the greater loss of GAD67 protein across PMI in the monkey (in which 
comparison was made to a true 0 hr PMI) relative to the human indicates that the real 
effect of PMI on GAD67 protein in human tissue may be slightly larger than what was 
observed. Consequently, we used a more stringent cut off than 24 hours, and selected 
pairs of schizophrenia and comparison subjects with PMIs<20 hrs for subsequent 
GAD67 protein quantification. 
2.3.3 Minimizing sources of variability with experimental design 
We found that Western blotting of human postmortem tissue is associated with 
substantial variability, especially across gels. In order to make quantitative measures, 
an appropriate gel loading design is needed to minimize, and account for, this 
variability. Since we observed the greatest variability in signal at the edges of a gel 
(lanes 1, 2, 11, and 12 of a 12-well gel), we utilized only the middle 8 lanes for 
quantification. Additionally, we made a total of 16 replicate measures for each subject 
pair using 4 gels, on which the subject pair was loaded 4 times (Figure 5). This 
approach maximized the number of replicates of a single pair per gel, thereby 
minimizing within-gel variability. In addition, replicate gels were processed within the 
same experimental run to further reduce variability. Since all data for a given subject 
pair were collected in the same run, and all measures per subject were averaged 
together, the within-pair comparison controlled for the remaining variability. 
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Figure 5. Gel loading design. A single pair of subjects was loaded per gel. Four 
identical gels were loaded per pair and run simultaneously, for a total of 16 replicates 
per subject. The molecular weight marker was loaded in the far left lane. Xs mark lanes 
that were not used for quantification. 
 
 
2.3.4 Selection of normalizer protein 
To maximize our ability to account for potential differences in the amount of protein 
loaded per well, we measured the levels of two commonly used normalizers, β-actin and 
β-tubulin. Mean values for both proteins did not differ between the schizophrenia and 
comparison subjects (n=15 pairs), but the coefficient of variation (CV) of the within-pair 
difference was 3 times greater for β-actin (0.104) than for β-tubulin (0.036). Therefore, 
we corrected each GAD67 OD measure by the β-tubulin OD measure from the same 
lane. 
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2.3.5 Selection of protein load 
To determine an appropriate protein load, we assessed the linearity and proportionality 
of the GAD67 and β-tubulin antibodies as a function of total protein loads of 10, 20, 30, 
and 40 µg (Figure 6). Assessing the linearity of the antibodies is possible due to the use 
of linear detectors in the LI-COR system. GAD67 and β-tubulin OD increased in a highly 
linear (r=0.99, p=0.001; r=0.99, p=0.026, respectively) and proportional fashion as 
protein load increased from 10-40 and 20-40 µg, respectively. Accordingly, we loaded 
each lane with 25 µg of total protein, which is within the range of linearity and 
proportionality of both antibodies. 
 
 
 
 
Figure 6. GAD67 (1:800) and tubulin (1:20,000) OD increase in a linear and 
proportional fashion as protein load increases between 20 and 40 µg. The gel 
images and plots show an increase in GAD67 (left) and tubulin (right) OD with 
increasing protein load. OD and µg protein are significantly correlated from 10-40 µg 
(r=0.99, p=0.001) and 20-40 µg (r=0.99, p=0.026) for GAD67 and tubulin, respectively. 
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Abbreviations: OD, optical density. Note that despite their appearance, none of the 
bands of the tubulin blot are saturated. 
 
2.4 ASSESSMENT OF GAD67 PROTEIN LEVELS IN PV AXON TERMINALS 
USING IMMUNOFLUORESCENCE, CONFOCAL MICROSCOPY, AND ITERATIVE 
THRESHOLD/MORPHOLOGICAL SEGMENTATION 
2.4.1 Challenges 
The majority of research on markers of GABA neurotransmission in schizophrenia has 
focused on whole cell studies that examine mRNA expression and protein levels 
(Hashimoto et al., 2005; Guidotti et al., 2000), without looking specifically at the major 
site of function of these proteins, the axon terminal. In order to comprehensively 
evaluate effectors of GABA neurotransmission in schizophrenia, the axon terminal must 
be examined. Multilabel fluorescence confocal microscopy provides a means to assess 
relative levels of fluorescence per axon terminal, and by looking at several proteins 
simultaneously, it is possible to examine cell-type specificity of GAD67 alterations, 
which thus far has only been assessed in schizophrenia in one mRNA study (Hashimoto 
et al., 2003). However, quantifying protein levels in axon terminals in postmortem 
human brain tissue is challenging for four main reasons. First, postmortem tissue, 
especially that from a disease state such as schizophrenia, is associated with widely 
varying fluorescence levels. Thus, it is important to utilize a microscopy system with 
adequate sensitivity to detect very low levels of fluorescence, and we therefore 
characterized the sensitivity of our confocal system (2.4.2.1). Second, because our 
confocal microscope was not equipped with stereological software, we generated a 
method to perform unbiased stereological imaging site selection (2.4.2.2). Third, in 
order to assess cell-type specificity, we adapted a recently-developed fluorescence 
intensity/morphological segmentation (2.4.2.3) and data analysis (2.4.3.4) approach for 
use in human tissue in order to quantify GAD67 protein levels specifically in PV 
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terminals. A fourth challenge associated with the measurement of axon terminal protein 
levels in postmortem human tissue is noise induced by the broad autofluorescence of 
lipofuscin, an intracellular lysosomal protein that accumulates with age in human cortex 
(Brody, 1960). Due to this autofluorescence, it has been extremely difficult, if not 
impossible, to differentiate “real” signal of the fluorophores of interest from lipofusin 
signal. To overcome this problem, we developed an approach to eliminate the lipofuscin 
signal (2.4.3). 
2.4.2 Quantification of axon terminal protein levels 
2.4.2.1 Sensitivity of the microscopy system 
A major challenge in the assessment of axon terminal protein levels in postmortem 
tissue is the need to quantify a large range of fluorescence levels. For example, in 
monkey DLPFC tissue, GAD67 protein levels exhibit a wide range of intensities (Fish et 
al., 2011). Furthermore, in schizophrenia tissue, where GAD67 mRNA levels in a 
population of PV neurons fell below detectability using dual ISH, protein levels are 
predicted to be especially low (Hashimoto et al., 2003). Thus, a microscopy system with 
a high degree of sensitivity is needed. After processing human DLPFC tissue sections 
for fluorescence immunocytochemical labeling of inhibitory axon terminal markers 
(GAD65, GAD67, and PV) (Appendix A), images were collected using an Olympus 
spinning disk confocal system (Center Valley, PA) using a 60X 1.42 N.A. oil immersion 
objective and a Hamamatsu C9100 Electron Multiplier Charge Coupled Device camera 
(Bridgewater, NJ). Using this system, when imaging fluorescence microspheres (beads) 
of varying relative intensities, we were able to successfully identify fluorescence 
intensity as low as 1.1X background. Additionally, with this system fluorescence 
intensity is highly linear as a function of both bead intensity and exposure time (Figure 
7), which allows for the accurate quantification of relative fluorescence levels over the 
dynamic range of the system. Accordingly, puncta with average fluorescence intensities 
barely over background and those with extremely high levels of fluorescence are 
identified equally well. Importantly, given that we hypothesize that schizophrenia 
subjects exhibit lower levels of GAD67 protein relative to comparison subjects, these 
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data suggest that this system is able to identify puncta with extremely low levels of 
protein. 
 
 
 
 
Figure 7. Fluorescence intensity is linear as a function of fluorescent microsphere 
intensity (A) and exposure time (B). A: The high degree of linearity of fluorescence 
intensity across microspheres (beads) of varying intensity at the same exposure 
demonstrates the ability of our system to function within a wide range of axon terminal 
intensities. B: The high degree of linearity of fluorescence intensity across exposure 
times allows each image to be captured at optimal exposures for that site. Corrections 
for differences in exposure times can then be made during analysis.  
 
 
2.4.2.2 Sampling strategy 
Due to the lack of stereological capabilities on the confocal system, we developed an 
alternative approach to sample the tissue in an unbiased, stereological fashion. First, 
the pia and white matter borders were traced on a separate microscope equipped with 
Stereoinvestigator software (MicroBrightField, Williston, VT). A region of interest 
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containing layers 3-4 (defined as 30-60% of the pia to WM distance) was identified in 
the largest continuous region with parallel pial and white matter borders. Next, the 
contours were printed onto a transparency, aligned with the tissue section using a 4X 
objective, and affixed to the top of each slide. Using the transparency, the microscope 
was driven to the center of the region of interest and a program written in Microsoft 
Excel was used to designate all possible sampling sites based on a randomly oriented 
grid. Due to limitations in the Stereoinvestigator software, the region of interest was 
constrained to a rectangular shape. As a result, a randomly oriented grid produced 
widely varying numbers of sampling sites within the region of interest across tissue 
sections. Therefore the maximum number of sites generated by the grid, up to 12, was 
sampled. Preliminary analyses indicated this number was sufficient to adequately 
sample the regions of interest, and after data collection we were able to show that all 
sections were adequately sampled using running means. The microscope was driven to 
the center of each optical dissector, and consecutive 512 x 512 pixel images (0.23 μm 
apart) were collected starting from a position that was 75% the thickness of the tissue 
section from the coverslip and ending at the coverslip (see Appendix A for additional 
details). Images were assembled into 3D sets. 
2.4.2.3 Post-image processing and fluorescence intensity/morphological 
segmentation 
Post-processing and data segmentation were performed using a recently-developed 
methodology that allows for the quantification of fluorescently-labeled puncta, the 
colocalization of different labels in the same puncta, and the quantification of 
fluorescence intensity in these same structures (Fish et al., 2008). Since image stacks 
were taken using optimal capture settings (best image quality/no saturated pixels), the 
mode of the histogram was subtracted from each pixel to control for differences in 
background fluorescence intensity across subjects, sections, and image stacks (Sweet 
et al., 2010). This method is a more unbiased, consistent way of dealing with 
differences in background intensity between subjects, sections, and image stacks than 
selecting regions within each image stack. However, the subtracted value used might 
not fully represent the background level. The fluorescence intensity was corrected 
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based on exposure time (see Figure 7B). In addition, at the time, all available 
objectives were color-corrected only from 450-620 nm. Two of the utilized channels 
were outside this range, resulting in an axial shift that was corrected for using 
TetraSpeck 0.1 µm microspheres (fluorescent blue/green/orange/dark red; Invitrogen). 
Importantly, the step size was chosen based on the need for correction. 
Threshold-based segmentation can be used to identify structures of interest in an 
image, in which a threshold value is applied to the fluorescence intensity histogram of 
the data set. This threshold can either be determined visually (assigning voxels above 
and below the threshold a separate color, e.g., black and blue) or by a thresholding 
algorithm. This creates a virtual layer of data in which all voxels are reassigned a binary 
value according to whether or not they exceed the threshold. The resulting virtual layer 
is referred to as the image mask, composed of individual mask objects (Figure 8). For a 
3D data set, the number of such object masks provides a count of the underlying 
objects within the image stack. For each mask object, data such as mean and total 
fluorescence intensity in each wavelength detected, volume, and center of volume can 
be generated (Sweet et al., 2010).  
 
 
 
 
Figure 8. Illustration of threshold segmentation. A single threshold is applied to the 
image, so that all voxels are reassigned a binary value according to whether they fall 
below (black bars; 1 and 2) or above (blue bars; 3) the threshold. Objects within an 
image (left) are selected according to a threshold value of the fluorescence intensity 
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histogram (middle). All pixels above the threshold value are pseudocolored blue and 
selected for further analyses (right). 
 
 
 
However, because terminal protein levels can vary naturally, with disease, or due 
to postmortem effects in human samples, a single threshold approach is unsuitable to 
mask all of the terminals of interest, and to precisely cover just those terminals that are 
masked, in postmortem schizophrenia tissue. As such, this single-threshold approach is 
not able to adequately measure fluorescence in both low- and high-expressing 
structures, and thus an alternative approach is needed.     
To identify axon terminals, we utilized a recently-developed approach that 
combines information from multiple iterations of the single threshold approach, in which 
the low threshold value progressively migrates toward the high value (Fish et al., 2008). 
This methodology is able to mask puncta with high fluorescence levels equally as well 
as puncta exhibiting low fluorescence levels, and the final mask shapes are highly 
representative of the original data. When compared with other available semi-
automated and automated software packages, this iterative approach was found to 
identify twice as many puncta and produced a much more uniform set of mask objects 
with final 3D ovoid shapes representative of true terminal shape (Fish et al., 2008). 
Because the density of GAD65-IR axon terminals is not altered in schizophrenia 
(Benes et al., 2000), GAD65 immunoreactivity was used to identify IR puncta, putative 
axon terminals. The final processed data set was threshold segmented, masked, and 
objects in the mask were selected by size using a range of 0.06 to 0.7 μm3 (Figure 9). 
This size range was empirically determined and corresponded to previously published 
methods (Fish et al., 2008; Fish et al., 2011). We performed 60 iterations of this 
intensity segmentation/mask/morphological segmentation protocol using different low 
threshold settings that progressively migrated towards the high value, which remained 
fixed. The number of iterations was determined empirically. As observed in Figure 9, as 
the iterations progress, lower intensity mask objects are no longer collected in favor of 
higher intensity objects. However, after the second iteration, the resulting size-gated 
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mask objects were combined with those from the first cycle into a single mask such that 
completely overlapping objects were represented by one mask object. This new mask 
containing the combined mask objects was then combined with those selected in the 
third iteration. This process of combining mask objects into a single mask continued 
throughout all iterations. Thus, early iterations were used to identify lower-intensity 
objects, while later iterations identified high-intensity objects and, due to the combining 
of objects from all iterations, the final mask therefore contained a relatively uniform set 
of object masks that approached the upper size limit of the selection criteria. 
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Figure 9. Illustration of the iterative threshold/morphological segmentation 
approach. Images are generated from a single z-plane. Raw data is shown in 
greyscale, selected data at each step is shown in blue. In the first iteration, a raw image 
(A) is threshold segmented according to the histogram in B, and intensities within the 
yellow highlighted region are selected, generating the blue mask objects in B’. Only 
selected objects are retained after size gating (B’’). The threshold intensity value 
progressively migrates toward the maximum intensity and the threshold/morphological 
segmentation process is repeated in the second (C, C’, C’’) and third (D, D’, D’’) 
iterations. As the iterations advance, the mask objects generated are combined (E and 
E’). After just 3 iterations, the resultant mask objects (E’’) are highly representative of 
the original data. In the final data set (F), generated using 60 iterations, all terminals are 
successfully masked, including those not identified using 3 iterations (designated by the 
arrow in E’ and F). 
 
2.4.2.4 Data Analysis 
After the iterative masking approach, analyses were performed to select only the data of 
interest. In order to eliminate potential confounds due to edge effects and antibody 
penetration, only selected regions of data in the x, y, and z axes were utilized in 
quantification. Additionally, only puncta IR for all 3 markers (GAD65, PV, and GAD67) 
were selected for final analyses. Finally, any masks containing fluorescence resulting 
from lipofuscin were eliminated, as described in 2.4.5. 
Mask objects falling within a 10-pixel border at the extreme x and y edges (pixels 
1-10 and 502-512 in both x and y) of each image were discarded to prevent edge 
effects. Given differences in antibody penetration across the z axis, only a portion of the 
z axis was selected for analysis. The upper and lower ~1 µm of z planes, selected 
based on the maximum observed terminal size, were excluded due to irregularity in the 
surface of the tissue and compression at the slide/coverslip. Fluorescence intensity, and 
thus puncta number, is greatest at the coverslip due to minimal blur (since there is the 
least amount of tissue to image through) and maximal antibody penetration. Therefore, 
the z plane located closest to the coverslip (after exclusion of ~1 µm as described 
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above) was selected as the starting point of the quantified region. Regression analyses 
were performed as planes were progressively added from the starting point to 
determine the largest number of z planes for which the slopes of the mean GAD65 
intensity, CV of mean GAD65 intensity, and number of GAD65 puncta regression lines 
were not statistically significantly different from 0 (all F≤2.884 all p≥0.165) (Figure 10). 
The selected region comprised 8% of the total thickness of the tissue.  
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Figure 10. Determination of region of z axis quantified. Plots of mean intensity (A), 
CV of intensity (B), and number of puncta (C) across the z axis in the GAD65 (568) 
channel. Regression analyses were performed to determine the region of z planes of 
which the slopes of each line were not statistically significant from 0. The shaded boxes 
depict the selected region utilized in quantification. 
 
 
 
Mask operations between channels were used to determine GAD65-IR puncta 
that were also -IR for PV (colocalized), and GAD67 intensity was quantified within 
GAD65+/PV+ terminals (Figure 11). In order to be classified as GAD65+/PV+, 1) a 
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minimum overlap between masks objects needed to be ≥ 4 voxels (the smallest 
allowable puncta size) and 2) the nonoverlapping voxels needed to comprise < 25% of 
the PV mask object volume. This second, more stringent, criterion was used to 
eliminate cases in which the signals were not truly colocalized despite a GAD65 and PV 
signal overlap ≥ 4 voxels. No statistical difference (t4=0.998, p=0.375) between the 
pairwise percent difference in GAD67 protein using criterion 1 compared to both criteria 
was observed. However, it is easy to imagine cases in which the results would 
significantly differ (e.g. in which one terminal type is always next to another type, thus 
producing bleed over). Accordingly, we utilized the more stringent criteria (1 and 2) in 
the final dataset. 
 
 
 
 
Figure 11. Illustration of GAD65 and PV colocalization. Images are generated from a 
single z-plane. The raw image of both GAD65-IR (red) and PV-IR (green) axon 
terminals (A) can be separated into single channels (B and C, respectively). Mask 
objects from GAD65-IR (B’) and PV-IR (C’) structures were generated as described in 
Figure 9. The overlay of GAD65-IR (red) and PV-IR (green) mask objects (D) 
demonstrates the colocalization (yellow) that was used to determine structures that 
contained both GAD65 and PV. 
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2.4.3 Elimination of confounding lipofuscin autofluorescence 
A potential confound of fluorescent intensity measures in human cortex is the broad and 
intense autofluorescence lipofuscin. Lipofuscin is an intracellular lysosomal protein that 
accumulates with age in many brain regions, including the cortex (Porta, 2002; Brody, 
1960), and autofluoresces across the usable spectrum of the microscope (~350-700 
nm) (Gray and Woulfe, 2005). At 5 years of age, lipofuscin is present in less than 5% of 
human cortical neurons, but is found in virtually all neurons by the third decade of life 
(Benavides et al., 2002). The number of lipofuscin granules per cell also increases with 
age, and the rate of lipofuscin accumulation is negatively correlated with longevity 
(reviewed in Brunk and Terman, 2002), earning it the nickname of “aging pigment.” 
Lipofuscin is composed primarily of protein, but also contains about 30% lipid, <10% 
carbohydrate, as well as traces amounts of metals such as iron, copper and zinc 
(Double et al., 2008). One prominent theory is that lipofuscin accumulates as the result 
of oxidative stress. Reactive oxygen species may result in crosslinking of proteins and 
lipids, producing cellular components that are indigestible by lysosomal enzymes (Chio 
et al., 1969; Chio and Tappel, 1969; Brunk and Terman, 2002). Schiff bases, 1,4-
dihydropyridines, and 2-hydroxy-1,2-dihydropyrrol-3-ones are thought to be responsible 
for the autofluorescent properties of lipofuscin. 
As shown in Figure 12, we detected lipofuscin signal in all 3 channels of interest. 
Our masking approach can erroneously identify bright spots of lipofuscin signal as axon 
terminals, and thus lipofuscin represents a significant confound of axon terminal 
fluorescence levels. Accordingly, we developed a novel approach to exclude lipofuscin 
autofluorescence from our analyses, and thus eliminate the potential confounds it 
presents. Lipofuscin was imaged in the 403 nm channel (which does not overlap with 
channels used to image GAD65, GAD67, or PV) and then masked for subsequent 
quantification and exclusion from the GAD67 data (Figure 12). Due to high signal 
intensity, the mask objects used to quantify and subsequently exclude the 403 nm 
signal were dilated by a 1-pixel diameter in 3D to ensure that the entirety of the signal 
was masked. Any GAD67+/GAD65+/PV+ puncta that overlapped with 403 nm masks 
were excluded. In addition, a 403 nm maximum intensity cut off of 200 was applied to 
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the data set to eliminate any lipofuscin that was not masked by our automated 
approach. 
 
 
 
 
 
Figure 12. Illustration of lipofuscin autofluorescence. The arrow in the single z-
plane images shows lipofuscin autofluorescence in the 403 (top left), GAD65 (top 
middle), GAD67 (bottom left), and PV (bottom middle) channels. To exclude lipofuscin 
signal, any GAD65 mask objects that overlapped with 403 nm mask objects 
(arrowheads; top right) were removed from final analyses (bottom right). Scale 
bar=10µm. 
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Consistent with previous studies (Benavides et al., 2002; Brody, 1960), subject 
age was significantly correlated with total lipofuscin volume (r=0.87, p=0.002) (Figure 
13). Additionally, the total volume of masked lipofuscin did not significantly differ 
between comparison and schizophrenia subjects (t4=-1.0, p=0.366), and lipofuscin 
volume per subject was not significantly correlated with GAD67 intensity in PV puncta 
(r=0.17, p=0.641). Importantly, these data demonstrate that our approach successfully 
excluded lipofuscin from our analyses and did not confound measures of GAD67 
intensity. 
 
 
 
 
Figure 13. Lipofuscin volume correlates with subject age. The plot shows the age of 
comparison (square), schizophrenia (circle), and schizoaffective (triangle) subjects 
against the total lipofuscin volume per subject. Subject age is significantly correlated 
with total lipofuscin volume (r=0.87, p=0.002). One outlier subject was excluded. 
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2.5 CONCLUSIONS 
The approaches presented here represent innovative solutions to the challenges 
associated with measurement of protein in postmortem human tissue. The quantitative 
Western blotting strategy provides a robust quantification of total GAD67 protein due to 
the use of only subjects with PMIs in which GAD67 protein is well-preserved, a paired 
study design with multiple replicates, a stable normalizer, and a protein load within the 
range of linearity and proportionality of the antibodies utilized. Immunofluorescence and 
confocal microscopy, coupled with a novel methodology, provides a robust assessment 
of GAD67 protein levels in a specific population of interneurons due to the use of a 
sensitive microscopy system, stereological sampling, an iterative 
threshold/morphological segmentation and data analysis approach that allows for the 
accurate quantification of a wide range of fluorescent intensities, and the elimination of 
the confounding autofluorescence of lipofuscin. Importantly, this marks the first time this 
approach has been utilized in postmortem human tissue. The total GAD67 protein and 
PV axon terminal GAD67 protein levels in schizophrenia resulting from these two 
approaches are presented in Chapter 3. 
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3.0  CORTICAL DEFICITS OF GLUTAMIC ACID DECARBOXYLASE 67 
EXPRESSION IN SCHIZOPHRENIA: CLINICAL, PROTEIN, AND CELL TYPE-
SPECIFIC FEATURES 
Curley AA, Arion D, Volk DW, Asafu-Adjei JK, Sampson AR, Fish KN, Lewis DA (2011) 
Cortical Deficits of Glutamic Acid Decarboxylase 67 Expression in Schizophrenia: Clinical, 
Protein, and Cell Type-Specific Features. Am J Psychiatry, in press. Reprinted with permission 
from the American Journal of Psychiatry (copyright 2011). American Psychiatric Association. 
3.1 ABSTRACT 
Cognitive deficits in schizophrenia are associated with altered activity of the dorsolateral 
prefrontal cortex (DLPFC), which has been attributed to lower expression of the 67 kDa 
isoform of glutamic acid decarboxylase (GAD67), the major GABA-synthesizing 
enzyme. However, little is known about the relationship of prefrontal GAD67 mRNA 
levels and illness severity, translation of the transcript into protein, or protein levels in 
axon terminals, the key site of GABA production and function. Quantitative PCR was 
used to measure GAD67 mRNA levels in the DLPFC from 42 subjects with 
schizophrenia and 42 matched comparison subjects. Western blotting was used to 
quantify tissue levels of GAD67 protein in a subset of subjects where potential 
confounds of protein measures were controlled. Multi-label, confocal 
immunofluorescence was used to quantify GAD67 protein levels in the axon terminals of 
parvalbumin (PV)-containing GABA neurons, known to have low levels of GAD67 
mRNA in schizophrenia. GAD67 mRNA levels were significantly 15% lower in 
schizophrenia subjects, but transcript levels were not associated with predictors or 
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measures of disease severity or chronicity. In schizophrenia subjects, GAD67 protein 
levels were significantly 10% lower in total gray matter and 49% lower in PV axon 
terminals. These findings, that lower GAD67 mRNA expression is common in 
schizophrenia, is not a consequence of having the illness, and leads to less translation 
of the protein, especially in the axon terminals of PV-containing neurons, support the 
hypothesis that lower GABA synthesis in PV neurons contributes to DLPFC dysfunction 
and impaired cognition in schizophrenia. 
3.2 INTRODUCTION 
Impairments in cognition are a core feature of schizophrenia and the best predictor of 
functional outcome (Green, 1996). The cognitive deficits span multiple domains (Keefe 
and Fenton, 2007), suggesting that they reflect an overarching alteration in cognitive 
control, the ability to adjust thoughts or behaviors in order to achieve goals (Lesh et al., 
2011). Cognitive control depends on the coordinated activity of a number of brain 
regions, including the DLPFC, which plays an integral role in the maintenance and 
selection of rules that govern behavioral responses (Miller and Cohen, 2001). Subjects 
with schizophrenia exhibit altered activation of the DLPFC (Minzenberg et al., 2009), 
and DLPFC dysfunction is correlated with cognitive impairment (Weinberger et al., 
1986).  
Frontal lobe γ band (30-80 Hz) oscillations, which appear to underlie higher-order 
cognitive processes (Tallon-Baudry et al., 1998), are positively associated with cognitive 
control processes in comparison subjects, but subjects with schizophrenia fail to exhibit 
the normal task-related increase in γ band power (Cho et al., 2006; Minzenberg et al., 
2010). Oscillations in the γ frequency are known to depend on the firing of GABA 
neurons (Gonzalez-Burgos and Lewis, 2008), and thus alterations in DLPFC GABA 
neurotransmission may contribute to impaired cognition in schizophrenia (Lewis et al., 
2005).  
GABA signaling is regulated by levels of its synthesizing enzyme, GAD. The 67 
kDa isoform, GAD67, is responsible for the majority of GABA synthesis in the cortex 
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(Mason et al., 2001), whereas the 65 kDa isoform, GAD65, contributes to GABA 
synthesis principally during conditions of high synaptic demand (Patel et al., 2006). 
Consistent with this interpretation, reducing GAD67 expression in mice results in lower 
GAD activity and GABA content (Asada et al., 1997), but reducing GAD65 expression 
does not significantly alter cortical GABA levels (Asada et al., 1996). Lower GAD67 
mRNA levels in the DLPFC have been consistently reported in schizophrenia 
(Gonzalez-Burgos et al., 2010). However, the relationship between GAD67 mRNA 
expression and the clinical features of the illness has not been examined in a large 
sample. Furthermore, since GAD67 expression is activity-dependent (Benson et al., 
1994), lower expression might just index the less stimulating social, occupational, and 
intellectual environment associated with illness chronicity. Accordingly, we quantified 
DLPFC GAD67 mRNA levels in 42 subjects with schizophrenia and matched 
comparison subjects, and examined their relationship to predictors of illness severity, 
measures of functional outcome, and duration of illness.  
Although lower GAD67 mRNA levels in the DLPFC are consistently found in 
schizophrenia, how this finding relates to levels of the cognate protein remains unclear 
despite a single prior study reporting lower mean levels of both GAD67 mRNA and 
protein in schizophrenia (Guidotti et al., 2000). This question is of particular importance 
given that mRNA and protein levels are not necessarily correlated, since a number of 
factors regulate transcription and translation (Nelson and Keller, 2007). For example, 
pharmacological manipulation of GABA levels is associated with changes in GAD67 
protein but not mRNA (Rimvall et al., 1993). Furthermore, measures of protein in 
postmortem human tissue are subject to confounds that do not influence transcript 
measures (Beneyto et al., 2009). Thus, we employed a quantitative Western blotting 
strategy that minimized sources of variability to test the hypothesis that cortical GAD67 
protein levels are lower in schizophrenia. 
Understanding the functional significance of altered GAD67 protein levels 
requires knowledge of the affected cell class. In schizophrenia, GAD67 mRNA levels 
are markedly lower only in about 25-35% of interneurons (Akbarian et al., 1995a; Volk 
et al., 2000), including the PV-containing GABA neurons (Hashimoto et al., 2003) that 
are crucial to the generation of γ oscillations (Cardin et al., 2009). Thus, if lower GAD67 
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mRNA and protein levels in PV neurons underlie the impaired γ band oscillations and 
cognitive control deficits in schizophrenia (Gonzalez-Burgos and Lewis, 2008), then 
lower GAD67 protein should be particularly apparent in PV cells at the principal site of 
GABA production and function, the axon terminal. Accordingly, we used quantitative 
fluorescence imaging (Fish et al., 2008) in a proof-of-concept test of the idea that 
GAD67 protein levels are much lower in PV axon terminals than in total cortical gray 
matter. 
3.3 MATERIALS AND METHODS 
3.3.1 Human Subjects 
Brain specimens (n=84) were obtained during autopsies conducted at the Allegheny 
County Medical Examiner’s Office (Pittsburgh, PA) after consent was obtained from the 
next of kin. Consensus DSM IV diagnoses for each subject were made by a committee 
of experienced clinicians on the basis of medical records and the results of structured 
interviews conducted with family members of the deceased (Hashimoto et al., 2008b). 
To reduce biological variance between groups and control for experimental variation, 
each schizophrenia subject was matched with one comparison subject for sex, and as 
closely as possible for age and PMI, and tissue samples from members of a pair were 
always processed together. Comparison subjects had no known history of neurological 
or psychiatric illness. Tissue was collected from Brodmann’s area 9 and samples were 
prepared as described in Appendix A. All procedures were approved by the University 
of Pittsburgh’s Committee for the Oversight of Research Involving the Dead and 
Institutional Review Board for Biomedical Research.  
For quantification of GAD67 mRNA levels in schizophrenia, tissue from all 42 
subject pairs was utilized. For every subject, the RNA integrity number (RIN) was >7, 
which is associated with excellent RNA quality (Imbeaud et al., 2005). Mean age, PMI, 
brain pH, RIN, and tissue storage time were not different for the two subject groups (all 
t82≤2.0, p≥0.051) (Table 1; for individual subject characteristics, see Appendix B). For 
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measures of total GAD67 protein, only the subject pairs (n=19) in which both members 
had PMIs less than 20 hrs (see 3.4.2 for rationale) were used (Table 1). Of these 19 
pairs, 5 pairs were selected for the PV axon terminal study (see 3.4.4 for rationale) 
(Table 1). 
 
 
 
Table 1. Summary of demographic characteristics for each studya 
 qPCR Western blotting Immunofluorescence 
 C S C S C S 
N 42 42 19 19 5 5 
Sex 31M/11F 31M/11F 14M/5F 14M/5F 5M 5M 
Race 34W/8B 29W/13B 14W/5B 14W/5B 5W 5W 
Age (years) 48±13 47±13 44±13 43±11 45±12 47±9 
PMI (hours) 17.8±5.9 18.1±8.7 12.5±4 11.4±5.4 14.3±3.6 12.3±4.7 
Brain pH 6.8±0.2 6.6±0.4 6.8±0.2 6.5±0.3 6.8±0.2 6.5±0.4 
RIN 8.3±0.6 8.2±0.7 8.5±0.6 8.2±0.6 8.6±0.4 8.1±0.6 
ST (months) 97±43 97±46 95±45 99±44 116±16 110±23 
 
aValues are group means±standard deviation. For each study, none of the between-
group comparisons were statistically significantly different, except for pH in the Western 
blotting study (t36=3.0, p=0.005). Abbreviations: C, comparison; S, schizophrenia; PMI, 
postmortem interval; RIN, RNA integrity number; ST, freezer storage time. 
 
 
3.3.2 GAD67 mRNA 
GAD67 mRNA levels were assessed by qPCR using the comparative threshold cycle 
measurement method (Hashimoto et al., 2008b). Four replicate measures were 
performed for each subject with a standard threshold for each transcript consistently 
applied across all subjects. Based on their stable level of expression between 
schizophrenia and comparison subjects (Hashimoto et al., 2008b), 3 reference genes 
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[β-actin, cyclophilin A, and glyceraldehyde-3-phosphate dehydrogenase (GAPDH)] were 
used to normalize GAD67 mRNA levels. 
3.3.3 Total GAD67 protein levels 
Western blotting was performed as described in Appendix A. Bands were measured in 
arbitrary OD units using the Odyssey® Infrared Imaging System software (LI-COR 
Biosciences, Lincoln, NE) by a single investigator (AAC). Red (680 nm) and green (800 
nm) channels were quantified separately. OD was measured by drawing a rectangle 
around each band. The size of the rectangle was adjusted to include the entire band 
without including signal from neighboring bands. Each band was measured 3 times with 
a new rectangle. Background OD was measured according to LI-COR specifications.  
In an effort to reduce, and account for, the within- and between-subject 
measurement variance, replicate measures for each subject pair were made both within 
and across gels. Samples from members of a pair were loaded in adjacent lanes of the 
same gel. Each pair of samples was loaded 4 times on a gel, and 4 replicate gels were 
run per pair and processed simultaneously (i.e. 16 replicate measures). Of the resulting 
608 data points, 28 were dropped before analysis due to obvious gel artifacts, with no 
more than 2 of the 16 measures per subject excluded. 
3.3.4 GAD67 protein levels in PV puncta 
Fluorescence immunohistochemistry was used to label 2 tissue sections per subject 
with antibodies against GAD65, GAD67, and PV (see Appendix A). Using a previously 
published method (Sweet et al., 2009), a region within area 9 where the tissue section 
was cut perpendicular to the pial surface was identified. Sampling sites were then 
placed in this region in a systematic random fashion within layers 3-4, defined as 30-
60% of the pia-to-white matter distance (Eggan et al., 2008). The GAD67 mRNA deficit 
in PV neurons in schizophrenia is most pronounced in these layers (Hashimoto et al., 
2003). Image stacks (n=180) were collected from the 5 subject pairs on a confocal 
microscope as described in Appendix A. 
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Because the density of GAD65-IR axon terminals is not altered in schizophrenia 
(Benes et al., 2000), GAD65 immunoreactivity was used to identify IR puncta (defined 
as labeled structures 0.06–0.7 μm3 in size) that represent putative axon terminals. Post-
processing and data segmentation were performed using a methodology that allows for 
the quantification of fluorescently-labeled puncta, the colocalization of different labels in 
the same puncta, and the quantification of fluorescence intensity in these same 
structures (Fish et al., 2008). In this method, a binary channel (mask) is made of the 
segmented pixels and used to assess fluorescence intensity. Each mask is composed 
of multiple mask objects (IR puncta). Mask operations between channels were used to 
determine GAD65-IR puncta that were also labeled for PV and GAD67. 
3.3.5 Statistical analyses 
Two analysis of covariance (ANCOVA) models were performed to test the effect of 
diagnosis on GAD67 mRNA level.  The first model included mRNA level as the 
dependent variable, diagnostic group as the main effect, subject pair as a blocking 
factor, and storage time, brain pH, and RIN as covariates. Subject pairing may be 
considered an attempt to balance diagnostic groups for sex, age, and PMI, and to 
account for the parallel processing of tissue samples from a pair, and thus not a true 
statistical paired design. Therefore, we also used a second model without subject pair 
as a blocking factor that included sex, age, PMI, storage time, brain pH, and RIN as 
covariates.  
A similar approach was used for total protein measures of GAD67, with 
appropriate adjustments made for covariates. However, to account for the across-gel 
measurement variability inherent in Western blotting, samples from a single subject pair 
comprised all lanes of a given gel (see 3.3.3) and thus only a paired ANCOVA model 
was used. The use of a paired model is supported by the similar results obtained with 
both paired and unpaired ANCOVA analyses of GAD67 mRNA levels (see 3.4.1).  
Paired t tests were used to assess whether the GAD67 protein levels in PV 
puncta differed between comparison and schizophrenia subjects.  
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The reported p values for comparisons of GAD67 levels are one-tailed because 
mRNA levels have been previously shown to be lower in schizophrenia (Gonzalez-
Burgos et al., 2010). All other p values are two-tailed. 
3.4 RESULTS 
3.4.1 GAD67 mRNA expression in schizophrenia 
Mean GAD67 mRNA levels were significantly 14.5% lower in the 42 subjects with 
schizophrenia relative to matched comparison subjects (paired: F1,38=7.3, p=0.005; 
unpaired: F1,76=6.5, p=0.006) (Figure 14). None of the covariates were significant in 
either of the models (all F≤1.5, p≥0.226) except for RIN (only in the paired model; 
F1,38=6.4, p=0.016). In 23 of these pairs, lower GAD67 mRNA levels had previously 
been reported by ISH (using a riboprobe designed against a different portion of the 
mRNA than the primer set employed here) (Hashimoto et al., 2005). The pair-wise 
differences in GAD67 mRNA expression as measured by ISH and by qPCR in the 
present study were strongly positively correlated (r=0.68, p=0.000). The new set of 19 
subject pairs also showed a significantly 12.3% lower level of GAD67 mRNA in 
schizophrenia (paired: F1,15=4.1, p=0.031; unpaired: F1,30=6.0, p=0.010).  
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Figure 14. GAD67 mRNA levels in schizophrenia and comparison subjects. The 
scatter plot indicates GAD67 mRNA levels for each matched pair of healthy comparison 
subject and subject with schizophrenia (circles) or schizoaffective disorder (triangles). 
Pairs below the diagonal unity line have lower GAD67 mRNA in the schizophrenia or 
schizoaffective subject relative to the comparison subject. Levels of GAD67 mRNA were 
significantly (F1,38=7.3, p=0.005) 14.5% lower in the schizophrenia subjects. 
 
 
 
GAD67 mRNA levels in the schizophrenia subjects did not differ as a function of 
diagnosis of substance abuse or dependence current at the time of death (ATOD); use 
of antidepressants, benzodiazepines or sodium valproate, antipsychotics, or nicotine 
ATOD; or history of cannabis use (all p≥0.486) (Figure 15). Additionally, regression 
models were built to look for significant interaction terms between the variables (with the 
exception of nicotine ATOD, because data were not available for all subject pairs) and a 
sequence of models with increasing interaction complexity was fit. A model with main 
effects and all two-way interactions revealed no significant effects (all p≥0.073).  
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The within-pair percent differences in GAD67 mRNA in schizophrenia relative to 
comparison subjects were heterogeneous (range:-67% to +34%) and thus we examined 
several factors that might contribute to the variability. Among schizophrenia subjects, 
GAD67 mRNA levels did not differ (all p≥0.214; Figure 15) as a function of factors that 
predict a more severe course of illness [male sex, a diagnosis of schizophrenia rather 
than schizoaffective disorder, first degree relative with schizophrenia, early age of onset 
(<19 years of age)], or measures of illness severity [suicide, no history of marriage, low 
socioeconomic status (SES) as measured by the Hollingshead Two Factor Index of 
Social Position, absence of independent living ATOD] (DSM-IV-TR, 2000).  Additionally, 
GAD67 mRNA levels were not significantly correlated with age of onset (r=0.09, 
p=0.561), age ATOD (r=-0.25, p=0.104), or age-corrected length of illness (r=0.31, 
p=0.134.
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Figure 15. Effect of substance abuse and psychotropic medications (top) and 
predictors of disease severity and measures of functional outcome (bottom) on 
GAD67 mRNA levels in schizophrenia subjects. GAD67 mRNA levels in 
schizophrenia (circle) or schizoaffective (triangle) subjects did not differ as a function of 
the presence or absence of substance abuse or dependence ATOD; history of cannabis 
use; nicotine use ATOD; or antipsychotic, antidepressant, or benzodiazepine and/or 
valproic acid medications ATOD (all p≥0.486) (top). Additionally, GAD67 mRNA levels 
did not significantly differ based on the presence or absence of predictors of disease 
severity (sex, schizophrenia vs. schizoaffective diagnosis, family history of first-degree 
relative with schizophrenia, or age of onset of illness) or measures of functional 
impairment (history of marriage, highest achieved socioeconomic status (SES), 
independent living, or death by suicide) (all p≥0.214). Abbreviations: M, male; F, female; 
SZ, schizophrenia; SA, schizoaffective disorder; SES, socioeconomic status; DX, 
diagnosis; Benzo, benzodiazepine; VPA, valproic acid. Numbers at the bottom of bars 
indicate number of schizophrenia subjects per group. *Information was not available for 
all subjects. 
3.4.2 Total GAD67 protein levels in schizophrenia 
Protein degradation begins upon death, but the effect of PMI on protein levels is 
variable across proteins and brain regions (Beneyto et al., 2009). Consequently, we 
examined the effect of PMI on GAD67 protein levels in the DLPFC from 6 comparison 
subjects as well as 1 monkey (See 2.3.2). Based on these findings, we only used 
subject pairs with PMIs<20 hrs for Western blot studies. 
Uncorrected and tubulin-corrected GAD67 protein levels were significantly 12.9% 
(F1,17=5.6, p=0.015) and 10.1% (F1,17=3.4, p=0.040) lower in the schizophrenia subjects 
(Figure 16). In contrast, uncorrected tubulin levels did not differ between schizophrenia 
subjects and comparison subjects (-3.4%; F1,17=2.3, p=0.151). Tissue storage time was 
not significant in either the uncorrected or corrected model (both F1,17≤3.4, p≥0.083). 
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As depicted by the scatter along the unity line in Figure 16, GAD67 protein levels 
varied substantially across subject pairs. This scatter was over 4 times greater than for 
GAD67 mRNA levels (Figure 14), suggesting that it represented measurement 
variance. Consequently, we performed an additional 16 replicates in 4 subject pairs. 
The absolute levels of GAD67 protein differed between the first and second 
measurement in the same subject, but the percent difference within each subject pair 
was highly consistent (intra-class correlation coefficient=0.97). Together, these findings 
indicate that measurement variance contributes substantially to the distribution of 
GAD67 protein levels along the unity line in Figure 16, but the distance from the unity 
line for each subject pair likely reflects the biological effect of schizophrenia. 
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Figure 16. GAD67 protein levels are significantly lower in schizophrenia subjects 
relative to comparison subjects. The top image shows lanes from a representative 
blot loaded with tissue from a comparison and schizophrenia subject pair. The bottom 
plot shows tubulin-normalized GAD67 protein values for each pair of comparison and 
schizophrenia (circle) or schizoaffective (triangle) subjects. Values below the diagonal 
unity line indicate lower GAD67 protein in the schizophrenia subject relative to the 
comparison subject. GAD67 protein levels were significantly (F1,17=3.4, p=0.040) 10.1% 
lower in schizophrenia subjects. Abbreviations: C, Comparison; S, Schizophrenia. 
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3.4.3 Correlation of total GAD67 mRNA and protein levels 
Due to a lack of tissue availability, different comparison subjects were utilized between 
the total mRNA and protein studies for subject pair 4 (Appendix B). In the remaining 18 
pairs of subjects, the within-pair percent differences in GAD67 mRNA and protein were 
positively correlated (r=0.40; p=0.105), supporting the idea that a reduction in GAD67 
mRNA expression results in less translation of the cognate protein. 
3.4.4 GAD67 protein levels in PV puncta 
The deficit in GAD67 mRNA is known to be present in a subset of interneurons, 
including those that express PV (Hashimoto et al., 2003). Thus, we conducted a proof-
of-concept test of the hypothesis that the deficit in GAD67 protein levels is much larger 
in the axon terminals of PV cells than in total cortical gray matter. Five subject pairs with 
a range of differences in total GAD67 protein levels (-24% to +16%; mean, -5%) were 
selected. We created masks of GAD65-IR puncta, with each mask object representing a 
putative axon terminal. In a total of 30,630 GAD65+/PV+ puncta, we measured GAD67 
fluorescence intensity.  
The fluorescence intensity of GAD67 in PV puncta was 48.8% lower (t4=3.9, 
p=0.008) in schizophrenia subjects (Figure 17), a difference nearly 10X greater than the 
5% reduction in total GAD67 protein found in these same subject pairs by Western 
blotting. These data suggest that GAD67 protein deficits are especially pronounced in 
PV neurons, consistent with prior findings of cell type-specific deficits in GAD67 mRNA 
(Hashimoto et al., 2003). 
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Figure 17. GAD67 protein levels in PV puncta are significantly lower in 
schizophrenia. The image projections (consisting of 3 z-planes) in the top panel show 
representative puncta obtained in the GAD65 (upper left), GAD67 (upper right), and PV 
(bottom left) channels. The bottom right image shows a color overlay of all 3 channels. 
Arrows indicate GAD65+/GAD67+/PV+ puncta; filled arrowheads indicate 
GAD65+/GAD67+/PV- puncta; open arrowheads indicate GAD65-/GAD67-/PV+ puncta. 
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Scale bar=10 µm. *For presentation purposes, pixel values were increased equally in 
order to visualize low, medium, and high intensity puncta in the PV channel, resulting in 
the saturation of some pixels. The scatter plot on the bottom shows GAD67 protein 
values in PV puncta plotted for each pair of comparison and schizophrenia (circle) or 
schizoaffective (triangle) subjects. Values below the diagonal unity line indicate lower 
GAD67 protein in PV puncta in the schizophrenia subject relative to the comparison 
subject. Mean GAD67 protein levels in PV puncta were significantly (t4=3.9, p=0.008) 
48.8% lower in schizophrenia subjects.  
 
3.5 DISCUSSION 
The results of this study document lower mean GAD67 mRNA levels in the DLPFC of 
schizophrenia subjects in the largest cohort reported to date. In a subset of this cohort, 
where potential confounds of protein measures were controlled, total GAD67 protein 
levels were also similarly lower, consistent with the hypothesis that lower mRNA levels 
lead to less translated protein. Finally, the GAD67 protein findings were especially 
pronounced in the axon terminals of PV neurons, providing evidence of a cell type-
specific deficit in GAD67 protein at the site of GABA synthesis and release. 
As in prior studies of GAD67 mRNA (Gonzalez-Burgos et al., 2010), the apparent 
magnitude of the GAD67 mRNA and protein deficits in the present study differed 
substantially across schizophrenia subjects. This variability does not appear to be due 
to differences across schizophrenia subjects in potential confounding factors such as 
substance abuse or psychotropic medication use ATOD. The similar levels of GAD67 
mRNA in subjects both on and off antipsychotic medications ATOD are consistent with 
both prior studies of schizophrenia (Lewis et al., 2005) and the absence of a deficit in 
GAD67 mRNA levels in monkeys treated long-term with high-dose haloperidol 
decanoate (Volk et al., 2000), or low-dose oral haloperidol or olanzapine (Hashimoto et 
al., 2008a). 
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 The variability in GAD67 mRNA levels across schizophrenia subjects also does 
not appear to be accounted for by factors that predict a more severe form of the illness, 
including male sex, a diagnosis of “pure” schizophrenia, a family history of 
schizophrenia, or an earlier age of onset. Additionally, factors that are a more direct 
metric of disease severity and functional outcome (death by suicide, lower SES, not 
living independently, and no history of marriage) were not associated with lower levels 
of GAD67 mRNA schizophrenia subjects. These data indicate that the GAD67 mRNA 
deficit is a conserved feature associated with a diagnosis of schizophrenia that is robust 
to the influence of multiple other factors.  
Since GAD67 expression is activity-regulated (Benson et al., 1994), it is possible 
that lower GAD67 mRNA in schizophrenia is a consequence of reduced cortical activity 
associated with having a chronic psychiatric illness or severe cognitive impairments. 
However, the latter explanations seem unlikely since 1) GAD67 mRNA levels did not 
differ between schizophrenia subjects with or without factors that predict or reflect a 
more severe illness course, and 2) the within-pair percent differences in GAD67 mRNA 
and protein levels were not significantly correlated with length of illness (r=0.31, 
p=0.134 and r=-0.13, p=0.605, respectively). Furthermore, lower frontal γ power, 
predicted to result from less GABA synthesis in PV neurons (Gonzalez-Burgos and 
Lewis, 2008; Cardin et al., 2009), is present during both the first episode (Minzenberg et 
al., 2010) and chronic (Cho et al., 2006) phases of schizophrenia. Taken together, these 
findings suggest that lower GAD67 mRNA is not attributable to substance abuse or 
psychotropic medication use, other factors related to illness course, or a consequence 
of having a chronic psychiatric illness. Thus, lower GAD67 levels appear to be a 
common component of, and not a consequence of, the disease process of 
schizophrenia.  
The substantially greater deficit of GAD67 protein in PV puncta than in total gray 
matter is convergent with prior findings that the deficit in GAD67 mRNA expression is 
prominent in PV neurons (Hashimoto et al., 2003) and not detectable in the majority of 
other GABA neurons (Akbarian et al., 1995a; Volk et al., 2000). Lower levels of GAD67 
protein in PV terminals suggest that these terminals synthesize less GABA, and 
therefore are less able to provide the inhibition of pyramidal neurons that is required for 
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γ oscillations (Gonzalez-Burgos and Lewis, 2008; Cardin et al., 2009). Thus, impaired 
GABA synthesis in PV terminals, resulting in lower inhibition, is a plausible mechanism 
for the reduced prefrontal γ oscillation power observed during cognitive control tasks in 
subjects with schizophrenia (Cho et al., 2006; Minzenberg et al., 2010).  
However, directly demonstrating that lower GAD67 mRNA and protein in the 
DLPFC [or other cortical regions where lower GAD67 mRNA has been observed 
(Gonzalez-Burgos et al., 2010)] lead to less cortical GABA in schizophrenia is 
challenging. Indeed, it is possible that GAD67 expression could be down-regulated in 
response to reduced GABA metabolism; for example, pharmacological inhibition of 
GABA transaminase, which metabolizes GABA, is associated with elevated cortical 
GABA and less GAD67 protein (Mason et al., 2001). Perhaps consistent with this 
interpretation, a magnetic resonance spectroscopy study reported elevated GABA 
levels in the anterior cingulate and parieto-occipital cortices of subjects with chronic 
schizophrenia (Ongur et al., 2010). However, some studies found no differences and 
others reported lower levels of cortical GABA in subjects with schizophrenia (Goto et al., 
2009b; Yoon et al., 2010). Interestingly, lower GABA levels in the visual cortex in 
subjects with schizophrenia were correlated with reductions in a behavioral measure of 
visual inhibition that is known to depend on GABA neurotransmission (Yoon et al., 
2010). Similarly, a trend-level negative correlation was found between frontal GABA 
levels and number of errors on a working memory task in patients with early-stage 
schizophrenia (Goto et al., 2009a), consistent with the idea that lower GABA synthesis 
results in cognitive impairments. However, since spectroscopic studies measure total 
tissue GABA levels, and not GABA levels in synaptic vesicles or the extracellular space, 
their relevance to GABA synthesis and transmission remain uncertain. The hypothesis 
that GABA hypofunction results in cognitive impairments in schizophrenia is supported 
by findings of impaired working memory performance in rats and monkeys after 
pharmacological blockade of prefrontal GABAA receptors (Enomoto et al., 2011; 
Sawaguchi et al., 1989). 
In concert, the findings of the present study demonstrate that lower levels of 
GAD67 mRNA are accompanied by less GAD67 protein, which is especially 
pronounced in the axon terminals of PV GABA neurons, providing a plausible 
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mechanistic basis for impaired cortical γ oscillations and cognitive control deficits in 
schizophrenia. Importantly, comparisons across the subjects with schizophrenia 
suggest that a deficit in GABA synthesis is likely to contribute to cognitive dysfunction in 
schizophrenia and not to be the consequence of experiencing the illness. 
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4.0  ROLE OF GAD67 IN REGULATING PARVALBUMIN AND GABA MEMBRANE 
TRANSPORTER 1 MRNA: IMPLICATIONS FOR SCHIZOPHRENIA 
Modified from: Curley AA, Eggan SM, Lazarus MS, Huang ZJ, Lewis DA. Role of 
GAD67 in regulating parvalbumin and GABA membrane transporter 1 mRNA: 
Implications for schizophrenia. In preparation. 
4.1 ABSTRACT 
Alterations in markers of GABA neurotransmission are present in the dorsolateral 
prefrontal cortex (DLPFC) of individuals with schizophrenia. Glutamic acid 
decarboxylase 67 (GAD67) mRNA and protein levels are lower, and are accompanied 
by lower levels of GABA membrane transporter 1 (GAT1) mRNA and protein. These 
alterations are thought to be most prominent in the parvalbumin (PV)-containing 
subclass of interneurons, which also contain lower levels of PV mRNA. Since PV and 
GAT1 can each reduce GABA levels available to postsynaptic receptors, it has been 
hypothesized that their reduction in schizophrenia may be a compensation to counteract 
upstream reductions in GAD67. However, it is not possible to directly test this 
hypothesis in schizophrenia. Thus, we characterized PV and GAT1 mRNA levels in two 
mouse models with lower GAD67. One model contains lower GAD67 specifically in PV 
neurons (PVGAD67+/-), while the other contains lower GAD67 in all interneurons 
(GABAGAD67+/-). Contrary to our hypothesis, neither PV nor GAT1 mRNA were altered at 
the tissue level in adult or developmental PVGAD67+/- mice. Furthermore, cellular 
analyses confirmed a lower level of GAD67, but not of PV, mRNA in these animals. 
Additionally, PV and GAT1 mRNAs were also unaltered in GABAGAD67+/- mice. Taken 
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together, these data suggest that lower GAD67 levels do not result in changes in PV or 
GAT1, and therefore lower GAD67 is unlikely to be the cause of reduced PV and GAT1 
mRNA in schizophrenia. 
4.2 INTRODUCTION 
Schizophrenia is associated with alterations in several markers of GABA 
neurotransmission in the DLPFC (Lewis et al., 2005), and other cortical regions 
(Hashimoto et al., 2008b). Both mRNA (see Gonzalez-Burgos, 2010 for review) and 
protein (3.4; Guidotti et al., 2000) levels of GAD67, the enzyme responsible for the 
majority of cortical GABA synthesis, are lower in the DLPFC of subjects with 
schizophrenia. Levels of GAT1 mRNA and protein, which removes GABA from the 
extracellular space, are also lower in schizophrenia (Hashimoto et al., 2008b; Volk et 
al., 2001; Ohnuma et al., 1999; Woo et al., 1998). These deficits in GABA synthesis and 
reuptake appear to be most prominent in the PV-containing subclass of interneurons 
(3.4.4; Woo et al., 1998; Hashimoto et al., 2003) that also contain lower levels of PV 
mRNA (Hashimoto et al., 2003). 
Through different mechanisms, PV and GAT1 can each reduce the amount of 
GABA available at postsynaptic receptors and therefore their lower expression in 
schizophrenia might be a compensatory response to counteract insufficient GABA 
synthesis (Lewis et al., 2005). PV is a slow Ca2+ buffer that increases the rate at which 
residual Ca2+ transients decay in GABA nerve terminals after neurotransmitter release 
(Collin et al., 2005; Muller et al., 2007). Therefore, during repetitive firing, reductions in 
PV levels in schizophrenia would increase the amount of calcium available to facilitate 
neurotransmitter release, resulting in increased synaptic GABA levels (Lewis et al., 
2005). In fact, mice deficient in PV show enhanced GABA release from fast-spiking 
neurons (Collin et al., 2005; Vreugdenhil et al., 2003). 
GAT1, one of four high-affinity Na+/Cl- transporters that take up extracellular 
GABA, is the most abundant GABA transporter in the cortex (Conti et al., 1998). 
Consistent with a role for GAT1 in removing extracellular GABA from the synaptic 
  71 
space, in the hippocampus of GAT1 KO mice 3[GABA] uptake is virtually absent, while 
tonic GABAA receptor-mediated current is substantially increased (Jensen et al., 2003). 
Blockade of GAT1 increases the duration of evoked IPSCs at inhibitory synapses 
(Overstreet and Westbrook, 2003), suggesting that reducing GAT1 in schizophrenia 
would maximize the effect of the lower GABA levels (Lewis et al., 2005).  
Although lower GAD67 in prefrontal PV neurons is well established in 
schizophrenia, whether this alteration produces the predicted downstream reductions in 
PV and GAT1 expression has not been directly tested in experimental models. 
Accordingly, in this study we measured developmental and adult levels of PV and GAT1 
mRNAs in a mouse model with reduced GAD67 expression specifically in PV neurons, 
as well as model with lower GAD67 mRNA in all interneurons. 
4.3 MATERIALS AND METHODS 
4.3.1 Animals 
4.3.1.1 PV-specific GAD67 Heterozygous (PVGAD67+/-) mice 
Pvcre/cre mice, in which cre expression is driven by the endogenous mouse Pv promoter, 
were produced as follows: A cassette containing the cre coding sequence, an internal 
ribosome entry site (IRES), and a polyadenylation site sequence (IRES-Cre-pA) was 
inserted into the 3’ untranslated region of exon 5 of the endogenous Pv gene. 
Electroporation was used to insert the construct into 129/Ola ES cells and cells 
containing the construct were injected into blastocyts. The chimeric animals that re-
sulted were crossed with C57BL/6 mice to yield Pvcre/cre animals.  
Pvcre/cre mice were bred with Gad1lox/+ mice (generated as described below) to 
produce litters containing mutant mice with one copy of the Gad1 gene removed in PV 
neurons (Pvcre/+Gad1lox/+; subsequently referred to as PVGAD67+/- mice) and control mice 
(Pvcre/+Gad1+/+; subsequently referred to as PVGAD67+/+). Animals were euthanized at 3 
different ages: postnatal day 17 [P17; n=5 (2 males and 3 females) per genotype], P30 
[n=6 (4 males and 2 females) per genotype], and P50 [n=6 (3 males and 3 females) per 
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genotype], and brains were removed, frozen, and stored at -80°C. Coronal sections 
from each brain were cut (12 um), thaw mounted onto SupraFrost slides (Fisher 
Scientific, Pittsburgh, PA), and stored at -80°C. 
4.3.1.2 Germ-line GAD67 Heterozygous (GABAGAD67+/-) mice 
As previously described (Chattopadhyaya et al., 2007), to generate GAD67 
heterozygous (GABAGAD67+/-) mice, exon 2 (the first coding exon) of the Gad1 gene was 
flanked by loxP sites using gene targeting in ES cells. Using FLP recombinase, the Sv-
NeoR selectable gene was removed to produce Gad1lox/+ mice, which were interbred to 
generate phenotypically normal Gad1lox/lox mice. Gad1lox/lox mice were bred with Mox2-
Cre mice to delete exon 2 in the germ-line (GABAGAD67+/-). Consistent with previously 
described GABAGAD67-/- mice (Asada et al., 1997), interbreeding of GABAGAD67+/- mice 
generated some animals that did not survive beyond the perinatal period. All animals 
were euthanized on P56 [n=7 (5 males and 2 females) per genotype]. Brains were 
processed and tissue was cut as described above. 
4.3.2 In situ hybridization  
ISH was performed as described previously (Hashimoto et al., 2005). A 311 base pair 
fragment corresponding to bases 151-461 of the mouse Gad1 gene (GAD67) (Genbank 
accession number Y12257), a 339 base pair fragment corresponding to bases 256-594 
of the mouse Pvalb gene (PV) (GenBank accession number X59382), and a 462 base 
pair fragment corresponding to bases 691-1152 of the mouse Slc6a1 gene (GAT1) 
(GenBank accession number NM_178703) were amplified by PCR. Nucleotide 
sequencing revealed 100% homology for the amplified fragments to previously reported 
sequences. Sense and antisense riboprobes were generated by in vitro transcription in 
the presence of 35S-CTP using T7 or SP6 RNA polymerase, followed by digestion with 
DNaseI, and purified by centrifugation through spin columns. Following a standard 
hybridization protocol (Hashimoto et al. 2003), sections from all mice for a given 
comparison were exposed to BioMax MR film (Kodak, Rochester, NY) for 21 (GAT1), 40 
(GAD67), or 72 (PV) hours. 
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For grain counting of GAD67 mRNA, slides were then coated with NTB2 
emulsion (Kodak) using a mechanical dipper, Auto-dip Emulsion Coater (Ted Pella, 
Redding, CA), at a constant withdrawal speed and temperature, to ensure the 
consistency of emulsion thickness across sections. After 10 days, slides were exposed 
at 4°C, developed with D-19 (Kodak), washed, and counterstained using cresyl violet. 
All slides for each comparison were contained in a single experimental run and 
exposed on the same film. Riboprobe specificity was confirmed by an absence of signal 
with sense probes and by the findings that each antisense probe produced the expected 
laminar pattern of mRNA expression (Hashimoto et al., 2005; Yasumi et al., 1997). 
4.3.3 Quantification 
To determine total GAD67, PV, and GAT1 mRNA levels, 3 evenly spaced coronal 
sections [spanning ~144 μm; +1.98 to +1.54 Bregma (Paxinos and Franklin, 2001)] 
containing primary and secondary motor (M1 and M2) and medial prefrontal cortex 
(mPFC), including the cingulate and prelimbic cortices, from each animal were 
quantified as described previously (Hashimoto et al., 2005). Briefly, autoradiographic 
film images were captured and digitized using a Microcomputer Imaging Device (MCID) 
system (Imaging Research Inc., Canada) (5.1 μm/pixel resolution). All slides for each 
comparison were acquired in the same session with identical room illumination, black 
and gain levels, and flatfield correction. OD levels of GAD67, PV, and GAT1 were 
measured in each hemisphere from the pial surface to the white matter and expressed 
as nanoCuries per gram (nCi/g) of tissue by reference to 14C standards (ARC, St. Louis, 
MO) exposed to the same film. All OD values were corrected by subtracting background 
measured in the white matter. In PVGAD67+/- mice, OD was measured within M1/M2, 
while in GABAGAD67+/-mice separate measures were made for M1/M2 and mPFC (see 
4.4 for rationale). Within a region, measures from each hemisphere were averaged into 
a single measure per section. 
To quantify the GAD67 and PV mRNA levels per neuron in the P50 PVGAD67+/- 
animals, emulsion-dipped and Nissl-counterstained sections were quantified as 
described previously (Hashimoto et al., 2005). MCID software and a Nikon microscope 
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(Melville, NY) with a motorized stage were used to place 2 (GAD67) or 4 (PV) 
immediately adjacent columns of sampling boxes (120 um x 170 um) continuously from 
the pial surface to the layer 6-white matter border in M1 of 2 of the 3 tissue sections 
utilized in the total GAD67 mRNA study. Sampling circles with a fixed diameter of 16 μm 
were placed over GAD67 or PV silver grain clusters, and the number of silver grains per 
circle was quantified. All values were corrected by subtracting background grains per 
cluster measured in a 120 um x 170 um sampling box placed in the white matter. One 
pair of animals was not counted for PV due to a damaged slide. A total of 1630 and 
1628 (GAD67) and 473 and 496 (PV) grain clusters were analyzed for PVGAD67+/+ and 
PVGAD67+/- mice, respectively. 
4.3.4 Statistical analyses 
In order to control for experimental variance, each wild type animal was paired with an 
experimental animal, matched for sex and litter. Accordingly, paired t tests were used to 
test the effect of genetic condition on OD measures and number of grains per cluster 
using mean values across all of the sections from each animal. Analysis of variance 
(ANOVA) was used to assess the effect of age on OD in PVGAD67+/- animals. Since 
GAD67 levels were genetically manipulated to be lower in both models, all reported p 
values for GAD67 are one-tailed. All other p values are two-tailed. 
4.4 RESULTS 
4.4.1 Transcript levels in PVGAD67+/- mice 
In addition to the DLPFC, lower levels of GAD67, PV, and GAT1 mRNAs in 
schizophrenia have been found in M1 (Hashimoto et al., 2008b). Since PV mRNA 
expression levels are low in the mouse mPFC (Thomsen et al., 2010; Hashimoto et al., 
2005), likely due to the presence of significantly fewer PV neurons in mPFC than motor 
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cortex (Fitzgerald et al., 2011), the latter may be a more sensitive region in which to 
detect changes in PV neurons. Maximizing sensitivity is especially important given that 
PVGAD67+/- mice exhibit lower GAD67 only in PV neurons. In fact, consistent with 
Fitzgerald et al. (2011), mean (±SD) GAD67 mRNA levels were only nonsignificantly 
8.7% lower (t5=1.18, p=0.146) in the mPFC, but significantly 17.4% lower (t5=2.23, 
p=0.038) in M1/M2 of P50 PVGAD67+/- mice (384±60) relative to PVGAD67+/+ mice (465±60) 
(Figure 18). Accordingly, we made all subsequent GAD67, PV, and GAT1 mRNA 
measures in M1/M2 in these animals.  
Contrary to our hypothesis, neither PV (t5=1.03, p=0.350) nor GAT1 (t5=-0.31, 
p=0.769) mRNA levels significantly differed between PVGAD67+/- mice and PVGAD67+/+ 
mice (Figure 18). In order to assess whether developmental compensations might 
account for the lack of change in PV and GAT1 in the P50 PVGAD67+/- mice, we 
examined 2 younger age groups of mice (P17 and P30). As shown in Figure 19, 
GAD67, PV, and GAT1 mRNAs all exhibited the predicted developmental trajectories in 
PVGAD67+/+ mice (Kiser et al., 1998; de Lecea et al., 1995; Yan et al., 1997). Across 
development, GAD67 mRNA levels increased significantly by 135% (F2,14=6.90, p=0.01) 
and PV mRNA increased significantly by 240% (F2,14=55.85, p=0.001). In contrast, 
GAT1 decreased significantly by 10% (F2,14=3.84, p=0.047) between P17 and P50. 
GAD67 mRNA levels exhibited similar magnitudes of reduction in PVGAD67+/- mice at 
both P17 and P30 as at P50 (Figure 20). In P17 animals, GAD67 mRNA was 15.8% 
lower in PVGAD67+/- mice (291±73 nCi/g) relative to PVGAD67+/+ mice (345±35 nCi/g), 
though this difference only reached trend-level statistical significance (t4=1.80, 
p=0.074). In P30 animals, GAD67 mRNA was significantly 17.7% lower (t5=6.09, 
p=0.001) in PVGAD67+/- mice (334±50 nCi/g) relative to PVGAD67+/+ mice (406±49 nCi/g).  
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Figure 18. GAD67, but not PV or GAT1, mRNA levels are reduced in PVGAD67+/- 
mice. Top, representative film autoradiograms illustrating the expression of GAD67, PV, 
and GAT1 mRNA in M1/M2 of P50 PVGAD67+/+ mice. The density of hybridization signal 
is presented in pseudocolor according to the calibration bars. Bottom, comparison of 
cortical GAD67, PV, and GAT1 mRNA levels by film OD in P50 PVGAD67+/+ and 
PVGAD67+/- mice (GAD67: t5=2.23, p=0.038; PV: t5=1.03, p=0.350; GAT1: t5=-0.31, 
p=0.769). Mean values for each group are indicated by the hash mark.  
 
 
 
PV mRNA levels were not significantly different between PVGAD67+/- and 
PVGAD67+/+ mice at P17 (t4=-0.35, p=0.740), although there was a 13.9% increase in PV 
mRNA levels in PVGAD67+/- (171±13 nCi/g) relative to PVGAD67+/- mice (150±12 nCi/g) at 
P30 (t=-2.61, p=0.048) (Figure 19). GAT1 mRNA levels were not significantly different 
between PVGAD67+/- mice and PVGAD67+/+ mice at either P17 (t4=-0.42, p=0.694) or P30 
(t5=0.72, p=0.510) (Figure 19).  
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Figure 19. GAD67, but not PV or GAT1, mRNA levels are reduced in PVGAD67+/- 
mice across development. Comparison of GAD67, PV, and GAT1 mRNA levels by 
film OD in PVGAD67+/+ and PVGAD67+/- mice (top left, top right, bottom left) (GAD67 P30: 
t5=6.09, p=0.001; GAD67 P50: t5=2.23, p=0.038; PV P30: t=-2.61, p=0.048; all others, 
p≥0.074). Mean values for each condition are indicated by the hash mark. GAD67, PV, 
and GAT1 mRNA exhibit the expected developmental trajectories in M1/M2 of 
PVGAD67+/+ mice (bottom right). GAD67 and PV mRNA increase, while GAT1 mRNA 
decreases, across development (GAD67: F2,14=6.90, p=0.01; PV: F2,14=55.85, p=0.001; 
GAT1: F2,14=3.84, p=0.047). 
 
 
 
PV neurons comprise approximately 50% of cortical interneurons in the mouse 
motor cortex (Tamamaki et al., 2003). Since PVGAD67+/- mice are predicted to have 50% 
lower GAD67 in all PV neurons, theoretically these animals should have approximately 
25% less GAD67 mRNA than PVGAD67+/+ mice. We performed a check of the genetic 
manipulation by quantifying GAD67 mRNA levels per neuron. The mean number of 
GAD67 grains per neuron was 30.5% lower (t5=9.55, p<0.001) in PVGAD67+/- mice (44±6) 
relative to PVGAD67+/+ mice (63±9) (Figure 20). These data confirm that the genetic 
manipulation did produce the expected reduction in GAD67. In contrast, the mean 
number of PV grains per neuron was not significantly different between PVGAD67+/- and 
PVGAD67+/+ mice (t4=-0.77, p=0.483) (Figure 20), suggesting that the lack of change in 
PV mRNA at the film level was not due to insufficient sensitivity. Since GAT1 is present 
in both PV cells as well as the non-PV cells that presumably contain normal levels of 
GAD67 mRNA, it would be difficult to detect a difference in only a subpopulation of 
GAT1 mRNA-containing cells. Thus, cellular levels of GAT1 mRNA were not quantified. 
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Figure 20. Cellular levels of GAD67, but not PV, mRNA are reduced in PVGAD67+/- 
mice. Comparison of M1 GAD67 (left) and PV (right) mRNA levels by grain counting in 
litter-matched pairs of P50 PVGAD67+/+ and PVGAD67+/- mice (GAD67: t5=9.55, p<0.001; 
PV: t4=-0.77, p=0.483). Mean values for each condition are indicated by the hash mark.  
 
 
4.4.2 Transcript levels in GABAGAD67+/- mice 
In PVGAD67+/- mice, GAD67 is reduced specifically in PV neurons beginning on 
approximately P11, when PV mRNA expression turns on in the murine neocortex (del 
Rio et al., 1994). Given the lack of change in PV and GAT1 in PVGAD67+/- mice, we also 
examined these transcripts in a more pronounced and earlier model of GAD67 
reduction, P56 germline GABAGAD67+/- mice, in which tissue levels of GAD67 mRNA are 
reduced in all interneurons in early prenatal development (Eggan et al., 2011). In 
M1/M2, GAD67 mRNA levels were significantly 37.2% lower (t6=7.89, p<0.001) in 
GABAGAD67+/- (872±78 nCi/g) compared to GABAGAD67+/+ (1375±111 nCi/g) mice (Figure 
21). In contrast, neither PV (t6=-1.03, p=0.344) nor GAT1 (t6=-0.36, p=0.731) mRNA 
expression levels were significantly different between GABAGAD67+/+ and GABAGAD67+/- 
mice in M1/M2 (Figure 21). In order to exclude the possibility that the lack of change in 
PV and GAT1 mRNA is region-specific, we also examined these transcripts in mPFC. 
Similar to the findings in M1/M2, no significant changes in PV (t6=0.33, p=0.754) or 
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GAT1 (t6=1.32, p=0.235) mRNA were detected in the mPFC of GABAGAD67+/- mice 
relative to GABAGAD67+/+ mice (Figure 21). 
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Figure 21. GAD67, but not PV or GAT1, mRNA levels are reduced in GABAGAD67+/-
mice. Top, representative film autoradiograms illustrating the expression of GAD67, PV, 
and GAT1 mRNA in P56 GABAGAD67+/+ mice. The density of hybridization signal is 
presented in pseudocolor according to the calibration bars. Middle, comparison of 
M1/M2 and mPFC GAD67, PV, and GAT1 mRNA levels by film OD in P56 GABAGAD67+/+ 
and GABAGAD67+/- mice (GAD67: t6=7.89, p<0.001; all others: p≥0.344). Bottom, 
comparison of mPFC GAD67, PV, and GAT1 mRNA levels by film OD of P56 
GABAGAD67+/+ and GABAGAD67+/- mice [GAD67: t6=7.67, p<0.001 (data from Eggan et al., 
2011); all others: p≥0.235]. Mean values for each group are indicated by the hash mark. 
 
4.5 DISCUSSION 
In PVGAD67+/- mice, GAD67 mRNA was significantly reduced by ~17% at the tissue level 
across development and by 31% at the cellular level in adult animals. Tissue-level 
GAD67 mRNA levels were significantly reduced by 37% in adult GABAGAD67+/- mice. 
However, PV and GAT1 mRNA levels were not significantly altered in either mouse 
model at the tissue level. Moreover, PV was not significantly altered at the cellular level 
in PVGAD67+/- mice. Thus, reduced GAD67 expression does not affect the levels of PV 
and GAT1 mRNAs, regardless of cell type-specificity or developmental age of the deficit 
in GAD67 mRNA expression. These data do not support the hypothesis that PV and 
GAT1 are down-regulated in schizophrenia as a consequence of lower GAD67 in PV 
neurons.  
It is possible that compensatory increases in other gene products, such as 
GAD65, or in protein levels of GAD67, may result in normal GABA levels in these 
animals. However, in visual cortex P30 PVGAD67+/- mice exhibit approximately 30% less 
GAD67 immunoreactivity in PV neurons, as well as several functional impairments 
(Lazarus and Huang, 2010). Significantly reduced IPSC amplitude and significantly 
faster IPSC decay time, as well as pyramidal cell hyperactivity have been observed, all 
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of which are consistent with lower GABA function (Lazarus and Huang, 2010). Although 
differences between motor and visual cortices may exist, both regions exhibit lower 
GAD67 mRNA in schizophrenia (Hashimoto et al., 2008b), and therefore these data 
suggest that the lack of change in PV and GAT1 mRNAs in PVGAD67+/- mice is not due to 
normal GABA levels resulting from compensatory changes in other effectors of GABA 
neurotransmission. 
Based on the 17% reduction in GAD67 mRNA in PVGAD67+/- mice, which is 
comparable to the mean 15% reduction in GAD67 mRNA in schizophrenia (3.4.1), these 
animals capture the average difference observed in schizophrenia. This suggests that 
the lack of change in PV and GAT1 mRNA is not because these mouse models exhibit 
a level of GAD67 reduction that is insufficient to model the changes in schizophrenia. 
However, the lack of PV and GAT1 mRNA changes could be due to an inappropriate 
modeling of the time course of the reduction of GAD67 in schizophrenia.  
Both genes and the environment are thought to play a role in the pathogenesis of 
schizophrenia; lower GAD67 resulting from genetic factors would likely occur at the 
onset of prenatal development, whereas an environmental insult, such as complications 
during late pregnancy, would produce a deficit later (Hoftman and Lewis, 2011). Here 
we have modeled these two possible time points of lower GAD67 expression. 
GABAGAD67+/- mice model a reduction in GAD67 early in prenatal development, whereas 
PVGAD67+/- mice do not exhibit lower GAD67 until later in development [P11, 
corresponding to roughly the third trimester of gestation in humans (Clancy et al., 
2001)]. Our data suggest that PV and GAT1 mRNAs are not reduced regardless of 
whether the GAD67 deficit is present from the birth of GABA neurons or not until later in 
development.  
However, it is currently unclear when GAD67 is reduced in schizophrenia. Allelic 
variations in the GAD1 gene are associated with schizophrenia, and with lower GAD67 
mRNA (Straub et al., 2007), suggesting that GAD67 may in fact be reduced early in 
prenatal development. On the other hand, the small effect size and low penetrance 
suggests that genetic variations of GAD1 may only play a role in the pathogenesis of 
schizophrenia in a minority of cases (Insel, 2010). Additionally, an argument against the 
role of prenatal risk factors in the etiology of schizophrenia has recently been made, 
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citing the lack of reproducibility of specific factors (van Os et al., 2010). Thus, it is also 
possible that GAD67 is not reduced until a postnatal time point in schizophrenia. In fact, 
in children who go on to develop schizophrenia as adults, working memory performance 
is normal at 7 years of age (Reichenberg et al., 2010). By ages 9-13, however, their 
performance lags behind that of their peers (Reichenberg et al., 2010), suggestive of a 
deficit in DLFPC circuitry that does not manifest until later in childhood development. 
Thus, reducing GAD67 very early in development, as we have done in the present 
study, may invoke different effects than a reduction during childhood in individuals with 
schizophrenia would. 
PV development occurs postnatally in rodents (de Lecea et al., 1995), but this 
time point corresponds to prenatal development in humans (Clancy et al., 2001). In 
contrast, PV development occurs postnatally in primates (reviewed in Hoftman and 
Lewis, 2011). Furthermore, there are clear differences in PVb cells between rodents and 
primates, with the latter being more excitable (Povysheva et al., 2008). Therefore, it is 
possible that reducing GAD67 in rodent and primate PV cells would produce different 
compensatory effects. Thus, our data do not support the hypothesis that PV and GAT1 
mRNA are lower in schizophrenia as a compensation for lower GAD67 in PV cells, but 
clear species differences in PV neurons prevent the definitive rejection of this 
hypothesis.  
Alternatively, it is possible that changes in PV or GAT1 may be upstream of lower 
GAD67 in schizophrenia. For example, lower levels of PV increase GABA release 
(Collin et al., 2005; Vreugdenhil et al., 2003) and the resulting increase in extracellular 
GABA might evoke a compensatory reduction in GABA synthesis via downregulation of 
GAD67 expression. Likewise, a deficit in GABA reuptake may result in increased GABA 
availability and a compensatory downregulation of GABA synthesis. However, GAT1 
KO mice actually exhibit increased GAD67 (Bragina et al., 2008).  
Although we cannot rule out that differences in the time point of the GAD67 
reduction, or disparities between mouse and human PV neurons, may account for the 
differences between the mouse model and schizophrenia data, the findings of the 
present study suggest that PV and GAT1 are not reduced in the illness as a 
consequence of lower GAD67 in PV neurons. Thus, an alternative, upstream 
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mechanism may be responsible for concomitant changes in GAD67, PV, and GAT1. For 
example, reduced signaling through tyrosine kinase B (TrkB) receptors, which exhibit 
lower mRNA expression schizophrenia (Hashimoto et al., 2005; Weickert et al., 2005), 
produces alterations in GAD67 and PV mRNA (Hashimoto et al., 2005). Additionally, 
lower signaling through NMDA receptor 1 (NR1), also altered in schizophrenia (Lewis 
and Moghaddam, 2006), produces lower levels of GAD67, PV and GAT1 mRNA 
(Behrens et al., 2007; Bullock et al., 2009; Belforte et al., 2010). Future studies are 
needed to further assess the mechanisms underlying lower PV and GAT1 expression in 
schizophrenia. 
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5.0  GENERAL DISCUSSION 
This dissertation assessed factors contributing to the heterogeneity of the GAD67 
mRNA deficit in schizophrenia, overcame significant technical challenges to quantify 
both total and PV axon terminal levels of GAD67 protein in postmortem human brain, 
and examined the consequences of lower GAD67 expression in PV neurons on PV and 
GAT1 mRNA levels. Briefly, we found that 1) lower GAD67 mRNA in schizophrenia is 
not associated with medication or substance use, predictors or measures of functional 
outcome, or length of illness; 2) GAD67 protein is similarly reduced in the DLPFC; and 
3) the GAD67 protein deficit is much greater at PV axon terminals, a major site of GABA 
production and function. Taken together, these data suggest that GABA synthesis is 
lower and consequently neurotransmission is impaired in a subset of cortical inhibitory 
neurons in schizophrenia. Additionally, we found that reducing GAD67 expression in PV 
neurons does not seem to alter PV or GAT1 expression. Thus, lower PV and GAT1 
mRNAs in schizophrenia are likely not a consequence of lower GAD67. 
The concluding section of Chapter 1 raised several questions concerning the 
nature of the GAD67 deficit in schizophrenia. In the following sections, I will address 
these questions, as well as several that arise from our data, and consider important 
future directions for research. First, I will discuss how common the GAD67 deficit is in 
schizophrenia, and identify sources that may contribute to the observed variability (5.1). 
Second, I will discuss the significance of lower total GAD67 protein levels in 
schizophrenia (5.2). Third, I will consider the implications of lower GAD67 protein levels 
at PV axon terminals (5.3). Fourth, I will review several potential mechanisms that may 
underlie lower GAD67 expression in PV neurons, and discuss the time point in the 
disease process when the deficit in GAD67 occurs (5.4). Lastly, I will examine the 
consequences of lower GAD67 in PV neurons (5.5).  
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5.1 HOW COMMON IS THE GAD67 MRNA DEFICIT, AND WHAT FACTORS 
CONTRIBUTE TO THE HETEROGENEITY? 
Schizophrenia is a disease characterized almost as well by its heterogeneity as by its 
common features. A diagnosis is often difficult due to the fact that it is made based 
solely on clinical features. Additionally, schizophrenia has a very broad presentation that 
includes several diagnostic subtypes. Finally, outcomes vary widely; a minority of 
patients experience full symptom remission, while others are severely disabled for the 
rest of their lives (Harrison et al., 2001; Insel, 2010). Throughout the literature, the 
GAD67 mRNA deficit is also characterized by substantial heterogeneity. Relative to 
comparison subjects, most patients exhibit lower levels of GAD67, while some exhibit 
normal, and even increased, levels of the enzyme (Volk et al., 2000; Hashimoto et al., 
2005; Hashimoto et al., 2008b). 
5.1.1 Proportion of schizophrenia subjects with lower GAD67 mRNA 
In the 13 published studies that have examined GAD67 mRNA expression in the 
DLPFC in schizophrenia to date, 5 provided data on the number of subject pairs with 
lower GAD67 mRNA in the schizophrenia subject (Table 2). Although limited by 
overlapping cohorts, averaging the results from each study in Table 2 together suggests 
that roughly 87% of schizophrenia subjects contain lower GAD67 mRNA. In the present 
study, we also observed heterogeneity in GAD67 mRNA levels (Figure 14). In 31 of the 
42 subject pairs (74%) the schizophrenia subject exhibited less GAD67 mRNA than the 
matched comparison subject. 
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Table 2. GAD67 mRNA studies utilized in analysis of GAD67 heterogeneitya 
Study Pairs with lower GAD67 mRNA in the schizophrenia subject 
Volk et al., 2000 (ISH) 8/10; 9/10; 8/10 depending on layer 
Hashimoto et al., 2005 (ISH) 15/15 in cohort 1; 9/12 in cohort 2 
Huang and Akbarian, 2007 (qPCR) 14/14; 13/14; 12/14 depending on primers 
Hashimoto et al., 2008a (qPCR, 
microarray) 10/14 by both qPCR and microarray 
Hashimoto et al., 2008b (qPCR) 12/12 
 
aAbbreviations: ISH, in situ hybridization. 
 
 
 
One advantage of using paired comparisons to assess the commonality of the 
GAD67 mRNA deficit is that this approach controls for the potential influence of pairing 
variables, such as sex and age, on GAD67 mRNA levels. However, paired comparisons 
are influenced by the variability of not only the schizophrenia subject but also the 
comparison subject. A second strategy that is more robust to comparison subject 
variability, though potentially confounded by differences in pairing variables, is to relate 
each schizophrenia subject to the mean of the comparison group. When utilizing this 
method in two of the studies from Table 2, 24 out of 27 subjects, assessed using ISH 
(89%; Hashimoto et al., 2005), and 10 out of 12 subjects, using qPCR (83%; Hashimoto 
et al., 2008b), exhibit lower GAD67 mRNA. When comparing schizophrenia subjects to 
the mean of comparison subjects in the current study, 30 of the 42 subjects (71%) 
exhibit lower GAD67 mRNA. The differences in GAD67 mRNA observed using this 
approach are quite similar to those observed using paired comparisons, suggesting that 
neither variability due to comparison subjects or pairing variables substantially 
confounds the measures of commonality.  
One limitation of the above analyses is that all differences in GAD67 mRNA, 
however small, are counted as biologically meaningful. In fact, a 5% reduction may not 
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be indicative of a functionally meaningful deficit. For example, Parkinson’s disease 
symptoms do not typically begin until 50-70% of dopamine cells have been lost in the 
substantia nigra (Halliday and McCann, 2010), and thus a 30% cell loss may not be 
clinically meaningful. However, determining the criterion for a meaningful difference in 
schizophrenia is difficult. One approach to this issue is to make a within-pair comparison 
of total GAD67 mRNA levels and GAD67 mRNA+ neuron density, the latter being an 
indicator of the proportion of GAD67 cells that drop below the threshold of detectability 
of grain counting, and thus exhibit marked reductions in GAD67. In fact, such data are 
available for the 8 subjects pairs in common between the qPCR study presented here 
(3.4.1) and the grain counting study by Volk et al. (2000). As observed in Figure 22, 
even very modest deficits in GAD67 by qPCR are associated with more than 20% fewer 
cells with detectable GAD67 levels. This comparison allows for a determination of what 
magnitude of a tissue-level reduction is needed in order to observe a large reduction in 
cellular levels of GAD67 mRNA. Examination of the levels of GAD67 mRNA per neuron 
is a biologically meaningful measure since it evaluates the proportion of cells without 
detectable levels of the transcript, thereby indexing cells that are presumably very 
functionally impaired. In fact, in PVGAD67+/- mice a 31% reduction in the GAD67 mRNA 
levels per neuron, but no loss in the number of neurons with detectable levels of GAD67 
(4.4.1), is able to produce functional impairments such as reduced IPSC amplitude 
(Lazarus and Huang, 2010). Thus, an even larger reduction, such as the one needed in 
order for some neurons to drop below detectability, is surely associated with functional 
deficits. These data suggest that even 5-10% decrements in total GAD67 mRNA in 
tissue homogenates may be biologically meaningful, since they indicate a marked 
decrease in GAD67 mRNA levels in a subset of neurons that produces functional 
impairment. Interestingly, when utilizing both total GAD67 mRNA and GAD67 neuronal 
density, 6 out of 8 pairs (75%) exhibit lower GAD67 in the subject with schizophrenia, 
which closely matches the above mean values observed across multiple studies. 
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Figure 22. Pairwise percent differences in GAD67 neuronal density plotted 
against percent differences in total GAD67 mRNA. GAD67 mRNA+ neuronal density 
was assessed using grain counting; total GAD67 mRNA was measured using qPCR. 
 
 
5.1.2 Sources of GAD67 mRNA variability 
Taken together, the results from the current study as well as from the literature suggest 
that approximately 75% of schizophrenia subjects do exhibit lower levels of cortical 
GAD67 mRNA. But what accounts for the proportion of patients that do not exhibit lower 
GAD67? Is the observed variability in GAD67 mRNA levels simply due to either 
methodological or biological variability that is inherent to human postmortem studies, or 
is it specific to schizophrenia? Methodological variability does not seem to play a large 
role in the heterogeneity among GAD67 mRNA levels, since different techniques 
converge on very similar results. For example, the within-pair percent changes in 
GAD67 mRNA assessed using qPCR and ISH are highly correlated (r=0.89, p<0.001) 
(Hashimoto et al., 2008a). Similarly, the same qPCR data are significantly correlated 
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with the expression differences detected by DNA microarray (r=0.71, p=0.005) 
(Hashimoto et al., 2008a). Additionally, as shown in Figure 22, assessments of both 
cellular and tissue levels of GAD67 in schizophrenia converge on the same disease 
effect. That is, across both measures, the directionality of the GAD67 change is 
identical for every pair.  
Interestingly, in the present study, the GAD67 mRNA CV for the schizophrenia 
subjects (0.247) was double that of the comparison subjects (0.125), suggesting that 
the heterogeneity observed is due, at least in part, to factors that differentially affect 
schizophrenia and comparison subject brains. In fact, this phenomenon is also 
observed throughout the literature, with virtually all studies for which data are available 
exhibiting higher variability in schizophrenia subjects relative to comparison subjects 
(Akbarian et al., 1995a; Volk et al., 2000; Hashimoto et al., 2005; Hashimoto et al., 
2008b; Hashimoto et al., 2008a; Woo et al., 2008). Thus, greater variability seems to be 
a conserved feature of schizophrenia, due to either the disease process itself or an 
associated factor. 
Importantly, the observed variability does not seem to be accounted for by 
confounding factors such as use of antipsychotics, benzodiazepine/valproic acid, or 
antidepressants; or with alcohol abuse or dependence, nicotine use, or a history of 
marijuana use, since GAD67 mRNA levels were not significantly different in 
schizophrenia subjects with or without these factors (Figure 15). Moreover, GAD67 
mRNA levels did not differ as a function of age or length of illness (see 5.4.2 for further 
discussion), suggesting that lower GAD67 mRNA in schizophrenia is not a 
consequence of having the illness. Importantly, the fact that the GAD67 alterations 
seem to be specific to the disease process of schizophrenia suggests that ameliorating 
these deficits may lead to an alleviation of cognitive control symptoms and improvement 
of functional outcome. 
Given that lower GAD67 mRNA is thought to underlie the cognitive dysfunction in 
schizophrenia, and cognitive symptoms are the best predictor of functional outcome 
(Green et al., 2000), we hypothesized that GAD67 mRNA levels may be different 
between schizophrenia subjects as a function of predictors of illness severity and/or 
measures of functional outcome. This, however, was not observed, as there was no 
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change in GAD67 mRNA levels in schizophrenia subjects as a function of sex, a 
diagnosis of schizophrenia rather than schizoaffective disorder, a first degree relative 
with schizophrenia, an early age of onset, suicide, no history of marriage, low SES, or 
independent living (Figure 15).  
It is possible that the above variables represent too crude of an assessment of 
illness severity and functional outcome in order to detect differences in GAD67 mRNA. 
For example, many healthy individuals never marry, and some schizoaffective disorder 
subjects experience a worse course of illness than some schizophrenia subjects. One 
approach that may increase the ability to detect a difference is to create a composite 
index of disease severity that incorporates multiple predictive factors into a single 
measure. To do this, we assigned each schizophrenia subject a +1 on each factor that 
was positively associated with a more severe illness course or more impaired functional 
outcome, and a -1 on each factor that was associated with a less severe illness course 
or less impaired functional outcome; a total was then made for each subject. Values 
ranged from -6 to +4; a more positive number is associated with greater illness severity. 
However, there was no significant correlation between composite index of severity and 
GAD67 mRNA levels (r=-0.045, p=0.778). One caveat from both the individual and 
composite measures is that, due to differences in subject age ATOD, each measure 
was assessed at different time points in the lifespan of individual subjects, which may 
influence some values obtained. Additionally, the measures are based on retrospective 
psychological autopsy records obtained from next of kin, and thus may be subject to 
inaccuracies. Ideally, though not available for the current cohort, data on more direct 
measures such as laboratory assessments of cognitive functioning would be the most 
informative. Future studies utilizing this type of information may provide insight into the 
sources of GAD67 heterogeneity. 
The variability in the GAD67 deficit does not seem to be accounted for by 
different schizophrenia subtypes, evidenced by the fact that we did not observe a 
significant effect of diagnosis subtype (chronic, paranoid, undifferentiated, or 
schizoaffective disorder) on GAD67 mRNA levels (F1,38=0.547, p=0.653). This is not 
particularly surprising given that the different subtypes are based on differences in 
positive and negative symptomatology, and not the cognitive impairments thought to 
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result from alterations in GAD67. Alternatively, it is possible that schizophrenia is 
caused by multiple mechanisms that converge on a common symptomatology, and thus 
the heterogeneity in GAD67 levels may be due to differing mechanisms between 
different subjects. For example, as described below in 5.3, lower GAD67 mRNA can be 
achieved in several ways, and perhaps each etiopathogenic mechanism gives rise to a 
different level of GAD67 reduction in schizophrenia. 
5.2 WHAT IS THE SIGNIFICANCE OF LOWER LEVELS OF TOTAL GAD67 
PROTEIN IN SCHIZOPHRENIA? 
Total GAD67 protein levels are significantly 10% lower in the DLPFC of subjects with 
schizophrenia relative to normal comparison subjects (Figure 16). Furthermore, the 
reductions in mRNA and protein are similar in magnitude and tend to be correlated, 
suggesting that the reduction in GAD67 message drives the reduction in protein. Thus, 
the large numbers of studies replicating lower levels of GAD67 mRNA can be 
reasonably interpreted as extending to the protein level. Lower levels of the enzyme 
responsible for the majority of cortical GABA synthesis (Battaglioli et al., 2003; Mason et 
al., 2001) presumably result in lower cortical GABA levels in schizophrenia. However, 
as discussed in 3.5, magnetic resonance spectroscopy studies of cortical GABA levels 
in schizophrenia have produced mixed results (Ongur et al., 2010; Goto et al., 2009b; 
Yoon et al., 2010). Given that spectroscopic studies measure total tissue GABA levels, 
not those associated with synapses, their relevance to GABA neurotransmission is 
unclear. Thus, future studies are needed to properly assess synaptic GABA levels in 
schizophrenia.  
The significant 10% reduction in total GAD67 protein by Western blotting 
observed here differs from the 50% lower (Guidotti et al., 2000) and unchanged (Straub 
et al., 2007; Dracheva et al., 2004) levels reported in the literature. An effect of PMI may 
explain these differences. Although we found that GAD67 protein is relatively well-
preserved at PMIs of up to 26 hours (with 82% of levels of 7 hr PMI group still present; 
2.3.2), tissue was not available with which to examine the effect of PMI at longer time 
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points. Given the substantially longer mean PMI of the schizophrenia group (34 hrs) 
than the normal comparison group (24 hrs) in Guidotti et al. (2000), their results may 
have been confounded by additional degradation of GAD67 protein in the schizophrenia 
group relative to the comparison group, accounting for the much larger observed 
reduction in GAD67 protein. Straub et al. (2007) reported no change in the DLPFC 
GAD67 protein levels. However, their results may also have been confounded by PMI, 
as long PMIs were present in both the comparison and schizophrenia groups (mean of 
31 hrs and 36 hrs, respectively), which may have resulted in both groups falling to a 
floor level. In the current study, PMI is unlikely to have confounded the results since the 
mean PMI of the schizophrenia and comparison groups were nearly identical and all 
subjects had a PMI of less than 20 hours, a value at which GAD67 protein levels are 
well-preserved (2.3.2). 
Another potential reason that the results of the current study are discrepant with 
the literature is that differences in Western blotting methodology between this study and 
the two that have reported unchanged GAD67 protein levels (Straub et al., 2007; 
Dracheva et al., 2004) may have precluded the latter studies from detecting a 
difference. For example, Dracheva et al. used a pan GAD antibody, which produces 
bands at both 67 and 65 kDa, corresponding to GAD67 and GAD65, respectively. In my 
experience with this antibody, the small 2 kDa separation of these bands makes it 
difficult to prevent contamination between the two bands during quantification. 
Additionally, Straub et al. utilized actin as a normalizing protein, which I have shown is 
associated with twice the variability of tubulin (2.3.4), the normalizer utilized here. In 
addition, the current study utilized a paired design with multiple replicates to further 
reduce variability, thus making it easier to detect a small difference. Finally, the current 
study utilized the LI-COR Odyssey Infrared Imaging System to visualize and quantify 
bands, an approach that has greater sensitivity and lower variability compared to the 
enzyme-based chemiluminescence utilized by both the Dracheva and Straub studies. In 
fact, a characterization of the LI-COR system at the antibody concentrations used in our 
study revealed a high degree of linearity as well as proportionality. In summary, our 
ability to detect to small differences in GAD67 protein that other studies failed to find 
highlights the importance of using a robust quantitative Western blotting strategy (2.3).  
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5.3 WHAT ARE THE IMPLICATIONS OF LOWER GAD67 PROTEIN LEVELS AT 
PV AXON TERMINALS? 
5.3.1 GAD67 protein is lower in PVb terminals; level in PVch terminals is unclear 
The seminal dual ISH study demonstrating that approximately 50% of PV neurons lack 
detectable levels of GAD67 mRNA (Hashimoto et al., 2003) was not able to determine 
which subpopulation(s) of PV neurons are affected. That is, is lower GAD67 mRNA 
present in PVb cells, PVch cells, or both? Below I will discuss the current evidence in 
favor of each of these outcomes. 
Given that a subpopulation of PV interneurons does not contain detectable levels 
of GAD67 mRNA (Hashimoto et al., 2003), and GAD67 is important in the development 
of the proper number of PV axon terminals (Chattopadhyaya et al., 2007), a reduced 
density of PV-IR puncta, presumably PVb axon terminals (Erickson and Lewis, 2002), in 
layers 3-4 of subjects with schizophrenia (Lewis et al., 2001) suggests that PVb cells 
may contain lower GAD67 in schizophrenia. Until now, however, direct evidence that 
PVb cells contain less GAD67 has been lacking. In the current measurement of GAD67 
protein in PV axon terminals (3.4.4), available evidence suggests that GAD67 was 
quantified only in PVb terminals. For example, a recent study in monkey DLPFC from 
our group using the same approach demonstrated that PVch cartridges express mainly 
GAD67, and express very low levels of GAD65 (Fish et al., 2011). Although not yet 
quantified, the same scenario appears to be present in human tissue (Ken Fish, 
personal communication), suggesting that because we utilized GAD65 to mask and 
identify axon terminals, only PV terminals not associated with cartridges (presumably 
PVb terminals) were quantified. Thus, our data support the idea that GAD67 protein is 
lower in PVb terminals in schizophrenia. 
The 49% reduction in GAD67 protein in PVb terminals is nearly 10X greater than 
the 5% reduction observed at the total protein level in the same subject pairs. 
Interestingly, all 5 pairs exhibit lower GAD67 protein at PV puncta in the schizophrenia 
subject, although only 2 of the pairs exhibited lower levels of total GAD67 protein. 
Although the sample size is small, these data suggest that some of the variability in the 
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tissue homogenate measures may be eliminated by examining GAD67 in the specific 
subpopulation of neurons that are affected. Importantly, these data provide not only the 
first evidence of a GAD67 protein alteration in PV neurons in schizophrenia, but also the 
first evidence of a GAD67 decrement at the axon terminal, the site of GABA production 
and function. Moreover, these data mark the first time this powerful approach has been 
used in postmortem human tissue. Immunofluorescence and confocal microscopy, 
coupled with a novel methodology, have provided a robust assessment of GAD67 
protein levels in a specific population of interneurons due to the use of a sensitive 
microscopy system, stereological sampling, an iterative threshold/morphological 
segmentation and data analysis approach that allows for the accurate quantification of a 
wide range of fluorescent intensities, and the elimination of the confounding 
autofluorescence of lipofusin (2.4). Going forward, this methodology will provide 
answers to a number of important questions that remain, some of which are described 
below. 
Alterations in a variety of effectors of GABA neurotransmission have been 
interpreted as compensatory responses to lower GAD67 in PVch cells (Lewis et al., 
2005). First, correlated reductions in GAD67, PV, and GAT1 mRNA (Hashimoto et al., 
2003; Volk et al., 2001) have been interpreted to mean that these changes are 
occurring in the same neurons. Additionally, the density of PVch cartridges that are 
GAT1-IR is 40% lower is schizophrenia, although the density of other GAT1-IR 
structures is unaltered (Woo et al., 1998). Given that the changes in GAD67 and GAT1 
seem to be present in the same neurons (Volk et al., 2001), this suggests that PVch cells 
exhibit lower GAD67. This hypothesis has been further supported by the observation of 
increased GABAA α2-IR AIS number in schizophrenia (Volk et al., 2002), interpreted as 
a compensation to increase effects of deficient GABA synthesis at PVch synapses. 
However, the hypothesis that PVch cells contain lower GAD67 has never been directly 
demonstrated. Thus, it is currently unknown whether or not PVch cells contain less 
GAD67, and future studies are needed to address this issue. 
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5.3.2 PV protein levels at PVb axon terminals 
PV protein levels at PVb axon terminals were also measured in this study, by quantifying 
the PV fluorescence intensity at puncta triple-labeled for GAD67, PV, and GAD65. PV 
axon terminal protein levels were nonsignificantly 27.3% lower (t4=0.894, one-tailed 
p=0.211) in the DLPFC of subjects with schizophrenia (Figure 23). However, a 
decrease in PV protein levels should have been more detectable than a decrement in 
GAD67. In the same cohort of subjects in which we found a 15% reduction in GAD67 
mRNA (3.4.1), the reduction in PV mRNA expression is larger in magnitude (22%; 
David Volk, personal communication), which is consistent with another report by our 
group (Hashimoto et al., 2008b). However, as shown in Figure 23, PV terminal levels 
exhibited substantially more variability than GAD67 axon terminal protein levels. In fact, 
the comparison subject of one pair seems to be driving the majority of the decrease, 
suggesting that PV levels may not be decreased in PVb cells. The increased variability 
in PV is consistent with the qPCR data in the current cohort (D. Volk, personal 
communication), as well as in a previous study (Hashimoto et al., 2008b). Thus, future 
studies with larger sample sizes are needed to accurately quantify PV protein levels in 
PV axon terminals. 
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Figure 23. PV protein levels in PV puncta plotted for each pair of comparison and 
schizophrenia (circle) or schizoaffective (triangle) subjects. Values below the 
diagonal unity line indicate lower PV protein in PV puncta in the schizophrenia subject 
relative to the comparison subject. 
5.4 WHAT ETIOPATHOGENIC MECHANISMS UNDERLIE LOWER GAD67 IN 
SCHIZOPHRENIA, AND WHAT IS THE TIMING OF THE DEFICIT? 
5.4.1 Potential mechanisms underlying lower GAD67 
A thorough interpretation of the GAD67 deficit in schizophrenia requires knowledge of 
the underlying mechanism(s). Despite the widely-characterized GAD67 mRNA deficit, 
the etiology of this change is poorly understood. Although there are many possibilities, 
below I will discuss a few of the most compelling candidates.  
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5.4.1.1 Allelic variation in GAD1 
The gene that encodes GAD67, GAD1, contains 18 exons across 45 kb of genomic 
DNA (Bu and Tobin, 1994) and is located on chromosome 2q31 (Bu et al., 1992). 
Recently, allelic variation in GAD1 has been implicated as a risk factor in schizophrenia. 
Several studies have associated single nucleotide polymorphisms (SNPs) in GAD1 with 
adult- (Straub et al., 2007; Du et al., 2008; Zhao et al., 2007) and childhood-onset 
schizophrenia (Addington et al., 2005), although others have reported no association 
(Lundorf et al., 2005; De Luca et al., 2004; Zhang et al., 2005). Additionally, GAD1 
SNPs have been associated with deficits in attention and working memory, and with 
DLPFC activation (Straub et al., 2007). GAD1 SNPs have also been associated with 
GAD67 mRNA levels (Straub et al., 2007), indicating that alterations in the gene may 
underlie lower GAD67 mRNA in schizophrenia. Existing data suggest several possible 
mechanisms by which alterations in the GAD1 gene in schizophrenia may lead to lower 
transcription of GAD67. Although no risk allele SNPs are located within the coding 
region of GAD1 (Akbarian and Huang, 2006), a risk SNP located in the promoter region 
is associated with increased transcription factor binding, which may lead to altered 
promoter function (Zhao et al., 2007). Additionally, epigenetic mechanisms, which 
control gene activity without altering the DNA sequence, may also play a role. 
Methylation of certain lysine residues on nuclear histone proteins, around which DNA is 
wound, result in shifts between active and repressed transcription (reviewed in 
Tsankova et al., 2007). In female schizophrenia subjects, GAD1 risk SNPs are 
associated with lower PFC GAD67 mRNA and a shift from active to repressed histone 
methylation (Huang et al., 2007), providing a potential mechanism through which allelic 
variation may lower GAD67 mRNA levels. However, the gender-specificity of the finding 
suggests that this mechanism may only be occurring in females. Therefore, the exact 
role of epigenetic mechanisms in GAD1 transcription remains to be elucidated. 
Although there is evidence implicating allelic variation in the GAD1 gene as a 
potential pathogenic mechanism, low penetrance, small effect sizes and a lack of 
concordance between studies regarding the specific SNPs involved suggest that allelic 
variation in GAD1 may play a contributing role in only a minority of cases and is not the 
only causative factor underlying lower GAD67 in schizophrenia (Insel, 2010). Further 
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confusing the issue, schizophrenia GAD1 risk alleles have recently been associated 
with increased GABA levels in the anterior cingulate cortex of healthy subjects 
(Marenco et al., 2010). Thus, the exact role of GAD1 risk alleles in the pathogenesis of 
GAD67 deficits in schizophrenia remains to be determined. While allelic variation in 
GAD1 may play a role in lower GAD67 in schizophrenia, other mechanisms must also 
be at work. 
5.4.1.2 Reduced signaling through TrkB 
The allelic variations in GAD1 described above support the idea that a GAD67 deficit is 
a primary, causative factor in the illness. Alternatively, lower GAD67 may be the 
consequence of a more upstream mechanism. One such mechanism that may be 
responsible for reductions in GAD67, as well as in PV and GAT1, in schizophrenia is 
reduced signaling through the TrkB receptor and its ligand brain-derived neurotrophic 
factor (BDNF). TrkB/BDNF signaling is important for the development of interneurons 
(Woo and Lu, 2006), especially PV cells, which comprise the majority of TrkB-
expressing interneurons (Gorba and Wahle, 1999; Cellerino et al., 1996). For example, 
TrkB/BDNF signaling has been implicated in a wide variety of developmental processes, 
including interneuron migration, differentiation, and synaptogenesis (Woo and Lu, 2006; 
Huang et al., 1999; Kohara et al., 2003; Kohara et al., 2007). BDNF treatment in vitro 
upregulates GAD and promotes GABA release (Yamada et al., 2002), and BDNF 
overexpressing mice exhibit accelerated PV interneuron maturation (Huang et al., 
1999). 
Both BDNF and TrkB mRNA are lower in the DLPFC of subjects with 
schizophrenia (Hashimoto et al., 2005; Weickert et al., 2003; Weickert et al., 2005). In 
fact, in the same subject pairs, the within-pair changes in TrkB mRNA are significantly 
correlated with those of both GAD67 and PV (Hashimoto et al., 2005). Additionally, TrkB 
hypomorphic, but not BDNF KO, mice exhibit lower levels of GAD67 and PV mRNA 
(Hashimoto et al., 2005), suggesting that reduced signaling through the TrkB receptor 
may underlie lower levels of both GAD67 and PV in schizophrenia. Furthermore, TrkB 
hypomorphs exhibit a reduced density of GAD67 mRNA+ cells, without a change in the 
mRNA levels per cell (Hashimoto et al., 2005), similar to the pattern observed in 
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schizophrenia (Volk et al., 2000). Although GAT1 has not been examined in these 
animals, it also appears to be modulated by the TrkB/BDNF signaling pathway. 
Inhibition of tyrosine kinases in hippocampal cells reduces GAT1 phosphorylation and 
GABA reuptake, while application of BDNF upregulates GAT1 function (Law et al., 
2000). 
5.4.1.3 NMDA hypofunction in PV neurons 
Glutamate-mediated excitatory neurotransmission occurs through a variety of fast 
ionotropic (NMDA, AMPA, and kainate) receptors, as well as the slower G protein-
coupled metabotropic receptors. The now widely-recognized NMDA receptor 
hypofunction hypothesis of schizophrenia originated from the observation that NMDA 
receptor antagonists mimic schizophrenia symptoms, and has been strengthened by 
findings of lower levels of glutamate receptors, such as the NR1 subunit, in 
schizophrenia, as well as studies demonstrating that several schizophrenia risk genes, 
such as neuregulin 1 and ErbB4, affect NMDA receptor signaling (reviewed in Lewis 
and Moghaddam, 2006).  
Interneurons are known to depend on NMDA-mediated excitation (Jones and 
Bühl, 1993; Maccaferri and Dingledine, 2002), and thus lower glutamatergic drive onto 
GABA neurons may result in subsequent reductions in markers of inhibitory 
transmission (Lewis and Moghaddam, 2006). The vast majority (80-90%) of PV neurons 
express NR1 receptors (González-Albo et al., 2001; Huntley et al., 1994), and thus PV 
neurons are thought to be particularly affected by reduced NMDA receptor signaling 
(Lewis and Moghaddam, 2006). In fact, NMDA receptor antagonists reduce GAD67 
(Behrens et al., 2007), PV (Cochran et al., 2003; Behrens et al., 2007), and GAT1 
(Bullock et al., 2009) mRNA. Additionally, mice with a selective knockout of the NR1 
receptor on ~50% of cortical and hippocampal interneurons, presumably mostly PV 
neurons, during early postnatal development exhibit reduced GAD67 and PV protein 
(Belforte et al., 2010). Moreover, mice with a selective knockout of NR1 on PV neurons 
exhibit alterations in γ oscillations (Carlén et al., 2011), which are disturbed in 
schizophrenia (Cho et al., 2006). 
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However, there are limitations of this version of the NMDA hypofunction 
hypothesis. First, the hypothesis is based largely on the observation that treatment with 
NMDA receptor antagonists in adults mimics the symptoms of schizophrenia in healthy 
subjects, and worsens the symptoms of schizophrenia subjects. However, GAD67 and 
PV protein levels are not affected when NR1 is knocked out during adulthood (Belforte 
et al., 2010), consistent with the finding that in adult mice NMDA receptors make only a 
weak contribution to PV cell excitatory postsynaptic currents (EPSCs) (Rotaru et al., 
2011; but see Carlén et al., 2011). A second limitation of the NMDA hypofunction 
hypothesis is that it predicts that reduced signaling through NR1 receptors on PV 
neurons leads to disinhibition of pyramidal neurons (Lisman et al., 2008). In fact, 
substantial evidence points not to an increase, but rather a decrease, in activity in the 
DLPFC. The majority of imaging studies suggest hypofunction of this brain region 
(Weinberger, 2001), and several studies have documented a lower power of γ 
oscillations as well (Cho et al., 2006; Minzenberg et al., 2010).   
5.4.1.4 Reduced excitatory neurotransmission 
In addition to the alterations in inhibitory interneurons that are present in the DLPFC of 
subjects with schizophrenia, a number of changes are also present in excitatory 
pyramidal cells. First, there is a significant reduction in the density of dendritic spines, a 
finding that is most pronounced in layer 3 (Glantz and Lewis, 2000; Kolluri et al., 2005). 
Additionally, although the total number of pyramidal neurons is not altered in the PFC 
(Akbarian et al., 1995b; Thune et al., 2001), somal size is significantly lower (Glantz and 
Lewis, 2000; Pierri et al., 2001; Rajkowska et al., 1998), and neuropil (Selemon and 
Goldman-Rakic, 1999) and dendritic tree size (Black et al., 2004; Kalus et al., 2000) are 
reduced. In addition to these morphological alterations in pyramidal neurons, a number 
of molecular changes have also been found. The mRNA levels for two spine markers, 
Duo and cell division cycle 42 (Cdc42), are lower in the DLPFC of subjects with 
schizophrenia, and are significantly correlated with the reduction in layer 3 spine density 
(Hill et al., 2006). In addition, immunoreactivity of synaptophysin, a synaptic vesicle 
protein, is also reduced in the DLPFC (Glantz and Lewis, 1997), suggestive of a 
disturbance in synaptic transmission. 
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The pyramidal cell alterations described above point to a reduction in excitatory 
function in the DLPFC of subjects with schizophrenia. Given that changes in both 
excitatory and inhibitory neurotransmission are found in schizophrenia, one hypothesis 
currently gaining momentum is that the reduced excitatory activity is an “upstream” 
pathology that produces compensatory downregulations in inhibitory activity, in an 
attempt to maintain the appropriate balance of excitatory and inhibitory activity (E/I 
balance) needed for proper cortical functioning (Lewis et al. in press). E/I balance is 
important to prevent both runaway excitatory activity (too much excitation) and a dying 
out of cortical activity (too much inhibition) (Turrigiano and Nelson, 2004). This balance 
is maintained through the scaling of excitatory and inhibitory strength, in a process 
termed homeostatic synaptic plasticity (Pozo and Goda, 2010). Scaling occurs through 
diverse mechanisms such as alterations in neurotransmitter content and postsynaptic 
receptor number (Pozo and Goda, 2010; Kilman et al., 2002). For example, activity 
deprivation using tetrodotoxin has been shown to reduce the amplitude of mIPSCs 
(Kilman et al., 2002). Thus, reduced excitatory activity of pyramidal cells may result in 
compensatory downregulation of inhibitory activity onto these neurons, as evidenced by 
lower GAD67 levels in PV cells.   
In fact, GAD7 is activity-dependent (Benson et al., 1994), and reductions in 
excitatory signaling have been shown to produce many of the same alterations in 
inhibitory function observed in the illness. For example, rats with neonatal lesions to the 
ventral hippocampus, which sends excitatory inputs to the PFC, exhibit lower GAD67 
mRNA levels (Lipska et al., 2003). Additionally, using tetrodotoxin, monocular 
deprivation of the lateral geniculate nucleus of the thalamus as well as the visual cortex 
results in lower GAD67 mRNA in primates (Huntsman et al., 1995). Interestingly, NR1 
KO mice exhibit a reduced spine density in layer 2/3 pyramidal neurons (Ultanir et al., 
2007). In addition to their localization on PV neurons, NR1 receptors are also located on 
the soma and dendrites of pyramidal neurons (Huntley et al., 1994), suggesting that 
perhaps NMDA hypofunction in schizophrenia is occurring on pyramidal neurons rather 
than on PV neurons. Thus, the aforementioned downregulations in PV neurons (lower 
GAD67 and PV) after treatment with NMDA antagonists may be occurring as a 
response to reduced excitation of pyramidal neurons. 
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5.4.2 Timing of the GAD67 deficit 
A critical issue in interpreting lower GAD67 in schizophrenia is when the deficit in 
GAD67, and presumably GABA, arises. Since GAD67 plays a role in development, an 
earlier vs. later reduction in GAD67 would have differing functional consequences. Early 
knockdown of GAD67 in PVb cells, during the development of PV synaptic architecture, 
as well as a germline reduction in GAD67 results in reduced axonal branching and 
arborization, and reduced bouton density (Chattopadhyaya et al., 2007). However, 
performing the same manipulation during adulthood does not produce the same 
synaptic deficits (Chattopadhyaya et al., 2007). Therefore, a GAD67 deficit in 
schizophrenia arising early in development would be expected to produce fewer 
numbers of PVb terminals. Both the reduced density of PV-IR puncta (Lewis et al., 
2001) and lower levels of α1 mRNA (Glausier and Lewis, 2011), which may reflect lower 
numbers of α1-containing GABAA receptors and thus fewer inputs from PVb cells, in 
schizophrenia suggests that the number of PV terminals may be reduced. Alternatively, 
these data may reflect lower expression per terminal, resulting in some that fall below 
detectability, rather than a loss of terminals. Furthermore, since PVb axons contact not 
only pyramidal neurons but also other PVb cells (Melchitzky et al., 1999), a lower 
number of PV terminals resulting from lower GAD67 early in development would be 
expected to reduce α1 mRNA on both targets, since the detrimental effects of lower 
GAD67 should be present in both locations. However, α1 mRNA levels were 
significantly reduced in pyramidal neurons but not interneurons (Glausier and Lewis, 
2011).  
In the current study of GAD67 protein levels in PV axon terminals (3.3.4), we did 
not observe a significant difference in the density of GAD67+/PV+/GAD65+ puncta 
between comparison (4.0 per 1000 μm3) and schizophrenia (4.4 per 1000 μm3) subjects 
(t4=-0.526, p=0.627). Since we could not estimate any tissue volume changes in 
schizophrenia, and therefore density measures are potentially confounded, there are 
caveats with these data, and thus their interpretative value may be limited. However, if 
they are real, it suggests that a GAD67 deficit in schizophrenia is occurring later in 
development, after GAD67 has contributed to bouton development. 
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The deficit in GAD67 does not appear to be progressive across the lifespan of 
the individual for a number of reasons. First, there was no significant correlation 
between GAD67 mRNA and age ATOD (r=-0.25, p=0.104; 3.4.1) Although others have 
reported a similar, negative correlation between GAD67 mRNA levels and age that did 
reach statistical significance (Straub et al., 2007), we also did not observe a significant 
difference in GAD67 mRNA between the youngest and old quarter of schizophrenia 
subjects, compared using either a t test or an ANCOVA (t18=1.586, p=0.130; 
F1,14=1.465, p=0.246). Additionally, there was no significant correlation between GAD67 
mRNA and age-corrected length of illness (3.4.1). Duncan et al. (2010) reported a 
significant negative correlation between GAD67 mRNA and length of illness, though this 
may be confounded by their reported significant negative effect of age. In summary, our 
data suggest that the GAD67 mRNA deficit is stable not only throughout the lifespan of 
an individual, but also throughout the course of the illness. Importantly, this suggests 
that lower GAD67 in schizophrenia is not a consequence of having the illness, and 
supports the idea that lower GAD67 underlies impairments in γ oscillations and 
cognition. Notably, γ oscillation impairments and cognitive deficits are also present in 
both first episode (Minzenberg et al., 2010) and chronic (Cho et al., 2006) schizophrenia 
patients. 
5.5 WHAT ARE THE CONSEQUENCES OF LOWER GAD67 IN PVB CELLS? 
5.5.1 Lower PV and GAT1 mRNA are not a consequence of lower GAD67 in PV 
neurons 
Since PV and GAT1 can each reduce the level of GABA available to postsynaptic 
receptors, it has been hypothesized that their reduction in schizophrenia may be a 
compensation to counteract upstream reductions in GAD67 (Lewis et al., 2005). Based 
on the results obtained in Chapter 4, lower PV and GAT1 mRNA do not seem to be a 
consequence of lower GAD67 in PV neurons, although we cannot rule out the possibility 
that differences between mouse and humans may have prevented detection of an 
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association (4.5). As reviewed above (5.4), it is possible that an upstream mechanism 
such as reduced signaling through TrkB receptors or NMDA hypofunction on PV 
neurons may result in concomitant changes in GAD67, PV, and GAT1. Another third 
possibility is that PV and GAT1 are lower specifically in PVch cells (Lewis et al., 2011), 
which recent evidence suggests may play an excitatory role in the cortex.  
Due to the exclusive input of PVch cells onto the AIS, the site of axon potential 
generation, of pyramidal neurons, PVch cells have classically been thought to play a 
powerful role in the inhibition of pyramidal cells (Miles et al., 1996). However, in the last 
5 years, evidence pointing to a depolarizing role of PVch cells has accumulated 
(reviewed in Woodruff et al., 2010). In 2006, the first report of a depolarizing effect of 
PVch cells was published, in which the authors reported that stimulation of PVch cells 
results in an excitation of postsynaptic pyramidal neurons (Szabadics et al., 2006). In 
addition, it was shown that the reversal potential (EGABA) in these cells was greater than 
the resting membrane potential (Vrest), likely due to a lack of the chloride extruding 
potassium/chloride cotransporter 2 (KCC2) at the AIS (Szabadics et al., 2006). A 
second study showed that pyramidal cells contain an EGABA gradient, with lowest EGABA 
levels (producing hyperpolarization) at dendrites, and highest EGABA levels (producing 
depolarization) at the axon (Khirug et al., 2008). However, by measuring extracellular 
field potentials, a less invasive method than the previous two studies, a purely inhibitory 
function of PVch cells has recently been demonstrated (Glickfeld et al., 2009). 
Importantly, neither of the two studies that demonstrated an excitatory function of PVch 
cells ruled out an inhibitory function. Thus, the role of PVch neurons in cortical function is 
still unknown, and future studies are needed to definitively determine whether they are 
excitatory, inhibitory, or both (Woodruff et al., 2010). 
In light of the recent evidence that PVch cells may depolarize their pyramidal cell 
targets, it is possible the PV and GAT1 are lower in these cells in an attempt to 
counteract upstream reductions in pyramidal cell excitation and restore E/I balance in 
schizophrenia (Lewis et al., 2011). Lower PV and GAT1 in excitatory PVch cells would 
function to increase excitation of pyramidal cells, although ultimately this compensation 
is insufficient to restore pyramidal cell activity, since γ oscillations and cognitive control 
deficits are still present in schizophrenia (Lewis et al., 2005).  
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This E/I balance hypothesis would predict that PV and GAT1 levels would be 
normal in PVb cells. The current nonsignificant change in PV protein levels in PV puncta 
(5.4.2), though potentially confounded by small sample size, suggests that this may be 
the case. However, one interpretation of the reduced density of PV-IR puncta, 
presumably PVb axon terminals (Erickson and Lewis, 2002), in layers 3-4 of subjects 
with schizophrenia (Lewis et al., 2001) is that lower PV levels in these cells fall below 
the thereshold of detectability. In fact, given that PV expression is activity dependent in 
the visual cortex (Blümcke et al., 1994; Pinheiro Botelho et al., 2006), it is possible that 
PV is downregulated in PVb cells in response to reduced activity in these cells resulting 
from lower GAD67. However, there are two problems with this interpretation. First, lower 
PV in PVb cells would have the net effect of increasing GABA neurotransmission in 
these cells, counteracting the reduction of GABA neurotransmission in PVb cells in 
response to reduced excitation in pyramidal cells. Second, this interpretation is 
inconsistent with the lack of change in PV and GAT1 mRNA that we obtained in the 
mouse models of lower GAD67 (Chapter 4). It is possible that a nonselective reduction 
in GAD67 in both PVb and PVch cells in the mouse models precluded the detection of a 
difference in PV levels.  
Alternatively, the lower density of PV-IR puncta in layers 3 and 4 in schizophrenia 
may not reflect lower PV levels, and instead may reflect fewer inputs from the medial 
dorsal (MD) nucleus of the thalamus, (Lewis et al., 2001). PV is expressed in excitatory 
neurons of the thalamus that project to layers 3 and 4 of the PFC (Jones, 1998; Giguere 
and Goldman-Rakic, 1988). Several studies have reported reduced volume and 
neuronal number in the MD thalamus (Pakkenberg, 1990; Young et al., 2000), however 
more recent studies are mixed (reviewed in Byne et al., 2009). Furthermore, in rats, 
lesions of the MD nucleus do not produce alterations in PFC GAD67 mRNA (Volk and 
Lewis, 2003). Thus, the status and consequences of MD thalamic alterations in 
schizophrenia is currently unclear, and therefore whether the lower density of PV-IR 
puncta reflects deficits in thalamic or PVb terminals is unknown. 
In contrast to the conflicting data for PV, the lower density of GAT1-IR cartridges 
(Pierri et al., 1999), but lack of change in GAT1-IR puncta (presumably all other non-
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cartridge puncta, including those from PVb cells) in schizophrenia (Woo et al., 1998), 
suggests that GAT1 may be selectively reduced in PVch but not PVb cells.  
Importantly, this E/I balance hypothesis provides a potential explanation as to 
why lower PV and GAT1 mRNA were not observed following reductions in GAD67 
(Chapter 4). Lower PV and GAT1 mRNA in PVch cells may be a response to reduced 
excitatory drive in pyramidal neurons, not a consequence of lower GAD67. Studies that 
can definitively establish PV and GAT1 protein levels in PVb and PVch axon terminals 
separately are an important next step in advancing this hypothesis. PV and GAT1 
expression levels would be expected to be unchanged in PVb cells, but decreased in 
PVch cells. Using similar methodologies as what we employed in 3.4.4, it is possible to 
selectively measure protein levels at synapses furnished by the two different cell types. 
This can be accomplished using antibodies against proteins such as GAT1 that 
selectively label cartridges, which are visually distinguishable from the PVb axon 
terminals that appear as puncta (Fish et al., 2011). 
5.5.2 Lower GAD67 in PVb cells underlies impaired γ oscillations and cognitive 
control deficits in schizophrenia 
PV neurons are known to be crucial in the generation of γ oscillations, the synchronized 
activity of networks of pyramidal neurons at 30-80 Hz, thought to underlie cognitive 
control (reviewed in Gonzalez-Burgos, 2010). For example, the γ local field potential is 
tightly coupled to the firing of PV neurons both in vitro (Hájos et al., 2004) and in vivo 
(Tukker et al., 2007). Moreover, recent evidence using optogenetic techniques has 
demonstrated that suppression and activation of PV neurons suppresses and 
generates, respectively, γ activity in vivo, indicating that PV neurons are both necessary 
and sufficient for the generation of γ oscillations (Sohal et al., 2009; Cardin et al., 2009). 
In fact, fast spiking PVb cells are known to be especially critical for γ oscillations 
(Gonzalez-Burgos, 2010). The GABAA α1-containing receptors that predominate at PVb 
cell synapses exhibit decay kinetics that are consistent with the firing rate of γ 
oscillations (Gonzalez-Burgos and Lewis, 2008). Furthermore, the firing of PVb cells is 
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more strongly coupled to the γ oscillation cycle than the firing of either PVch or CCK cells 
(Gulyas et al. 2010).  
Importantly, γ oscillations are thought to underlie higher order cognitive 
processes (Fries, 2009). For example, γ band activity is induced during the delay period 
of working memory tasks (Tallon-Baudry et al., 1998), and the power of γ synchrony 
increases in proportion to working memory load (Howard et al., 2003). Thus, given the 
crucial role of PVb neurons in the generation of γ oscillations, the alterations in PVb 
neurons demonstrated here are a plausible mechanism underlying the lower γ band 
power, and cognitive control deficits, observed in the illness (Figure 24). 
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Figure 24. Schematic summary, and predicted functional consequences, of lower 
GAD67 mRNA and protein in the DLPFC of subjects with schizophrenia. In healthy 
subjects, normal tissue levels of GAD67 mRNA and protein in DLPFC area 9 (purple 
shaded area, top left) are associated with normal levels of GAD67 mRNA and protein in 
PV-containing cell bodies and axon terminals, respectively, and normal levels of GABA 
release from synaptic vesicles onto pyramidal (P) neurons (top right), providing the 
inhibitory inputs required for normal γ band power as measured by 
electroencephalography during cognitive control tasks (top left). In schizophrenia, 
modest reductions in tissue levels of GAD67 mRNA and protein (bottom left) are 
associated with pronounced reductions of GAD67 mRNA and protein in PV neurons and 
axon terminals, respectively (bottom right). The predicted reduction in GABA (red dots) 
available to be released from synaptic vesicles (bottom right) leads to the lower γ band 
power present over the DLPFC during cognitive control tasks (bottom left). Warmer 
colors in the heat maps of γ band power indicate higher power and cooler colors 
indicate lower power. Heat maps are from Cho et al. Copyright, 2006, Proceedings of 
the National Academy of Sciences. 
 
5.6 CONCLUDING REMARKS 
Lower GAD67 mRNA in schizophrenia has been replicated by numerous studies since 
the initial report was published in 1995 (Akbarian et al.). Nearly a decade later, it was 
demonstrated that lower GAD67 mRNA is present in PV neurons (Hashimoto et al., 
2003). However, a number of important aspects of this deficit have remained undefined. 
Accordingly, this dissertation examined factors that may contribute the heterogeneity of 
the mRNA deficit, total protein levels of GAD67 as well as those in PV axon terminals, 
as well as the consequences of lower GAD67 in PV neurons. Following the 
development of innovative solutions to the challenges associated with measurement of 
protein in postmortem human tissue, we found the following four key results: 
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1) Lower GAD67 mRNA is common in schizophrenia and is not associated with 
potential confounding factors such as medication use or substance abuse; 
predictors of illness severity or measures of functional outcome; or illness 
chronicity (3.4.1). Using qPCR in the largest cohort to date, we did not find a 
relationship between GAD67 mRNA and these factors. Thus, the lack of a GAD67 
mRNA deficit in roughly 25% of schizophrenia patients is likely to result from additional 
causes. Importantly, lower GAD67 does not seem to be a consequence of illness 
treatment or chronicity. 
 
2) Total GAD67 protein is significantly reduced in schizophrenia (3.4.2). We 
utilized a Western blotting methodology that provided a robust quantification of total 
GAD67 protein levels due to the use of only subjects with PMIs in which GAD67 protein 
is well-preserved, a paired study design with multiple replicates, the use of a stable 
normalizer, and the linearity and proportionality of the antibodies used. We found that 
GAD67 protein levels are significantly lower in the DLPFC of subjects with 
schizophrenia, with a magnitude that is similar to the mRNA deficit. 
 
3) GAD67 protein levels in PV axon terminals, the site of GABA production and 
function, are substantially reduced in the DLPFC of subjects with schizophrenia 
(3.4.4). We used immunofluorescence and confocal microscopy, coupled with a novel 
methodology, to provide a robust assessment of GAD67 protein levels in a specific 
population of interneurons due to the use of a sensitive microscopy system, 
stereological sampling, an iterative threshold/morphological segmentation and data 
analysis approach that allows for the accurate quantification of a wide range of 
fluorescent intensities, and the elimination of the confounding autofluorescence of 
lipofuscin. The reduction in GAD67 protein observed in PV axon terminals was much 
greater than that observed at the total protein level.  
 
4) Lower PV and GAT1 mRNA are not a consequence of lower GAD67 in PV 
neurons (4.4). Using ISH in two different mouse models of lower GAD67, one with 
lower GAD67 specifically in PV neurons (PVGAD67+/-) and the other with lower GAD67 in 
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all interneurons (GABAGAD67+/-), we examined the consequences of lower GAD67. 
Neither PV nor GAT1 mRNA were altered at the tissue level in adult or developmental 
PVGAD67+/- mice. Additionally, cellular analyses confirmed a lower level of GAD67, but 
not of PV, mRNA in these animals. Finally, PV and GAT1 mRNAs were also unaltered 
in GABAGAD67+/- mice. Taken together, these data suggest that lower GAD67 levels do 
not result in changes in PV or GAT1, and therefore lower GAD67 is unlikely to be the 
cause of reduced PV and GAT1 mRNA in schizophrenia. 
  
Together, these data provide an important characterization of the GAD67 deficit in 
schizophrenia. The findings that lower GAD67 mRNA expression is common in 
schizophrenia, is not a consequence of illness treatment or chronicity, and leads to less 
translation of the protein, especially in the axon terminals of PVb neurons, support the 
hypothesis that lower GABA synthesis in PVb neurons contributes to DLPFC 
dysfunction, impaired γ oscillations, and cognitive control deficits in schizophrenia. 
Additionally, the lack of change in PV and GAT1 mRNA in two different mouse models 
of lower GAD67 suggests that these transcripts are not reduced in schizophrenia as a 
consequence of lower GAD67. 
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APPENDIX A 
SUPPLEMENTARY METHODS 
A.1 GAD67 MRNA LEVELS 
Tissue collection and preparation 
The right hemisphere of each brain was blocked coronally, frozen immediately, and 
stored at -80ºC (Volk et al., 2000). Cryostat sections from the anterior-posterior level 
corresponding to the middle portion of the superior frontal sulcus were cut serially and 
confirmed to contain DLPFC area 9 from adjacent Nissl-stained sections using 
cytoarchitectonic criteria (Volk et al., 2000). Cortical gray matter was dissected in a 
manner that excluded white matter contamination and provided excellent RNA 
preservation, and collected into tubes containing Trizol reagent (Invitrogen, Carlsbad, 
CA). Total RNA was isolated from Trizol homogenates, cleaned by RNeasy columns 
(Qiagen, Valencia, CA), and used for qPCR, as described below. RIN and pH were 
determined as described previously (Hashimoto et al., 2008a). 
 
Quantitative PCR 
cDNA was synthesized from total RNA for each subject using a High Capacity cDNA 
Reverse Transcription Kit (Applied Biosystems, Foster City, CA). All primer pairs (Table 
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3) demonstrated: 1) high amplification efficiency (>96%) across a wide range of cDNA 
dilutions; 2) specific single products in dissociation curve analysis; and 3) melting 
temperatures similar to those predicted by oligonucleotide software.  Quantitative PCR 
was performed with Power SYBR Green dye and an ABI StepOne Plus Real Time PCR 
System (Applied Biosystems). The difference in cycle threshold (dCT) for GAD67 
mRNA expression was calculated by subtracting the geometric mean of the cycle 
threshold for the three reference genes from the cycle threshold of GAD67 mRNA. 
Because this dCT represents the log2-transformed expression ratio of the target 
transcript to the geometric mean of the 3 reference genes, the relative expression level 
of GAD67 mRNA was determined as 2-dCT (Hashimoto et al., 2008b; Vandesompele et 
al., 2002). 
 
 
 
Table 3. Design of the 4 primer sets used in qPCRa 
 
aAbbrevations: bp, base pairs; BA, beta actin; CyPA, cyclophilin A; GAPDH, 
glyceraldehyde-3-phosphate dehydrogenase; GAD67, glutamic acid decarboxylase 67 
kDa 
Gene Accession # Amplicon  Size (bp) Position 
Forward Primer (F) 
Reverse Primer (R)  
BA NM_001101 101 1146-1246 
(F) GATGTGGATCAGCAAGCA 
(R) AGAAAGGGTGTAACGCAACTA 
CyPA NM_021130 126 159-284 (F) GCAGACAAGGTCCCAAAG (R) GAAGTCACCACCCTGACAAC 
GAPDH NM_002046 87 556-642 (F) TGCACCACCAACTGCTTAGC (R) GGCATGGACTGTGGTCATGAG 
GAD67 NM_000817 86 2495-2580 
(F) GTTTCCCGCTCCAAGAGAAT 
(R) TGGAGTTGTTGGACAAGCTG 
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A.2 GAD67 PROTEIN LEVELS 
Tissue collection and preparation 
Gray matter from the right hemisphere of each brain was obtained as described above 
and collected into tubes for total protein analysis (average of 22 mg of tissue per tube). 
Tissue was homogenized by sonication in a volume of SDS buffer (125mM Tris pH 7, 
2% SDS, 10% glycerol) equal to 10 times the tissue weight. Protein was extracted from 
homogenates by incubation at 70°C for 10 min with occasional vortexing, followed by 
centrifugation at 16,000 g for 10 min. This method allows for optimal protein extraction 
with minimal degradation (Ericsson et al., 2007). The supernatant was collected and an 
aliquot was used for total protein concentration determination in triplicate using a BCA 
assay kit (Thermo Fisher Scientific, Rockford, IL) according to the manufacturer’s 
protocol. The remaining supernatant from protein extraction was frozen in aliquots. A 
single aliquot was then used to prepare samples in 1X Protein Loading Buffer (LI-COR 
Biosciences, Lincoln, NE) containing 10% β-mercaptoethanol that were stored in single-
use aliquots at -20ºC. To limit its effect on protein levels, samples were exposed to only 
2 freeze-thaw cycles. 
Western blotting 
Unless otherwise noted, all reagents were obtained from Thermo Fisher Scientific, all 
incubation steps were performed at room temperature, and all washes were performed 
for 5 min each in Tris-buffered saline with Tween-20 (10mM Tris pH 7.5, 150mM NaCl, 
0.05% Tween 20). 
After denaturing at 70ºC for 5 min, samples were resolved by SDS PAGE in 10% 
Precise Protein Gels in Tris-HEPES SDS running buffer (100 mM Tris, 100 mM HEPES, 
3 mM SDS) at 60-62 volts for 2.5 hrs. Proteins were transferred to nitrocellulose 
membrane (LI-COR Biosciences) at 85 volts for 45 min in Tris-Glycine blotting buffer 
(25mM Tris, 192mM glycine, 20% methanol). Membranes were blocked for 1 hr in 50% 
Odyssey® Blocking Buffer (LI-COR Biosciences) and 50% Tris-buffered saline, and 
  117 
washed once. Membranes were then incubated in a primary antibody mixture containing 
β-tubulin (mouse, 1:20,000, Millipore, Billerica, MA) and GAD67 (goat, 1:800, R&D 
Systems, Minneapolis, MN) in SuperBlock Blocking Buffer with 0.05% Tween 20 
overnight at 4°C, and subsequently washed 5 times before incubation for 1 hr in a 
mixture of secondary antibodies containing IRDye® donkey anti mouse 680 and 
IRDye® donkey anti goat 800 (both 1:20,000; LI-COR Biosciences) in 50% Odyssey® 
Blocking Buffer and 50% Tris-buffered saline with Tween-20 and 0.01% SDS. Following 
5 washes, signal was detected using the LI-COR Odyssey® Infrared Imaging System. 
A.3 GAD67 PROTEIN LEVELS AT PV PUNCTA 
Tissue collection and preparation 
The left hemisphere of each brain was processed in 4% paraformaldehyde (Sweet et 
al., 2009) and tissue blocks containing the superior frontal gyrus were sectioned 
coronally at 40 µm on a cryostat and stored in antifreeze solution at −30°C until 
processing for immunohistochemistry. 
Immunohistochemistry 
Tissue sections were processed for fluorescent immunohistochemistry as described 
previously (Fish et al., 2008). Sections were incubated for 48 hrs in the following 
primary antibodies: GAD67 (mouse, 1:500, Millipore), GAD65 (rabbit, 1:1000, Millipore), 
and PV (goat, 1:1000, Swant, Bellinzona, Switzerland). Tissue sections were then 
incubated for 24 hrs with secondary antibodies (donkey) which were conjugated to 
Alexa 488 (1:500), 568 (1:500), or biotin (1:200; all from Invitrogen). For the biotin 
secondary, a tertiary incubation (24 hrs) with streptavidin 647 was performed. All 
sections were processed together in a single immunohistochemical run, and slides were 
coded so that subsequent steps were performed in a blinded fashion. 
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Microscopy 
Image stacks (512x512 pixels; 0.23 µm z-step) were collected on an Olympus IX71 
inverted microscope (Center Valley, PA) equipped with an Olympus DSU spinning disk 
confocal using a 60X 1.42 N.A. oil immersion objective and a Hamamatsu C9100 CCD 
camera (Bridgewater, NJ). SlideBook 4.2 software (Intelligent Imaging Innovations, Inc., 
Denver, CO) was used to control the microscope and for image processing. A total of 6-
12 sites per section were imaged, with the number determined by the size of the region 
of interest. Running means were used to confirm that the number of sites per section 
was sufficient to adequately sample the region. 
A.4 ANTIBODY SPECIFICITY 
All antibodies are commercially available and have had specificity demonstrated by 
multiple approaches per the manufacturers’ data sheets. In addition, the specificity of 
each antibody was verified by Western blot in our laboratory (data not shown), with the 
exception of the PV antibody which has been verified by others (Kagi et al., 1987). 
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APPENDIX B 
COMPLETE SUBJECT TABLE 
 
Table 4. Characteristics of human subjects used in this dissertationa 
 
Comparison Subjects Subjects with Schizophrenia
Pair Case Sex/ Race Age PMI
d Storage 
Timee
RIN pH Cause of Death Case DSM IV diagnosis Sex/  Race Age PMI
d Storage 
Timee
RIN pH Cause of Death Cannabis History
Nicotine 
ATOD
Antipsychotic 
ATOD 
Antidepressant 
ATOD
Benzodiazepine/ 
VPA ATOD
1 592 M/B 41 22.1 159 9.0 6.7 ASCVD 533 Chronic undifferentiated schizophrenia M/W 40 29.1 169 8.4 6.8
Accidental 
Asphyxiation None U Y N N
2a 567 F/W 46 15.0 163 8.9 6.7
Mitral Valve 
prolapse
537 Schizoaffective disorder F/W 37 14.5 168 8.6 6.7 Suicide by 
hanging
None U N N N
3a 516 M/B 20 14.0 171 8.4 6.9
Homicide by gun 
shot
547 Schizoaffective disorder M/B 27 16.5 167 7.4 7.0 Heat Stroke None U Y Y Y
4c 630 M/W 65 21.2 153 9.0 7.0 ASCVD 566
Chronic undifferentiated 
schizophrenia; AAR M/W 63 18.3 164 8.0 6.8 ASCVD None Y Y Y Y
4a,c 1322 M/W 62 16.5 37 8.6 6.8 ASCVD --
5 604 M/W 39 19.3 157 8.6 7.1 Hypoplastic coronary artery 581
Chronic paranoid 
schizophrenia; ADC; OAC M/W 46 28.1 161 7.9 7.2
Accidental 
combined drug 
overdose
Use U Y N Y
6 546 F/W 37 23.5 167 8.6 6.7 ASCVD 587 Chronic undifferentiated schizophrenia; AAR F/B 38 17.8 160 9.0 7.0
Myocardial 
hypertrophy Use Y Y N Y
7 551 M/W 61 16.4 166 8.3 6.6 Cardiac Tamponade 625
Chronic disorganized 
schizophrenia; AAC M/B 49 23.5 154 7.6 7.3 ASCVD None Y Y Y N
8a,b 685 M/W 56 14.5 146 8.1 6.6
Hypoplastic 
coronary artery 622
Chronic undifferentiated 
schizophrenia M/W 58 18.9 154 7.4 6.8
Right MCA 
infarction None U N N N
9a 681 M/W 51 11.6 147 8.9 7.2
Hypertrophic 
cardiomyopathy 640
Chronic paranoid 
schizophrenia M/W 49 5.2 152 8.4 6.9
Pulmonary 
embolism None U Y Y N
10 806 M/W 57 24.0 125 7.8 6.9 Pulmonary embolism 665
Chronic paranoid 
schizophrenia; ADC M/B 59 28.1 149 9.2 6.9
Intestinal 
hemorrhage None Y Y Y N
11 822 M/B 28 25.3 123 8.5 7.0 ASCVD 787 Schizoaffective disorder; 
ODC
M/B 27 19.2 129 8.4 6.7 Suicide by gun 
shot
Dependence N Y N N
12a 727 M/B 19 7.0 140 9.2 7.2 Trauma 829
Schizoaffective disorder; 
ADC; OAR M/W 25 5.0 121 9.3 6.8
Suicide by 
salicylate 
overdose
Abuse in 
remission Y N N Y
13a,b 871 M/W 28 16.5 112 8.5 7.1 Trauma 878
Disorganized 
schizophrenia; ADC M/W 33 10.8 111 8.9 6.7 Myocardial fibrosis Use Y Y Y Y
14a 575 F/B 55 11.3 162 9.6 6.8 ASCVD 517
Disorganized 
schizophrenia; ADC F/W 48 3.7 170 9.3 6.7
Intracerebral 
hemorrhage None Y Y N N
15 700 M/W 42 26.1 144 8.7 7.0 ASCVD 539 Schizoaffective disorder; ADR M/W 50 40.5 168 8.1 7.1
Suicide by 
combined drug 
overdose
None U Y Y Y
16 988 M/W 82 22.5 91 8.4 6.2 Trauma 621 Chronic undifferentiated schizophrenia M/W 83 16.0 154 8.7 7.3
Accidental 
asphyxiation None U N N N
17 686 F/W 52 22.6 146 8.5 7.0 ASCVD 656 Schizoaffective disorder; 
ADC
F/B 47 20.1 150 9.2 7.3 Suicide by gun 
shot
None Y Y N N
18 634 M/W 52 16.2 153 8.5 7.0 ASCVD 722 Chronic undifferentiated schizophrenia; ODR; OAR M/B 45 9.1 140 9.2 6.7 Upper GI bleeding Use Y Y N N
19a,b 852 M/W 54 8.0 115 9.1 6.8
Cardiac 
tamponade
781 Schizoaffective disorder; 
ADR
M/B 52 8.0 130 7.7 6.7 Peritonitis None Y Y Y N
20 987 F/W 65 21.5 91 9.1 6.8 ASCVD 802 Schizoaffective disorder; ADC; ODR F/W 63 29.0 126 9.2 6.4
Right ventricular 
dysplasia None Y Y N Y
21 818 F/W 67 24.0 124 8.4 7.1 Anaphylactic reaction 917
Chronic undifferentiated 
schizophrenia F/W 71 23.8 104 7.0 6.8 ASCVD None Y Y N N
22a,b 857 M/W 48 16.6 114 8.9 6.7 ASCVD 930
Disorganized 
schizophrenia; ADR; OAR M/W 47 15.3 100 8.2 6.2 ASCVD Abuse Y Y N Y
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Comparison Subjects Subjects with Schizophrenia
Pair Case Sex/ Race Age PMI
d Storage 
Timee
RIN pH Cause of Death Case DSM IV diagnosis Sex/  Race Age PMI
d Storage 
Timee
RIN pH Cause of Death Cannabis History
Nicotine 
ATOD
Antipsychotic 
ATOD 
Antidepressant 
ATOD
Benzodiazepine/ 
VPA ATOD
23a,b 739 M/W 40 15.8 139 8.4 6.9 ASCVD 933
Disorganized 
schizophrenia
M/W 44 8.3 100 8.1 5.9 Myocarditis None N Y Y Y
24a 1047 M/W 43 13.8 84 9.0 6.6 ASCVD 1209 Schizoaffective Disorder M/W 35 9.1 64 8.7 6.5
Suicide by 
diphenhydramine 
overdose
None N Y N N
25 1086 M/W 51 24.2 78 8.1 6.8 ASCVD 10025 Disorganized Schizophrenia; OAR M/B 52 27.1 57 7.8 6.7 ASCVD
Abuse in 
remission Y N N N
26a 1092 F/B 40 16.6 77 8.0 6.8
Mitral Valve 
Prolapse
1178 Schizoaffective Disorder F/B 37 18.9 69 8.4 6.1 Pulmonary 
embolism
None Y Y N Y
27 10005 M/W 42 23.5 65 7.4 6.7 Trauma 1256 Undifferentiated 
Schizophrenia
M/W 34 27.4 57 7.9 6.4 Suicide by 
hanging
None N Y N N
28 1336 M/W 65 18.4 42 8.0 6.8 Cardiac Tamponade 1173
Disorganized 
Schizophrenia; ADR M/W 62 22.9 69 7.7 6.4 ASCVD None Y Y N N
29a 1122 M/W 55 15.4 74 7.9 6.7
Cardiac 
Tamponade
1105 Schizoaffective Disorder M/W 53 7.9 76 8.9 6.2 ASCVD None Y Y N N
30a 1284 M/W 55 6.4 53 8.7 6.8 ASCVD 1188
Undifferentiated 
Schizophrenia; AAR; OAR M/W 58 7.7 67 8.4 6.2 ASCVD
Abuse in 
remission Y Y N N
31 1191 M/B 59 19.4 66 8.4 6.2 ASCVD 1263 Undifferentiated Schizophrenia; ADR M/W 62 22.7 56 8.5 7.1
Accidental 
asphyxiation Use Y Y Y N
32 970 M/W 42 25.9 95 7.2 6.4 ASCVD 1222 Undifferentiated Schizophrenia; AAC M/W 32 30.8 62 7.5 6.4
Suicide by 
combined drug 
overdose
Use N Y Y N
33 10003 M/W 49 21.2 66 8.4 6.5 Trauma 1088 Undifferentiated Schizophrenia; ADC; OAC M/W 49 21.5 78 8.1 6.5
Accidental 
combined drug 
overdose
Abuse Y Y Y N
34 1247 F/W 58 22.7 58 8.4 6.4 ASCVD 1240 Undifferentiated Schizophrenia; ADR F/B 50 22.9 59 7.7 6.3 ASCVD None Y Y N N
35 1324 M/W 43 22.3 45 7.3 7 Aortic Dissection 10020 Paranoid Schizophrenia; AAC; OAC M/W 38 28.8 58 7.4 6.6
Suicide by 
salicylate 
overdose
None Y Y Y Y
36a 1099 F/W 24 9.1 76 8.6 6.5 Cardiomyopathy 10023 Disorganized Schizophrenia
F/B 25 20.1 57 7.4 6.7 Suicide by 
drowning
None N Y N Y
37a 1307 M/B 32 4.8 48 7.6 6.7 ASCVD 10024 Paranoid Schizophrenia M/B 37 6.0 57 7.5 6.1 ASCVD None N N N N
38a 1391 F/W 51 7.8 34.0 7.1 6.6 ASCVD 1189
Schizoaffective Disorder; 
AAR F/W 47 14.4 67 8.3 6.4
Suicide by 
combined drug 
overdose
None Y Y Y Y
39 1282 F/W 39 24.5 53 7.5 6.8 ASCVD 1211 Schizoaffective Disorder F/W 41 20.1 64 7.8 6.3 Sudden unexplained death Use Y Y Y N
40a 1159 M/W 51 16.7 70 7.6 6.5 ASCVD 1296
Undifferentiated 
Schizophrenia
M/W 48 7.8 50 7.3 6.5 Pneumonia None Y Y Y N
41 1326 M/W 58 16.4 44 8.0 6.7 ASCVD 1314 Undifferentiated 
Schizophrenia
M/W 50 11.0 47 7.2 6.2 ASCVD None N Y Y N
42 902 M/W 60 23.6 109 7.7 6.7 ASCVD 1361 Schizoaffective Disorder; 
ODC
M/W 63 23.2 39 7.7 6.4 Cardiomyopathy Use Y Y N Y
Mean 48.5 17.8 104.2 8.3 6.8 47.0 18.1 106.0 8.2 6.6 26Y/8N/ 
8U
36Y/6N 17Y/25N 15Y/27N
SD 13.3 5.9 43.9 0.6 0.2 12.8 8.7 45.6 0.7 0.4
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Subjects with Schizophrenia (continued)
Case DSM IV diagnosis
Family 
Historyf
Age at 
Onset of 
Illness
History of 
Marriage
Hollingshead 
Two Factor ISP
Living 
Independently 
ATOD
533
Chronic 
undifferentiated 
schizophrenia
N 25 N 20 N
537 Schizoaffective 
disorder
N 29 Y 20 Y
547 Schizoaffective 
disorder
N 18 N 17 N
566
Chronic 
undifferentiated 
schizophrenia; 
AAR
N 43 Y 16 N
581
Chronic paranoid 
schizophrenia; 
ADC; OAC
Y 16 Y 19 Y
587
Chronic 
undifferentiated 
schizophrenia; 
AAR
N 18 N 17 N
625
Chronic 
disorganized 
schizophrenia; 
AAC
Y 35 Y 34 N
622
Chronic 
undifferentiated 
schizophrenia
N 42 N 27 N
640 Chronic paranoid schizophrenia N 21 N 63 N
665
Chronic paranoid 
schizophrenia; 
ADC
Y 27 N 16 Y
787 Schizoaffective 
disorder; ODC
N 24 N 30 N
829
Schizoaffective 
disorder; ADC; 
OAR 
Y 20 N 22 N
878
Disorganized 
schizophrenia; 
ADC
N 16 N 57 N
517
Disorganized 
schizophrenia; 
ADC
N 28 Y 53 N
539 Schizoaffective disorder; ADR N 19 Y 45 Y
621
Chronic 
undifferentiated 
schizophrenia
Y 28 N 8 N
656 Schizoaffective 
disorder; ADC
Y 17 N 19 Y
722
Chronic 
undifferentiated 
schizophrenia; 
ODR; OAR
N 26 N 24 N
781 Schizoaffective 
disorder; ADR
N 37 Y 24 N
802
Schizoaffective 
disorder; ADC; 
ODR
N 20 N 42 Y
917
Chronic 
undifferentiated 
schizophrenia
Y 24 Y 19 N
930
Disorganized 
schizophrenia; 
ADR; OAR
N 19 N 17 N
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Subjects with Schizophrenia (continued)
Case DSM IV diagnosis
Family 
Historyf
Age at 
Onset of 
Illness
History of 
Marriage
Hollingshead 
Two Factor ISP
Living 
Independently 
ATOD
933 Disorganized 
schizophrenia
N 22 N 27 N
1209 Schizoaffective Disorder N 21 Y 35 Y
10025
Disorganized 
Schizophrenia; 
OAR 
N 22 N 27 N
1178 Schizoaffective 
Disorder
N 26 N 40 N
1256 Undifferentiated 
Schizophrenia
N 28 N 36 N
1173
Disorganized 
Schizophrenia; 
ADR 
N 29 Y 16 Y
1105 Schizoaffective 
Disorder
N 48 N 24 N
1188
Undifferentiated 
Schizophrenia; 
AAR; OAR
Y 25 N 45 N
1263
Undifferentiated 
Schizophrenia; 
ADR 
N 21 N 11 N
1222
Undifferentiated 
Schizophrenia; 
AAC 
N 16 N 14 Y
1088
Undifferentiated 
Schizophrenia; 
ADC; OAC 
N 25 Y 45 N
1240
Undifferentiated 
Schizophrenia; 
ADR 
N 25 N 32 N
10020
Paranoid 
Schizophrenia; 
AAC; OAC
N 18 N 27 N
10023 Disorganized 
Schizophrenia
Y 15 N 17 Y
10024 Paranoid 
Schizophrenia
N 20 Y 27 N
1189 Schizoaffective Disorder; AAR N 43 N 66 Y
1211 Schizoaffective Disorder N 29 Y 30 N
1296 Undifferentiated 
Schizophrenia
N 13 N 14 N
1314 Undifferentiated 
Schizophrenia
N 17 N 19 N
1361 Schizoaffective 
Disorder; ODC
N 16 N 17 N
9Y/33N 13Y/29N 11Y/31N
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aPairs utilized in total protein study; bPairs utilized in puncta study; cSubjects 630 and 
1322 were used as the comparison subjects in pair 4 for qPCR and Western blotting 
studies, respectively; dPMI, postmortem interval (hours); eStorage time (months) at -
80C; fFirst degree relative with schizophrenia; Other abbreviations: ASCVD, 
arteriosclerotic cardiovascular disease; MCA, middle coronary artery; Benzo, 
benzodiazepines; VPA, valproic acid; ATOD, at time of death; ADC, alcohol 
dependence, current ATOD; ADR, alcohol dependence, in remission ATOD; AAC, 
alcohol abuse, current ATOD; AAR, alcohol abuse, in remission ATOD; ODC, other 
substance dependence, current ATOD; ODR, other substance dependence, in 
remission ATOD; OAC, other substance abuse, current ATOD; OAR, other substance 
abuse, in remission ATOD; ISP, Index of Social Position. 
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